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ABSTRACT 
 
Previous studies have reported that the adult periodontal ligament (PDL) may contain 
progenitor/stem cells that function as precursors for periodontal tissue regeneration, although 
the ability of this population to differentiate into the multiple lineages present in the PDL is 
not yet certain.  In addition, although Enamel Matrix Derivative (EMD; Emdogain®), derived 
from the enamel matrix of developing teeth) has been used extensively to help re-build new 
periodontal tissue, its effect on bone regeneration remains inconclusive and its effect on PDL 
blood vessels and nerve cell development not yet known, because it comprises a 
heterogeneous mixture of proteins. EMD has recently been separated into two main fractions: 
Fraction C, containing proteins < 6 kDa (mainly the tyrosine-rich amelogenin peptide TRAP); 
and Fraction A, containing proteins > 6 KDa (including the full-length amelogenin, sheathlins 
and a leucine-rich amelogenin peptide LRAP). The present study examined the effects of 
EMD Fractions on multi-lineage differentiation pathays of PDL cells in vitro. The results of 
the present study have shown that that Fraction C and Fraction A differentially regulate multi-
lineage specification of PDL cells. Thus, Fraction C was found to up-regulate chondrogenic, 
vasculogenic, angiogenic, neurogenic and gliogenic genes and ‘terminal’ differentiation, 
whereas Fraction A was found to stimulate osteogenic genes and terminal osteogenic 
differentiation in vitro; both fractions suppressed adipogenesis. Moreover, the TRAP and 
LRAP peptides of Fraction C and Fraction A, respectively, were found to be at least partly 
responsible for the differential activities of these two fractions. In addition, at least some 
components in these EMD Fractions bound to and were internalized into PDL cells, most 
probably by receptor-mediated endocytosis. These findings thus demonstrate that the PDL 
contains cells with multi-lineage differentiation potential and that the components of EMD 
have differential effects on the diverse activities on the heterogeneous cells present in the 
PDL. 
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Chapter 1                                                                                                    General Introduction                 
Chapter 1 
 
1.1. Periodontal anatomy and function 
The periodontium, a specialized tissue compartment responsible for tooth support, comprises 
cementum, periodontal ligament, alveolar bone and gingival tissue. Each of the periodontium-
associated tissue has specialized anatomical structures and physiological relevance.  
 
 
 
 
 
 
 
 
 
 
Figure 1.1 The structure of the healthy periodontium, comprising the gingival epithelium, 
gingival connective tissue, alveolar bone, cementum and periodontal ligament (PDL). 
(photograph taken from www.studiodentaire.com) 
 
1.1.1. Cementum 
Cementum, a mineralized avascular connective tissue that binds firmly to dentin and covers 
the entire root surface (Lindhe and Karring, 2009; Nanci et al., 2006), is believed to be 
produced by cementoblasts that originate from dental follicle cells that are induced by enamel 
matrix proteins (Slavkin, 1974). Root cementum is primarily responsible for the attachment of 
periodontal ligament fibres to the enamel surface. In addition, it is also responsible for 
adjustment of tooth position to continuously changing environment, protection of the dental 
pulp and repair of enamel defects. Two types of cementum tissue are found in human 
periodontium, acellular extrinsic fibre cementum (AEFC) and cellular intrinsic fibre 
cementum (CIFC). They vary in their location, collagen matrix content, structural 
organization of the matrix, the presence of cells in the matrix, rate of formation, biochemical 
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composition and degree of mineralization (Lindhe and Karring, 2009; Melcher and Eastoe, 
1969; Williams et al., 1992a).   
AEFC (primary cementum or acellular cementum) is found on the cervical half to two 
thirds of the root and approximately 45-60% of the total AEFC completely mineralized. The 
development of acellular cementum is relative slow. High number of periodontal ligament 
sharpey’s fibre, a type of fibre found in periodontal ligament, insertion into acellular 
cementum indicates the functional importance in tooth attachment (Fig. 1.1). CIFC 
(secondary cementum or cellular cementum) is found along the apical half of the root and in 
the furcation areas. CIFC is also produced in response to resorptive defects and root fractures 
and is characterized by the presence of intrinsic collagen fibres and cementoblasts trapped in 
the matrix of cementum (Figs. 1.2 and 1.3). The heterogeneous collagen organization, rapid 
speed of formation and the presence of the cells in CIFC may be the reason of CIFC being 
less mineralized compared with AEFC (Lindhe and Karring, 2009; Melcher and Eastoe, 1969; 
Williams et al., 1992a).  
 
 
 
 
 
 
 
Figure 1.2. Transmission electron micrograph demonstrating the cervical root surface of 
human tooth. The micrograph exhibits periodontal ligament fibres (PLF) entering the AEFC 
layer at the mineralization front (MF). Cb, cementoblast; N, nucleus (photo taken from Nanci 
et al., 2006). 
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Figure 1.3 Backscattered scanning electron micrographs showing the CIFC in a human pre-
molar. The micrograph demonstrates thick layer of CIFC containing cementocytes trapped in 
the matrix. Cc, cementocytes; D, dentine (photo taken from Nanci et al., 2006). 
 
Although cementum appears to have different characteristics than bone, such as it does not 
have blood or lymphatic vessels or nerve innervations or undergo physiological remodeling, 
the compositions of these tissues are similar. Cementum primarily contains about 50% 
mineral and 50% organic matrix and predominantly collagen type I constituting 90% of the 
organic matrix is found in this tissue. Other collagen such as type III, less cross-linked 
collagen found during development and repair/regeneration, and type XII, a fibril associated 
collagen that binds to type I and non-collagenous matrix proteins (Lindhe and Karring, 2009; 
Melcher and Eastoe, 1969; Williams et al., 1992a; Nanci et al., 2006).   
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1.1.2. Periodontal ligament (PDL) 
The PDL is a highly cellular and vascular soft connective tissue of the periodontium 
interposed between root cementum and the alveolar bone and it anchors the roots of the teeth 
to the alveolar bone which provides support during mechanical stress or trauma (Hassell et 
al., 1993; ten Cate, 1994). The PDL also contains sensory nerve innervations which sense 
various stimuli such as temperature and pressure applied during mastication and pain 
(Terranova et al., 1990; Lindhe and Karring, 2009).  
 
 
 
 
 
 
 
 
 
 
Figure 1.4. PDL interposed between the root cementum (C) and bone (B) showing 
collagenous fibre network. Note the presence of sharpey’s fibres in the bone (arrows). (Photo 
taken from Beertsen et al., 1997). 
Dental follicle cells, derived originally from the inner layer of the ectomesenchyme 
(Fig 1.4), give rise to the progenitor cells that synthesize cementum, PDL and alveolar bone 
(Palmer and Lumsden, 1987; Ten Cate et al., 1971; Ten Cate and Mills, 1972; Yoshikawa and 
Kollar, 1981) (Fig. 1.4). One of the most remarkable features of the PDL is its adaptability to 
rapidly changing applied force levels that occur during mastication and the capacity to repair 
and regenerate (Beertsen et al., 1997; Nancy et al., 2006; Lindhe and Karring, 2009). The 
PDL is also composed of a number of different types of cells and collagenous and non-
collagenous extracellular matrix components. The PDL contains fibroblasts, epithelial rest of 
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malassez, osteoblasts, osteoclasts, monocytes, macrophages, cementoblasts, odontoclasts, 
neural and endothelial precursors and primitive undifferentiated stem cell-like population. 
The fibroblasts subpopulations in the PDL are primarily responsible for the synthesis and 
repair/regeneration of structurally oriented collagen and non-collagenous fibres (Lindhe and 
Karring, 2009).   
 These collagen fibres are organized in defined and distinct fibre bundles called 
principal fibres. The extreme ends of these fibre bundles are embedded into cementum and 
bone. The embedded portions of the fibres are called sharpey’s fibres. Sharpey’s fibres in 
primary acellular cementum are completely mineralized whereas those in bone or cellular 
cementum are generally only partly mineralized. Other fibre bundles such as gingival 
ligament fibres, transseptal ligament fibres and elastic fibres are also found in the PDL 
(Beertsen et al., 1997; Nancy et al., 2006; Lindhe and Karring, 2009).  
 The epithelial rest of malassez in the PDL are the remnant of Herthwig’s epithelial 
root sheet (HERS). They are found close to the cementum as a cluster of cells which may 
form epithelium. The function of these cells is not clear but it has been suggested that they 
may be involved in homeostasis, repair/regeneration of the PDL. Furthermore, primitive 
stem/precursor cells are important cellular constituent of the PDL, which help rebuilt the PDL 
and the PDL-associated tissues such cementum, bone, blood vessels and nerves after 
injury/damage. PDL stem/precursor cells are further discussed in section 1.3.4.   
 
1.1.3. Alveolar bone (AB) 
The mammalian skeleton has three distinct origins: the paraxial mesoderm, which gives rise 
to the axial skeleton; the lateral plate mesoderm, which gives rise to the appendicular 
skeleton; and the ectoderm (i.e. the neural crest), which gives rise to the facial skeleton, 
including AB (Chung et al., 2004). Two different mechanisms of bone formation have been 
reported to occur during morphogenesis (Sommerfeldt and Rubin, 2001). 
i)  the differentiation of mesenchymal cells directly into osteoblasts, which proceed to 
form mature bone. This ‘intramembranous’ bone formation is found during skull 
development, and also in maxilla (AB of the upper jaw) and mandibular (AB of the 
lower jaw) morphogenesis;  
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ii)  the differentiation of mesenchymal cells which proceeds via chondrogenic pathway 
and forms the cartilaginous template of future bones. The hypertrophy of 
chondrocytes, a process of the enlargement of chondrocytes, of the cartilage is 
followed by the terminal differentiation of the hypertrophic cells into osteoblasts, 
ultimately leading to ossification. The whole process is also known as ‘endochondral 
ossification’ which primarily occurs during long bone development. 
                   (A)                                                  (B) 
           
  
 
 
 
Figure 1.5. Unstained specimen of human mandible showing  (A) a cross section and (B) a 
transverse sections at the middle region of the mandible. The AB houses the roots of erupted 
tooth (T), PDL while the outer (O) and inner (I) cortical plates of compact bone (C) are found 
on the right and left sides of the region of the cancellous bone (S), respectively. (Adopted 
from Hylander, 1975 and http://www.dental.pitt.edu/informatics/periohistology) 
A schematic illustration of the structure of AB is shown in Figure 1.5. The maxilla and 
mandible of adult humans is subdivided into two portions: the AB that houses the roots of 
erupted teeth and the basal bone that is not involved in housing the roots. The AB consists of 
the thin part of the bone that forms the alveolar wall of the tooth socket, the inner and outer 
cortical plates and the cancellous bone. Within the cancellous bone are numerous marrow 
spaces, with smaller marrow spaces present in the cortical bone (Schroeder, 1986; Sodek and 
O 
I 
S 
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McKee, 2000). During embryonic development, the intramembranous bone of the maxilla and 
mandible initially forms from osteoblasts arising from condensing ectomesenchyme in the 
facial region. As osteogenesis progresses, bone surface become lined by a contiguous layer of 
osteoblasts that continue to produce bone, which enlarges the dimensions of the trabeculae. 
Concomitant with the growth of this bone, new mesenchyme condensations arise in 
neighbouring areas and produce new osteoblasts and new trabeculae, all of which will 
collectively form the foetal maxilla and mandible (Sodek and McKee, 2000). Although AB 
has specialized features relating to its functional properties, the cellular compartment and the 
composition of the extracellular matrix of AB appear to be similar to the other bone tissues, 
e.g., skull and long bones.  
The general functions of AB are to house the roots of teeth and to absorb and 
distribute ocular pressures generated from tooth contact during mastication. Their most 
important and unique function is to anchor the roots of teeth to the maxilla and mandible, 
which form the primary support structure for teeth (Cho and Garant, 2000; Sodek and McKee, 
2000). Due to its primary function to house the tooth along with the PDL, bundles of 
sharpey’s fibres penetrate these bone layers and thus, contribute to the characteristic 
appearance of this bundle bone, although this type of bone exhibiting mineralized sharpey’s 
fibres may not be found at all the sites at the same time because AB undergoes constant 
homeostasis.    
 
1.1.4. Gingival connective tissue and epithelium  
The gingival connective tissue and gingival fibroblasts are considered to originate from 
mesenchyme (Listgarten, 1972; Luthman et al., 1989). The dentogingival junction, a gingival 
attachment to the tooth surface and non-keratinized epithelium, is an adaptation of the oral 
mucosa that comprises epithelial and connective tissue components. The gingival connective 
tissue is characterized into superficial and deep compartments and epithelium is divided into 
gingival, sulcular and junctional epithelium. The junctional epithelium plays a pivotal role in 
sealing-off the periodontal tissues from the oral environment and destruction of junctional 
epithelial structure leads to periodontal disease.   
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1.2. Etiology and pathogenesis of periodontitis  
Periodontitis is an inflammatory disease of the periodontium that is considered to be caused 
primarily by a number of different bacterial pathogens and resulting in the progressive 
destruction of periodontal tissues, possibly by three separate pathways (Nishihara & Koseki, 
2004): 
i) pathogens directly release proteolytic enzymes that degrade periodontal structures 
without the intervention of host cells; 
ii) pathogens produce products, such as toxins, enzymes and lipopolysaccharides, which 
may trigger the host cells to produce degenerative enzymes; 
iii) pathogens stimulate an immune response resulting in release of a number of pro-
inflammatory cytokines such as interleukin (IL)-1, IL-6 and tumor necrosis factor-α. 
Collagen which is one of the periodontal extracellular matrix (ECM) components appears to 
be the main target of degradation in periodontitis. Among the host proteases degrading the 
ECM, matrix metalloproteinases (MMP) and collagenases which seem to be highly associated 
with tissue destruction and remodeling events in periodontal disease (Nishihara & Koseki, 
2004).  
 The classification of periodontal disease (Armitage et al., 1999) identifies two general 
clinical manifestations, termed Chronic Periodontitis (CP) and Aggressive Periodontitis 
(AgP). CP is the most common form of the disease and has been widely investigated 
(Pihlstrom et al., 2005), with the following characteristics: prevalence mainly in adults; 
generally slow to moderate rate of destruction of the periodontium; and major role of local 
factors (e.g. plaque and calculus) as well as smoking and emotional stress (Flemming, 1999). 
Association with systemic diseases such as diabetes mellitus has also been reported 
(Pihlstrom et al., 2005). AgP is a severe form of periodontal disease, and affects less than 1% 
of the population (Loe & Brown, 1991; Saxby, 1987). The characteristics of AgP differ from 
CP, as follows: high prevalence in young individual; rapid loss of clinical attachment and 
bone destruction; lack of association with systemic diseases (Tonetti & Mombelli, 1999).  
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Figure 1.6. The structure of the healthy and diseased periodontium. The healthy periodontium 
comprises the cementum, PDL, AB and part of the gingivae facing the tooth (creating the 
space called ‘gingival sulcus’). The diseased periodontium is marked by the loss of gingival 
attachment to the tooth surface, an increase of depth of the gingival sulcus that is known as 
the periodontal pocket depth (PPD) and destruction of AB. (photo adopted from Oral B 
laboratory MA, USA) 
 Chronic gingivitis, characterized by edematous swelling, redness, bleeding of 
gingival, deepening of gingival sulcus, partial loss of attachment of the junctional epithelium 
from the dentine and structure change such as enlargement of the free surface area of 
epithelium leading to an increased exposure to bacterial plaque, can progress into chronic 
periodontitis. Periodontal lesions can be clinically characterized by apical growth and 
migration of the junctional epithelium, deepening of periodontal pocket and destruction of the 
PDL and AB. The degradation of the collagen-rich ECM by the bacterial plaque causes the 
loss of connective tissue attachment to both AB and root cementum.  Furthermore, cementum 
structure and composition are also altered and superficial accumulation of bacteria and hyper 
mineralization are also observed (Pihlstrom et al., 2005; Nanci et al., 2006). Since 
periodontitis causes the destruction of the AB, cementum and the PDL, untreated periodontal 
lesions may lead to early tooth loss (Pihlstrom et al., 2005; Nanci et al., 2006).   
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1.3. Periodontal regeneration 
1.3.1. Basic principles of tissue regeneration 
The main goal of periodontal therapy is to restore healthy and normal periodontal function. 
The initial phase of periodontal treatment is aimed to eliminate infection and inflammation by 
removing root surface deposits and to control the bacterial infection by an effective oral 
hygiene programme (Garrett, 1996). However, if the periodontal defect still persists, surgical 
procedures are then undertaken to regenerate periodontal tissues. 
Tissue regeneration is considered to be dependent on three fundamental elements: i) 
appropriate signalling molecules; ii) progenitor cells; and iii) sufficient blood supply. Each of 
these factors is of crucial importance in the healing process and is internally dependent on 
each other for a successful regeneration of damaged/diseased tissues. Stem/progenitor cells 
provide the machinery for tissue growth and differentiation. Signalling molecules, such as 
growth factors and biological mediators, modulate cell proliferation activity and stimulate cell 
differentiation and the production of ECM. New vascular networks promoted by angiogenic 
signals provide sufficient blood supply for the new tissue growth (Taba et al., 2005).  
 
1.3.2. Periodontal Access Flap surgery (AF) 
AF is a surgical procedure aiming at providing access to the root surface for debridement 
procedures resulting in reduction of PPD and may attain improved periodontal architecture 
(Wennstrom et al., 2003). However, the healing which occurs following AF often involves the 
down-growth of the gingival epithelium (Caton et al., 1980) which attaches to the root surface 
and often prevents the re-growth of the slower-growing PDL and AB (Ellegaard & Loe, 
1971). Due to lack of periodontal connective tissue attachment and insufficient AB at 
damaged sites the original architecture of the periodontium may not be restored which leads 
to often an unsuccessful clinical outcome. Nevertheless, AF leads to a significant reduction of 
PPD (Rosling et al., 1976) and has been widely used as a standard clinical treatment 
(Cortellini et al., 1998).  
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1.3.3. Guided Tissue Regeneration (GTR) 
GTR is aimed at restoring the original architecture of the periodontal tissue, which is not 
generally achieved by AF. It involves the placement of an occlusive barrier (resorbable or 
non-resorbable) into an intrabony defect in such a manner that apical down-growth of the 
junctional epithelium along the root surface and growth of the gingival connective tissue are 
prevented (Fig. 1.7) (Karring et al., 1993). At the same time, the occlusive barrier provides 
adequate space and time for the PDL and AB cells to repopulate the root surface and the bone 
defect, respectively. GTR was developed for the purpose that the PDL contained progenitor 
cells required for the regeneration of bone, cementum and PDL and these cells would 
selectively repopulate the wounded/damaged site that would lead to clinical improvements 
(Karring et al., 1993).  
 
  
 
 
 
 
 
                 Figure. 1.7. Guided tissue regeneration. 
 
Systematic reviews have suggested that GTR has been more consistently effective than 
AF at gaining LCAL and reducing PPD in the treatment of periodontal defects of CP patients 
(Needleman et al., 2005; Murphy & Gunsolley, 2003). However, such trials as well as 
experimental models have indicated that the extent and predictability of positive clinical 
outcomes of GTR are limited, and thus there is widespread interest in the development of new 
therapeutic strategies for promoting more effective periodontal regeneration. 
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1.3.4. PDL stem/progenitor cells 
Stem cells are defined functionally as cells that are able to give rise to at least one 
differentiated cell type throughout the lifetime of the organism as well as having the unique 
capacity to self-renew.  In contrast to the large majority of the cell population of adult tissues 
that are committed to a specific function, stem cells are uncommitted and remain as such, 
until they receive signals from the environment to generate specialized cells (Lemoli et al., 
2005).  Thus, stem cells are considered to play a key role in tissue homeostasis and the 
replenishment of cells that have died because of apoptosis, injury and disease  (Weissman et 
al., 2000). 
Adult stem cells have been isolated from various types of human and animal tissues 
including bone marrow (Jiang et al., 2002; Haynesworth et al., 1992), central nervous system 
(Johe et al., 1996), olfactory epithelium (Barnett et al., 2004), dental pulp (Gronthos et al., 
2000), epidermis of the skin (Niemann et al., 2002; Cotsarelis et al., 1990), gastrointestinal 
track (Potten et al., 1998), blood vessels (Asahara et al., 1997), skeletal muscle (Collins et al., 
2005), cornea (Chen et al., 2004), heart (Laugwitz et al., 2005), adipose tissue (Zuk et al., 
2001), lung (Wu et al., 2004) and PDL (Singhatanadgit et al., 2009).  
  
Figure 1.8. Cellular differentiation in the periodontal tissues. (photographs taken from 
http://www.scielo.br/)   
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During embryogenesis, the PDL is believed to be formed by cells residing within the 
dental follicle. These cells are considered to be derived from the ectomesenchyme, as shown 
in Fig. 1.8. The presence of putative stem cells within the adult PDL was first reported almost 
20 years ago (McCulloch et al., 1987), with an increasing number of reports since that time. 
The most compelling evidence that such cells are present in the PDL was provided by 
McCulloch (1987), who identified a small population of progenitor cells adjacent to blood 
vessels within the PDL. These cells demonstrated some typical cytological features of a stem 
cell-like population, including small size, responsiveness to stimulatory growth factors, slow 
cell cycle time, higher number of population doublings and colony forming capacity. More 
recently, several groups have confirmed that the adult PDL contains an adult stem cell-like 
population that exhibits certain characteristic features of mesenchymal stem cells, and 
expresses embryonic stem cell-associated antigenic markers such as Oct3/4, nanog and Sox-2 
(Huang et al., 2009; Singhatanadgit et al., 2009; Kawanabe et al., 2010). Whether the stem 
cells isolated from adult human PDL are comparable to bone marrow derived mesenchymal 
stem cells (BMSC) is still unclear, but it is notable that the putative stem cell marker, STRO-
1, used to isolate and purify BMSC, has been shown to be expressed by human PDL cells (Xu 
et al., 2009; Fujii et al., 2008). In contrast, other reports have suggested that this stem cell-like 
population residing in adult PDL does not express STRO-1 and may be a more primitive cell 
population that differs from BMSC (Singhatanadgit et al., 2009; Chen et al., 2006). 
Nevertheless, adult PDL stem cells share with BMSC the common expression of the 
perivascular cell marker CD146, alpha-smooth muscle actin and the pericyte-associated 
antigen 3G5 (Singhatanadgit et al, 2009), suggesting a perivascular origin for these cells as 
reported previously (McCulloch et al., 1987).  
PDL stem cell-like populations have been shown to differentiate into some of the 
mesoderm-associated lineages (i.e. osteogenic, adipogenic, chondrogenic). Seo et al., 2004 
were the first group to isolate PDL ‘stem-like’ cells using ring-cloning technique. These were 
capable of undergoing osteogenesis and form bone-like mineralized nodules in vitro and, 
moreover, when cultured under adipogenic differentiation conditions, they were also capable 
of forming lipid-like droplets, a key feature of mature adipocytes in vitro. In addition, under 
chondrogenic differentiation conditions, these cells underwent chondrogenic differentiation, 
staining positive for proteoglycans (Singhatanadgit et al., 2009, Xu et al., 2009). Thus, while 
PDL stem cells have been reported to be able to differentiate to various extents into these 
three mesenchymal lineages, the ‘non-mesenchymal’ vasculogenic, angiogenic, neurogenic 
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and gliogenic lineage-associated differentiation capability has not been studied previously, 
despite their physiological, structural and fundamental importance in the PDL. Consequently, 
although PDL cells have been reported to express a series of embryonic stem cell-associated 
markers, it is still uncertain whether the PDL contains a primitive pluripotent stem cell-like 
population. 
  
1.3.5. Mesenchymal lineage differentiation pathways 
Osteoblasts, adipocytes, chondrocytes and muscle cells are believed to be derived from 
multipotent MSC originating in the bone marrow, although alternative pathways have also 
been reported to be involved in the origin and formation of these different cell types, for 
example, pericytes, mesenchymal cells adherent to the endothelial layer of vessels, have also 
been shown to undergo osteogenesis, adipogenesis, chondrogenesis and myogenesis (Schor et 
al, 1995). PDL stem/progenitor cells have been reported to express several markers associated 
with BMSC, pericytes and embryonic stem cells, and have been shown to be capable of 
differentiating along osteogenic, adipogenic and chondrogenic (discussed in 1.3.4). Lineage-
specific pathways, as described below.  
 
1.3.5.1. Osteogenic differentiation 
Osteogenic differentiation in vitro is considered to be the process by which primitive stem 
cells progress to osteoprogenitor cells and form fully functional osteoblasts. This process 
involves three stages, with characteristic changes in gene expression during each stage (Stein 
GS et al., 1996):  
(i) proliferation stage: the genes c-fos and c-myc, transcription factors reported to be involved 
in cell division in response to growth factors/stimuli, are associated with the proliferation 
stage, while cyclin-B and –E, cell cycle regulation-associated proteins, are up-regulated post-
poliferatively (Stein GS et al., 1996); 
 
(ii) ECM production and maturation stage: differential expression of osteoblast-related genes 
occurs as osteoprogenitor cells differentiate to mature bone cells. This involves the early 
osteogenesis-associated transcription factor runt-related transcription factor (Runx2) and 
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ECM enzyme alkaline phosphatase (ALP) genes which are initially up-regulated (although 
down-regulated later as mineralization progresses), while the secretion of the ECM 
glycoprotein osteopontin (OP) followed by the expression of other matrix proteins such as 
bone sialoprotein (BSP) and osteocalcin (OC) (Aubin, 1998b) (BSP is transiently expressed at 
a very early stage and then increases again in differentiated osteoblasts, while OC is detected 
mainly during mineralization (Aubin, 1998b)). Thus, the expression of these genes that are 
closely associated with osteoblast differentiation has been widely used as osteoblast-related 
markers, for example, Runx2 and OC being early and late markers for osteoblastic 
differentiation, respectively (Aubin, 2001). 
 (iii) mineralization stage: the mineralization process involves the secretion of small, round, 
lipid bilaminar vesicles from osteoblasts at sites of initial mineralization (Manolagas, 2000; 
Anderson, 2003). The initial crystals of bone mineral are formed within these matrix vesicles, 
facilitated by the activity of ALP and calcium-binding molecules such as annexin I, which are 
concentrated at the matrix vesicle membrane. Subsequently, the pre-formed crystals are 
released through the matrix vesicle membrane and exposed to the extracellular environment 
containing sufficient calcium and phosphate ions to support continuing crystal growth, with 
the pre-formed crystals serving as ‘seed’ nuclei (Anderson, 1989; Anderson, 2003). However, 
other glycoproteins, such as OC and phosphoproteins, appear to have a regulatory role in 
preventing excessive mineralization (Anderson, 1989; Ducy et al., 1996). Histochemical 
staining methods (alizarin red and von Kossa) are widely used to detect the calcium and 
phosphate ions, respectively, present in the mineralized tissue/cells. 
   
1.3.5.2. Adipogenic differentiation 
Several reports have shown that PDL cells are capable of adipogenic differentiation (Huang et 
al., 2009; Singhatanadgit et al., 2009; Kawanabe et al., 2010; Xu et al., 2009; Fujii et al., 
2008), despite the fact that anatomically adipocytes are not detected in PDL tissue. The 
presence of adipogenic precursors may be due to the presence of a primitive mesenchymal 
stem cell-like population in the PDL, as discussed in Section 1.3.4. Such cells can be induced 
to undergo adipogenic differentiation using an ‘adipogenic cocktail’ containing hormones and 
growth factors such as insulin, DEX, IBMX, IGF-1, glucocorticoid and c-AMP (Huang et al., 
2009; Singhatanadgit et al., 2009; Kawanabe et al., 2010; Xu et al., 2009; Fujii et al., 2008).     
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 The first hallmark of the adipogenesis in vitro is a noticeable change from a spindle 
shape fibroblastic morphology to a spherical shape appearence. This morphological 
modification is accompanied by marked sequential change in the gene expression categorized 
into the early, the intermediate and the late phase (Feve et al., 2005; Ntambi et al., 2000). 
Thus, exposure of confluent PDL stem cells to the adipogenic differentiation cocktail initially 
induces expression of CCAAT/enhancer binding protein (C/EBP)-β and C/EBPδ, which then 
activate peroxisome proliferator-activated receptor-γ (PPARγ)-2 and C/EBPα. In addition to 
C/EBPs and PPARγ2, several other adipogenic transcription factors are also involved, 
including GATA-binding transcription factors GATA-2, 3, and c-AMP response element 
binding protein (CREB) which play critical roles in adipogenesis (Feve et al., 2005; Ntambi et 
al., 2000).  During the terminal phase of adipogenic differentiation, activation of the 
transcription factors leads to increased enzyme activity, for triacylglycerol synthesis and 
degradation. Expression of lipoprotein lipase (LPL) mRNA has also been shown to be up-
regulated by these transcription factors, and is then secreted by mature adipocytes, playing 
central role in controlling lipid accumulation by hydrolyzing circulating triglycerides (Preiss-
Landl et al., 2002).         
Terminally differentiated adipocytes also produce low-density lipoprotein (LDL) and 
high-density lipoprotein (HDL), which can be visualized in a form of lipid-droplets on 
differentiated adipocytes surface (Preiss-Landl et al., 2002; Murphy et al., 1999). Thus, 
elevated levels of PPARγ2 and LPL mRNA at early and late stage of adipogenic 
differentiation, respectively, and production of lipid-like droplets are frequently used as 
reliable markers of adipogenic-capabilities of precursor cells.  
 
1.3.5.3. Chondrogenic differentiation 
Although most of the vertebrate skeleton has been reported to develop from chondrogenic 
precursors via a process known as ‘endochondral ossification’ as described in 1.1.2, the 
maxilla and mandibular bone of the skeleton is considered to develop from MSC via a process 
known as ‘intramembranous ossification’, and therefore chondrogenic precursors are likely to 
be absent in periodontium including the PDL (Lee et al., 2001). However, it has been reported 
previously that the PDL contains stem/precursor cell population capable of undergoing 
chondrogenesis in vitro (Huang et al., 2009; Singhatanadgit et al., 2009; Kawanabe et al., 
2010; Xu et al., 2009; Fujii et al., 2008).  
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 Much of the current understanding concerning chondrogenic differentiation has been 
delineated using a micro mass culture system in vitro, a three-dimensional, high-density cell 
culture that is comprised of chondrogenic precursor cells characterized by the potential to 
differentiate into chondrocyte-like cells (Ahrens et al., 1977). High-seeding density 
apparently stimulates pre-cartilage cells to mimic the condensation and differentiation events 
that normally occur during embryonic hyaline cartilage formation in vivo (Ahrens et al., 
1977). Specifically, precursor cells first undergo condensation, giving rise to aggregates that 
subsequently differentiate into cartilage nodules (thus simulating the normal progression of in 
vivo chondrogenesis in which mesenchymal condensation precedes observable differentiation 
(Goldering et al., 2006)). In vitro chondrogenesis can be stimulated by addition of growth 
factors such as TGFβ, IGF-1, EGF and FGF. The sequence of gene expression during 
chondrogenesis is characterized by the expression of the transcription factor Sox-9, followed 
by collagen type II and aggrecan, similarly observed in vivo and in vitro micro mass culture 
(Goldering et al., 2006; Kulyk et al., 2000). The resulting differentiated chondrocytes secrete 
proteoglycans (PG) and glycosaminoglycans (GAG) which can be stained with Alcian blue. 
Thus, the expression of Sox-9, aggrecan, Col2a1 and secretion of PG and GAG by 
differentiating micro-mass cultures is often accepted as an indication of chondrogenic 
differentiation in vitro. 
   
1.3.6. Non-mesenchymal lineage differentiation pathways 
1.3.6.1. Vasculogenic and angiogenic differentiation 
Although the PDL contains highly developed vasculature, little is known about 
neovascularization, a process of new blood vessel formation, by PDL stem cells/precursors in 
vivo or in vitro. Neovascularization can be categorized into two general processes: (i) 
vasculogenesis, the differentiation of angioblast precursors/stem cells into endothelial cells 
(Flamme et al., 1997); and (ii) angiogenesis, the formation of new capillaries from pre-
existing vessels which occurs either by the sprouting of vascular endothelial cells into 
surrounding tissue or by intussusceptive microvascular growth (D’amore et al., 1987; Flamme 
et al., 1997).  
    Although it was previous thought that vasculogenesis occurred exclusively during 
embryonic development, it is now recognized that the more complex process of 
neovascularization involves both vasculogenesis and angiogenesis simultaneously in both 
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adult as well as developing microenvironments (D’amore et al., 1987; Flamme et al., 1997). 
In general, although the molecular regulation of vasculogenesis and angiogenesis differ, 
various vascular endothelial growth factors (VEGF-A, B, C and D) play pivotal roles in both 
of these processes (Larrivee et al., 2000; D’amore et al., 1987; Flamme et al., 1997; Ambrosi 
et al., 2005). It has been shown that VEGF receptor-1 (VEGFR-1) and VEGF receptor-2 
(VEGFR-2) knockout mice die within 8.5-9.5 days of embryonic development suggesting, 
VEGF receptors play pivotal role in vasculogenesis during embryonic development. In 
vasculogenesis, initially VEGF-A is responsible for VEGFR-2 up-regulation followed by 
VEGFR-1 stimulation. Similar to its role in vasculogenesis, VEGF-A and C are also 
responsible for the regulation of angiogenesis. However, while VEGFR-2 receptor is 
dominant during early vasculogenesis, VEGFR-1 receptor is prominent during remodeling of 
the primary vasculature and subsequent angiogenesis (Hanahan et al., 1997). Numerous 
studies have shown in vitro that these VEGFs promote migration, proliferation and tube 
formation by endothelial cells (Larrivee et al., 2000; D’amore et al., 1987; Flamme et al., 
1997).  
Unlike VEGF receptors, angiopoietin (Ang) receptors tie-1 and 2 have been shown to 
be expressed by endothelial cells only. Tie-1 and tie-2 knockout mice undergo severe vascular 
malformations and die during embryonic development (Larrivee et al., 2000; D’amore et al., 
1987; Flamme et al., 1997; Hanahan et al., 1997). Differentiated endothelial cells express von 
willebrand factor, a blood glycoprotein produced in specialized endothelial cell vesicle 
weibel-palade bodies, VE-cadherin and PE-CAM (CD31), endothelial cell junction/adhesion 
proteins (Cockerill et al., 1995; D’amore et al., 1987; Flamme et al., 1997). Expression of 
these markers along with morphological evidence of tube-like structures in vitro and in vivo is 
often used as a good indication for vasculogenesis and angiogenesis.   
     
1.3.6.2. Neurogenic differentiation 
The PDL receives dense sensory nerve innervations from both the trigeminal ganglion and 
mesencephalic trigeminal nucleus that are responsible for touch, pressure and pain sensations. 
They are regarded as an important component of the sensory system for controlling the jaw 
movement. At least two types of sensory receptors have been recognized in the PDL; (i) 
nociceptive free nerve endings; and (ii) specialized mechanoreceptive endings, also known as 
‘ruffini endings’. Moreover, previous studies have suggested that mature periodontal ruffini 
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endings regenerate rapidly following trauma or injury (Atsumi et al., 1999b; Hiroshima et al., 
1998; Youn et al., 1997), indicating that they have a high potential for neuroplasticity and 
possibly contain neural stem/precursor cells with the capacity to regenerate new nerves.  
The PDL is also known to contain myelinating and non-myelinating glial-associated 
Schwann cells known as lamellar or terminal Schwann cells, which play a crucial role during 
neural development and regeneration by guiding developing/regenerating nerve axons 
(Bhatheja et al., 2006). Schwann cells stain positive for glial markers such as S-100β and 
GFAP. Protein gene product 9.5 (PGP9.5), also known as ubiquitin carboxy-terminal 
hydrolase L1 (uclh1), abundantly found in nerve cells and is involved in protein turnover, in 
nerve cells, and used as a marker for the identification of periodontal ruffini endings in PDL 
tissue (Nandasena et al., 2007).  
It has previously been suggested that neural precursor may be present in PDL tissue 
and may be the cellular source of periodontal nerves and glial cells observed in vivo although 
PDL cells have hitherto not been reported to undergo neurogenesis or gliogenesis in vitro or 
in vivo. Well-developed differentiation systems are now available to investigate the pathways 
of neurogenesis and gliogenesis in vitro, mainly using laminin, a basal membrane protein 
which has been found in almost all the cells and tissue and involved in cell adhesion, 
proliferation and differentiation. Two major culture systems used for neurogenesis and 
gliogenesis in vitro are:  
(i) a free floating neurosphere serum-free culture in which putative neural progenitors are 
placed into non-adherent plastic culture dishes and allowed to form aggregates in the 
presence of growth factors such as bFGF and EGF. After several disaggregation and 
transfers of the cell spheres, they are dissociated and seeded on laminin-coated plates 
under neurogenic or gliogenic inductive conditions to differentiate the cells into mature 
nerves and/or glial cells (Hermann et al., 2004).  
(ii) confluent monolayer cultures of cells seeded onto laminin-coated culture dishes and the 
monolayer of adherent cells incubated until 80-90% confluency, at which neurogenic or 
gliogenic growth factors are added to differentiate the cells into mature nerve or glial 
cells (Donato et al., 2007). 
Neuronal differentiation in vitro is stimulated by the addition of β-mercaptoethanol and 
forskolin (which raises cAMP levels), all-trans-retinoic acid, brain-derived growth factor 
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(BDNF), neurotrophine-3 (NT-3), bFGF and EGF whereas, the glial differentiation pathway 
is induced by foskolin and a growth factor hereguline-β2. Morphologically neurons exhibit a 
cell with long ‘axonal’ projection and several dendritic projections with a small neuronal 
body known as a ‘soma’, whereas glial cells can be visualized as a star-shaped cell with 3-10 
dendritic projections known as ‘astrocyte’, with 20-30 dendritic projections known as 
‘oligodendrocytes’ and with 2 dendritic projections known as ‘Schwann cells’. 
Immunostaining using neuron-specific-βIII tubulin and microtubule-associated protein-2 
(MAP-2) antigens as early neural cell filament markers, and PGP9.5, neurofilament M/H/L 
and enolase as late neuronal antigens have been widely used. GFAP, oligodendrocytic-
specific O4 and S-100 markers are used for the immunodetection of glia-associated cells such 
as astrocytes, oligodendrocytes and Schwann cells, respectively (Hermann et al., 2004; 
Donato et al., 2007; Cora et al., 2009). Expression of these markers together with 
morphological evidence of neural and glial-like cells in vitro and in vivo often used as the 
evidence of neurogenic and gliogenic differentiation. 
 
1.3.7. Growth factors/biological mediators for periodontal regeneration 
A number of growth factors and biological mediators have been used as an alternative to the 
surgical treatment approach for periodontal regeneration (Lee et al., 2009; Shirakata et al., 
2010; Giannobile et al., 1996; Cornelini et al., 2003; Camelo et al., 2003; Jones et al., 2006; 
Hammarstrom, 1997; Kao et al., 2009; Brett et al., 2004; Zhao et al., 2002; Strayhorn et al., 
1999; Chien et al., 1999; Takayama et al., 1997). These include platelet-derived growth 
factors (PDGF), IGF-1, bFGF, TGF-β, bone morphogenetic proteins (BMPs), and EMP, 
which have been shown to have stimulatory effects to some extent on periodontal 
regeneration in vivo (Lee et al., 2009; Shirakata et al., 2010; Giannobile et al., 1996; Cornelini 
et al., 2003; Camelo et al., 2003; Jones et al., 2006; Hammarstrom, 1997) and variable effects 
on periodontal cell proliferation and differentiation activity in vitro (Kao et al., 2009; Brett et 
al., 2004; Zhao et al., 2002; Strayhorn et al., 1999; Chien et al., 1999; Takayama et al., 1997). 
Table 1 presents a list of growth factors and their effects on PDL cells, cementoblasts and 
osteoblasts in vitro. Table 1 with EMP having greater overall stimulatory effect on 
periodontal cells in vitro compared with the effects of other growth factors on periodontal 
cells. Moreover, EMP has been shown to stimulate PDL, cementum and AB regeneration in 
vivo, in animals and in humans, as described in 1.4.3.  
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Table 1. Effects of growth factors and EMP on PDL cells (PDL), cementoblasts and 
osteoblasts (OB) in vitro (Kao et al., 2009; Brett et al., 2004; Zhao et al., 2002; Strayhorn 
et al., 1999; Chien et al., 1999; Takayama et al., 1997) 
Growth factors Cell migration Cell proliferation Cell 
differentiation 
Matrix gene 
expression 
Cell types PDL CM OB PDL CM OB PDL CM OB PDL CM OB 
PDGF ++ ? ++ +++ +++ +++ - - - ++ 0 + 
IGF-1 ++ ? ++ + ++ + - ? + + +/- ++ 
FGF-2 +++ ? 0 +++ ? +++ - ? - +/- ? +/- 
TGF-β + ? ++ ++ ++ ++ + - +/- ++ +/- ++ 
BMPs ? ? ++ 0 - + ? + +++ ? ++ ++ 
EMP +++ ? ++ +++ +++ +++ + + + + +++ +++ 
(-) Inhibitory effect, (0) no effect, (+) mild stimulatory effect, (++) modest stimulatory 
effect, (+++) strong stimulatory effect, (?) unknown effect 
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1.4. Enamel Matrix Proteins (EMP) 
1.4.1. Secretion of EMP 
Enamel, a unique and highly mineralized ectodermal tissue covering vertebrate teeth, is 
synthesized and secreted by specialized cells called ameloblasts. During the process of 
enamel development ameloblasts secrete EMP that binds to hydroxyapatite to structure the 
enamel and to modulate crystal growth (Deutsch et al., 1995; ten Cate et al., 1996; Heritier et 
al., 1982; ten Cate et al., 1996). The secretion of EMP can be observed during three distinct 
stages of enamel formation: (i) the pre-secretory stage (ten Cate et al., 1996); (ii) the secretory 
stage (also called forming stage) (Heritier et al., 1982); and (iii) the maturing stage (also 
called the secondary mineralization stage). Although the major biosynthesis and secretion of 
EMP has been reported to take place in the secretory stage, the full-length amelogenin and its 
splicing forms (e.g., LRAP), major protein components of EMP, are also secreted in the early 
pre-secretory and late maturation stages (Deutsch et al., 1995). In addition to EMP, growth 
factors such as BMP and TGFβ have also been shown to be secreted during enamel 
development (Deutsch et al., 1995; Ten cate et al., 1996; Heritier et al., 1982; ten Cate et al., 
1996). Within hours after secretion, progressive proteolytic clipping of amelogenin peptides 
has been shown to give rise to breakdown products of amelogenin (including TRAP), and 
secreted EMP components have also been shown to be gradually degraded by enzymatic 
digestion (Deutsch et al., 1995; Deutsch, 1989), suggesting that the secretion of EMP 
components varies between different stages of enamel development.  
EMP secreted by ameloblasts has been shown to play a crucial role in enamel 
formation and biomineralization (Deutsch et al., 1995). Other findings indicate that EMP also 
has a function other than enamel development, such as in dentine root formation 
(Hammarstrom et al., 1997a; Heijil et al., 1996). The involvement of EMP in root cementum 
formation was first proposed by Slavkin (1974), who suggested that Hertwig epithelial root 
sheath (HERS) cells produce a basement membrane containing EMP that directs the induction 
of cementoblast differentiation from dental follicle cells (Slavkin, 1974). Several hypotheses 
explaining the role of EMP in root cementum formation have been proposed: (i) it is involved 
in the attachment of root dentine; (ii) it initiates cementogenesis; (iii) it serves as an inducer 
of dental follicle cell differentiation into cementoblasts (Slavkin, 1974). EMP may also have a 
significant role in periodontal development and regeneration, for example, Hammarstrom 
(1997a) demonstrated that porcine EMP placed in experimental cavities created in monkeys 
by extracting incisors induced the formation of a tissue identical to acellular, extrinsic fibre 
Chapter 1                                                                                                    General Introduction 
  43 
cementum (Hammarstrom et al, 1997a). Thus, treatment with extracted crude EMP was found 
to result in 60-80% formation of new cementum and bone in such surgically produced 
periodontal defects (Hammarstrom et al., 1997a).  
 The major EMP components secreted by ameloblasts, have been partly identified and 
characterized, and comprise the hydrophobic amelogenins, sheathlins, the acidic tuftelin, a 
high molecular weight enamelin and various isoforms of these proteins. However, as 
described above, the content of  EMP  varies between different stages of enamel development 
and it is therefore likely that there are also variations between different EMP preparations. A 
commercial product derived from EMP, called Enamel Matrix Derivatives (EMD; 
Emdogain®) and designated as FDA approved ‘material’ for periodontal regeneration since 
1997, has been obtained via a rigidly controlled industrial process of purification and heat-
treatment of an acidic extract of developing enamel from six-month-old piglets. In this thesis, 
EMP designation refers to the relatively crude and non-heat-treated mixture of proteins that 
are obtained from developing porcine enamel, whereas EMD designation refers to the 
commercially prepared heat-treated lyophilized proteins isolated from porcine enamel during 
a specific stage of development. 
 
1.4.2. Composition of EMP 
The major components of EMP are amelogenins, a family of hydrophobic proteins that 
accounts for more than 90% of the organic matter of the enamel matrix (Brookes et al., 1995). 
The amelogenins have been remarkably conserved through evolution, suggesting that they 
may be of critical biological importance (Brookes et al., 1995). Other abundant ‘non-
amelogenin’ components in EMP include enamelins (Brookes et al., 1995), tuftelin (Deutsch 
et al., 1991) and sheathlin proteins (Hu et al., 1997). As shown in Fig. 1.9, these four matrix 
proteins, amelogenins (Hu et al., 1996), enamelins (Hu et al., 1997b), tuftelin (Deutsch et al., 
1991) and sheathlins (also called ameloblastin or amelin) (Hu et al., 1997a), and also 2 
enzymes matrix metalloproteinase (MMP)-20 and enamel matrix serine proteinase (EMSP)-1 
(Fukae et al., 1987), are present in EMP.  
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 Figure 1.9. 
Composition of EMP 
Investigation of possible growth factors in EMP concluded that they were not present in such 
preparations (Gestrelius et al, 1997b), but other studies indicated the presence of low levels of 
TGF-β1 and BMP-2 (Kawase et al., 2001; Iwata et al., 2002). These growth factors have been 
shown to be secreted along with EMP during enamel developmental process (Deutsch et al., 
1995; ten Cate et al., 1996; Heritier et al., 1982; ten Cate et al., 1996) and, as noted above, 
their can also vary between different stages of enamel development and thus differ between 
preparations. However, because of this, since 2005 the commercially available preparation 
EMD, which is heat-treated and  unlikely to have any enzyme or growth factor activity, has 
been widely used.     
 
1.4.2.1. Amelogenins 
Amelogenin is a major protein component of EMD, accounting for approximately 90% of the 
protein secreted by ameloblasts (Gestrelius et al., 2000). It is a hydrophobic protein, rich in 
proline, glutamine, leucine and histidine and exhibiting a very high degree of sequence 
homology (>80%) among the higher vertebrates examined (Fincham et al., 2000). The 
multiple amelogenin peptides present in EMD are the products of alternative splicing of the 
amelogenin gene and also of proteolytic processing of the parent proteins, as shown in Fig. 
1.10. Although the primary transcript of the amelogenin gene is highly conserved between 
species, the alternative splicing forms vary in number and structure between species. For 
example, 5 different splicing variants of amelogenin have been identified in human, whereas 
in the mouse there are at least 14 different splicing isoforms. In pig, 4 different splicing forms 
Chapter 1                                                                                                    General Introduction 
  45 
of amelogenins have been identified, each translated into the 4 corresponding amelogenin 
peptide isoforms (27, 25, 18 and 6.5 kDa), as shown in Fig. 1.10. The smallest splicing 
variant is a 6.5 kDa (56-amino acid) leucine-rich amelogenin peptide (LRAP) containing the 
N-terminal (33 amino acids) and C-terminal (23 amino acids) sequences of the full-length 
amelogenin (tan Cate et al. 1996; Fincham et al., 1994).  
 The 25 kDa splicing variant of amelogenin is the main source of the majority of the 
proteolytic products of amelogenin. It is converted either to the 20 kDa amelogenin, which is 
the most abundant amelogenin in secretory porcine enamel and in EMD, and to the 23 kDa 
amelogenin. It has been shown that the 20 kDa amelogenin is further processed 
proteolytically to 5.3 and 5.1 kDa tyrosine rich amelogenin peptides (TRAP) (Fincham et al., 
1994). 
Figure 1.10. A schematic diagram of extracellular porcine amelogenin mRNA splicing and 
proteolytic processing. Numbers in gray boxes represent exons.   
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The N-terminal of TRAP has been shown to be identical to the N-terminal of the 20 kDa 
amelogenin. Other pathways of proteolytic degradation of the 18 kDa splicing variant also 
produce a 5 kDa TRAP as well as additional uncharacterized proteins. All these different 
forms of amelogenins shown in Fig. 1.10 have been reported to be present in EMD (Fincham 
et al., 1994), although their precise functions are not yet known.  
 
1.4.2.2. Non-amelogenins 
Enamelin is the largest enamel protein and is concentrated along the secretory face of the 
ameloblasts. Following secretion by ameloblasts, it is processed to other low-molecular 
weight proteins associated with progressive enamel mineralization, and is also believed to 
have a role in enamel biomineralization (Brookes et al., 1995). 
Tuftelin is an anionic non-amelogenin enamel protein first fully characterized by Deutsch et 
al., 1991. It is expressed as early as the bud stage of tooth development and may be involved 
in crystal formation of the tooth and also in ameloblast differentiation and/or extracellular 
matrix secretion (Paine et al., 2000). 
Sheathlin (also known as ameloblastin and amelin) represents 5% of the non-amelogenin 
mRNA and has a domain homologous with the α2β1 integrin recognition site present in 
collagen type I (Cerny et al., 1996). It is localized in ameloblasts and in the sheath space in 
enamel, and may have a role in enamel biomineralization. The sheathlin gene is localized in 
the region where the autosomal dominant Amelogenesis Imperfecta gene has been identified 
(Forsman et al., 1994), again suggesting that this protein is important for enamel formation.  
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1.4.3. Role of EMD in periodontal regeneration 
1.4.3.1. In vivo studies 
The regeneration of acellular cementum was first demonstrated in monkeys, in which 
attachment to dentin was observed after 8 weeks of treatment with crude porcine EMP 
(Hammarstrom et al, 1997a), whereas healing of the control sites that were not treated with 
EMP were reported to be uneven with a thick layer of a cellular, hard tissue that was poorly 
attached to the denuded dentin (Hammarstrom et al., 1997a). Another study of buccal 
dehiscence defects in monkeys reported 60-80% regeneration of the cementum after 
application of whole EMP or an acid extract of EMP (both crude non-commercial 
preparations) to the denuded root surface (Hammarstrom et al., 1997b). However, compared 
with cementum regeneration, the extent of new bone formation in this study was much less 
(Hammarstrom et al., 1997b). These studies thus suggested that although crude EMP could be 
a useful mediator for cementum regeneration, the bone regenerative activity of this material 
was uncertain.  
Several animal studies have been performed to compare histological outcomes following 
flap surgery with and without EMD treatment. ‘Critical-size fenestration’, ‘infrabony’ and 
‘furcation recession’ were produced surgically in the AB of monkeys, and then treated for 5 
months with flap + EMD or a coronally repositioned flap as a control (Donos et al., 2003; 
Sculean et al., 2000a; Sculean et al., 2000b; Araujo et al., 1996; Gkranias et al., 2010). The 
results demonstrated that one out of three EMD-treated defects exhibited complete closure 
with regenerated bone while the defects in the other two animals showed only partial closure, 
but all three animals treated with EMD exhibited fully regenerated PDL and cementum with 
inserting PDL fibres. In the control specimens in which the defect was not treated with EMD, 
the defect was found to be remained open with very little if any PDL, cementum and bone 
regeneration, indicating that EMD may have had stimulatory effects on PDL and cementum 
regeneration, but again bone regeneration in the presence of EMD was inconsistent in this 
animal model.     
The osteoinductive activity of EMD has been examined using an immune-deficient 
(nude) mice in a heterotopic (outside the skeletal tissue) bone formation model (Boyan et al., 
2000; Kawana et al., 2001). Although no bone formation was observed when EMD alone 
(used at a significantly higher concentration (4 mg) than the recommended concentration for 
clinical use (300 µg)) was implanted into muscle, when the same amount of EMD was 
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implanted together with osteoinductive demineralised freeze-dried bone allograft (DFDBA), 
enhanced bone stimulation was observed compared with the osteoinductive DFDBA alone. 
These results thus indicated that high concentrations of EMD might increase the 
osteoinductive properties of the bone graft material. In contrast, a study evaluating the 
osteoinductive properties of EMD and deproteinized bovine bone mineral (DBBM) in the 
muscle of rats reported that EMD alone, DBBM alone or both combined did not stimulate 
bone (Donos et al., 2006). The lack of osteogenic potential of EMD has also been 
demonstrated in two established models of bone regeneration; the ‘dome’ model in the 
mandibular ramus of rat and the critical-size calvarial defect (Donos et al., 2004; Donos et al., 
2005), again indicating the inconsistent effects of EMD on bone regeneration, possibly due to 
varying experimental conditions including different animal models/defects, varying age and 
healing conditions.  
In humans, using a mandibular incisor extracted for orthodontic reasons, a buccal 
dehiscence defect was created and treated with EMD (Heijl et al., 1997). After 4 months of 
healing, the results showed formation of new acellular cementum, new PDL with inserting 
and functionally oriented collagen fibres, and associated AB covering the area of the defect 
(Heijl et al., 1997). In contrast, another study observed that only 2 out of 7 intrabony defects 
treated with EMD developed fully regenerated PDL, cementum and AB, whereas the other 5 
defects were characterized by insufficient bone regeneration (Sculean et al., 1999). Similarly, 
another clinical study observed that only 3 out of 10 intrabony defects exhibited full 
periodontal regeneration (PDL, cementum and AB) (Yukna and Mellonig, 2000). A number 
of clinical studies carried out to evaluate the effects of EMD on periodontal soft tissue wound 
healing also showed discrepancies Wennstrom et al., 2002; Hagennars et al., 2004). For 
example, periodontal wounds treated topically with EMD exhibited rapid and complete 
healing and PDL regeneration, compared with the control sites that were not treated with 
EMD which exhibited only partial healing and PDL regeneration (Wennstrom et al., 2002). In 
contrast, it was shown that a test patient group treated with EMD exhibited only partial PDL 
regeneration, similar to the control group that did not receive EMD (Hagennars et al., 2004). 
The reason for these discrepancies is not yet clear, but it may partly be due to varying 
experimental conditions, including age of patients, severity of periodontal and other systemic 
diseases (e.g., diabetes), life style (i.e., eating habits, smoking) and oral hygiene/removal of 
bacterial plaque prior to regenerative procedures.  
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In summary, in the presence of EMD ‘true’ periodontal regeneration, which includes 
PDL, attachment of acellular cementum and AB regeneration, is not yet predictable and 
reproducible. In addition, the establishment of new BV and the formation of proprioceptive 
sensory nerve innervations are also key features of ‘true’ periodontal healing/regeneration 
(Imai et al., 2003), but the effects of EMD on regeneration of BV and nerves during 
periodontal regeneration have not hitherto been investigated in vivo or in vitro. 
 
1.4.3.2. In vitro studies 
A number of investigations have been carried out to clarify the effects of EMD on periodontal 
regeneration (Schwartz et al., 2000; Tokiyasu et al., 2000; Jiang et al., 2001; Ohyama et al., 
2002; Yoneda et al., 2003), using several different types of cell in vitro. For example, 
Schwartz (2000) showed that EMD induced proliferation and stimulated the osteogenic 
markers OC and ALP in a normal human osteoblast cell line although in the same study it was 
also observed that EMD induced proliferation but suppressed OC and ALP expression of a 
pre-osteoblast cell line 2T9 (Schwartz et al., 2000). Moreover, it was also shown that EMD 
suppressed proliferation but induced OC and ALP expression by the osteosarcoma cell line 
MG63 (Schwartz et al., 2000), whereas EMD suppressed OC gene expression and 
mineralization by the osteoblast and cementoblast cell lines OCT-1 and MC3T3 Tokiyasu 
(2000). In addition,  EMD enhanced the proliferation of primary osteoblasts but stimulated 
the bone resorption markers IL-6 and prostaglandin G/H synthase 2, while failing to stimulate 
OC gene expression (Jiang et al., 2001). The studies noted above clearly indicate 
discrepancies in the effects of EMD on osteogenic differentiation in vitro, possibly because of 
the use of different cell types, varying culture conditions and varying length of incubation 
time.        
Similarly, in studies of other lineages, Ohyama (2002) showed that the osteogenic and 
chondrogenic markers (ALP, OC, Col X) of a pluripotent mesenchymal cell line C2C12 were 
stimulated by EMD, whereas EMD suppressed the myogenic markers (myoD1 and desmin), 
indicating that at least some components in EMD were capable of differentially regulating 
these pathways in C2C12 cells. In contrast, Dean (2002) showed that although EMD 
increased proliferation of pre-mature chondrocytes, it inhibited chondrogenic differentiation 
as measured by ALP activity and had no measurable effects of collagen synthesis, 
proteoglycan secretion and TGF-β production. Another study using pre-chondrocytes also 
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concluded that EMD up-regulated proliferation but failed to increase ALP activity and PGE2 
production (Yoneda et al., 2003), again indicating discrepancies in the effects of EMD on 
chondrogenesis.   
Several studies using PDL cells to investigate the effects of EMD on osteogenesis found 
that it stimulated ALP activity and bone-like nodule formation under growth as well as 
differentiation conditions (Gestrelius et al., 1997; Van der Pauw et al. 2000). Similarly, in a 
study by Nagano (2004), expression of ALP mRNA and ALP activity were dose-dependently 
increased when PDL cells were treated with EMD under growth conditions. In contrast, 
Cattaneo (2003) observed the lack of ALP activity stimulation in human PDL cells cultured 
on EMD-coated tissue culture dishes. Hakki et al., (2001) showed that EMD suppressed OC 
gene expression and blocked mineralization of murine dental follicle cells under 
differentiation conditions in vitro. Thus, in some cases EMD appeared to stimulate osteogenic 
marker genes and terminal osteogenic differentiation, indicating the possible presence of 
osteoinductive component(s) in EMD. However, other contradictory results have 
demonstrated the lack of consistency between studies of the effects of EMD on osteogenic 
differentiation, possibly due to differences in cell type and varying experimental conditions 
(eg, treatment with EMD on cell monolayers, culture of cells on EMD-coated tissue culture 
dishes and differences in culture media).  
Because of the discrepancies observed on the responses of PDL and other bone-forming 
cells in vitro, several attempts have been made to fractionate freshly isolated porcine EMP in 
order to evaluate the specific component which could have osteoinductive activity. Iwata 
(2002) fractionated EMP from developing porcine teeth and reported the osteoinductive 
fraction contained mainly 20 kDa proteins. This fraction enhanced ALP activity and 
mineralized nodule formation and up-regulated OC, BSP and ALP gene expression in the 
mouse bone marrow stromal cell line ST2. However, the methodology used in this study 
could not exclude the possibility that the osteoinductive fraction might contain additional 
low-molecular weight amelogenins and other proteins. In addition, crude extracts of EMP 
derived from developing pigs are known to contain growth factors such as BMPs and TGF-β, 
which may have also contributed to the osteoinductive effects observed in this report (Iwata et 
al., 2002). Nagano (2006) used crude EMP fractions to look at osteogenic differentiation by 
ST2 cells and concluded that the crude EMP contained TGF-β1, again demonstrating the 
importance of using more purified EMP components to examine biological activity. There is 
therefore a need for less heterogeneous and more consistent preparations of EMP, such as 
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EMD, in order to understand the mechanism(s) by which specific components influence PDL 
cell differentiation in vitro and may lead to successful regeneration of damaged periodontal 
soft and hard tissue, BV and nerves in vivo.  
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1.5. Interaction between EMD and target PDL cells  
Endocytosis is the main mechanism whereby macromolecules are internalized into 
mammalian cells and targeted to specific intracellular vesicles, ultimately to lysosomes where 
they are usually degraded (Mukherjee et al., 1997). The process is generally initiated by the 
binding of an exogenous ligand, which can include morphogens, growth factors, cytokines, 
lipids, some pathogenic bacteria and certain viruses, to transmembrane receptors (Mukherjee 
et al., 1997). The ligand-receptor complex is then internalized via one of three distinct 
pathways, involving: (i) clatherin-coated vesicles; (ii) caveolae-coated vesicles; (iii) clatherin- 
and caveolae-independent vesicles. Clatherin-mediated endocytosis occurs via clatherin-
coated pits, 150 nm invaginated structures on the plasma membrane in which the 
transmembrane receptors are concentrated and which can occupy as much as 2-4% of the 
surface of cells such as fibroblasts (Mukherjee et al., 1997; Conner and Schmid, 2003). 
Ligand-receptor complexes become located within the clatherin-coated pits which then pinch-
off to form clatherin-coated vesicles, subsequently transporting the complex inside the cell to 
specific intracellular compartments (Fig. 1.11) (Mukherjee et al., 1997; Conner and Schmid, 
2003). 
In certain types of cell including endothelial cells, adipocytes, smooth muscle cells 
and fibroblasts, macromolecule internalization can also occur via caveolae-mediated 
endocytosis. This involves the invagination of caveoli protein-rich plasma membrane vesicles 
50-100 nm in diameter, in which ligand-receptor complexes are also concentrated (Anderson, 
1998). Macromolecules such as albumin, certain signalling molecules (e.g. the 
glycophosphatidylinositol (GPI)-linked protein CD59) and simian virus-40 are known to be 
internalized via this caveolae-dependent endocytic pathway (Anderson, 1998). Although it 
has been suggested that macromolecules internalized via caveolae-mediated endocytosis may 
have a different intracellular fate compared with clatherin-mediated endocytosis, the exact 
intracellular trafficking events and their physiological relevance are not yet clear. Another 
mechanism of internalization, involving neither clatherin nor caveolae endocytosis, is also not 
well characterized (Conner and Schmid, 2003), but is considered to be involved in uptake of 
some glycosphingolipids and bacterial toxins such as cholera and shiga (Conner and Schmid, 
2003; Anderson, 1998).  
Endocytosis via clatherin-coated vesicles has been the most widely studied process of 
ligand internalization. Soon after the clatherin-coated vesicles pinch-off from the plasma 
membrane, the clatherin coats begin to disassemble and the vesicles fuse with ‘early 
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endosomes’, a membrane-bound intracellular compartment identified by the early endosome 
antigen-1 (EEA-1) and Rab5 protein (Mukherjee et al., 1997; Conner and Schmid, 2003) (Fig. 
1.7). These early endosomes may be transported back directly to the plasma membrane (direct 
recycling) or transported via ‘recycling endosomes’ to the perinuclear trans-Golgi network 
(TGN), identified by the antigen markers TGN38 and 58K (Mukherjee et al., 1997; Conner 
and Schmid, 2003).  
 
Figure 1.11. Illustration of macromolecule internalization via clatherin-mediated endocytosis 
followed by intracellular trafficking. 
Early endosomes may also fuse into ‘multivesiclular bodies’ which then become ‘late 
endosomes’ having an intra-luminal membrane system. Both late endosomes and TGN 
components can be transported to the lysosomes, a membrane-bound cellular compartment 
containing nucleases, proteases and glycohydrolases which bring about macromolecular 
degradation. These organelles are often defined by their surface lysosomal-associated 
membrane proteins (LAMP) (Mukherjee et al., 1997; Conner and Schmid, 2003). Notably, 
most of the types of intracellular target vesicle, particularly the lysosomes, have an acidic pH 
that facilitates the dissociation of the receptor-ligand complexes which are then either 
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degraded or re-cycled back to the plasma membrane (e.g. LDL receptor, G protein-coupled 
receptor). A number of proteins, including ubiquitin molecules and small regulatory SMURF 
proteins bind to the macromolecules and direct their trafficking for lysosomal destruction 
(Mukherjee et al., 1997; Conner and Schmid, 2003). 
Several reports suggest that at least some components present in EMD may be 
internalized into cells by receptor-mediated endocytosis. For example, Resland et al., (2006) 
reported that EMD was internalized into osteoblasts via clathrin-coated pits, observed by co-
labelling the cells with anti-EMD and anti-AP-2, a clathrin adaptor protein which is 
responsible for linking the ligand-receptor complex (cargo) into the clathrin-coated pits 
intracellularly. However, in this study the binding of EMD to the cell membrane and 
intracellular transport and fate of EMD were not examined (Reseland et al., 2006). Moreover, 
EMD is a complex mixture of various proteins including amelogenin, sheathlins and enamelin 
(Brookes et al., 1995; Hu et al., 1997). Thus, the specificity of antibody raised against EMD 
and the specific component(s) internalized into the osteoblasts remain unclear in this report 
(Reseland et al., 2006). In addition, mouse full-length amelogenin and a spliced form, LRAP, 
both major components of EMP (Section 1.4.2), have been shown to be internalized and 
transported to epithelial cell lysosomes (Xu et al., 2008), most probably by the same 
clatherin-coated endocytosis. This process is crucial in cell differentiation and development as 
it modulates the level of surface signalling receptors and thereby the response to extracellular 
stimuli e.g. growth factors, cytokines, morphogens. However, at present only a little 
information is available about the interaction of commercially prepared heat-treated 
EMD/Emdogain® components with PDL cells, and, it also remains unclear how many and 
which type(s) of cell in the heterogeneous PDL population expresses receptor(s) capable of 
binding and internalization of EMD components. 
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1.6. Statement of problem 
The precise effects of EMD and the components of EMD on the differentiation of PDL cells 
in vitro and PDL regeneration in vivo are still uncertain partly because: 
(i) previous studies of PDL cell differentiation have been limited mainly to mesenchymal 
lineages (osteogenic, adipogenic and chondrogenic), while the capacity to undergo 
vasculogenic, angiogenic, neurogenic and gliogenic differentiation in vitro, the 
corresponding tissues being key features of PDL regeneration in vivo, have not been 
investigated in vitro; 
(ii) there are many discrepancies and uncertainties about the effects of EMD and EMD 
components on bone forming cells in vitro and bone regeneration in vivo; 
(iii) it is still unknown which specific EMD components may be active in regulating PDL 
differentiation into multiple pathways in vitro and modulating periodontal 
regeneration in vivo. 
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1.7. Hypothesis of study 
It has previously been reported that the adult PDL may contain a stem cell-like population 
that functions as a precursor for periodontal tissue regeneration (Huang et al., 2009; 
Singhatanadgit et al., 2009; Menicanin et al., 2010; Kawanabe et al., 2010), although the 
precise characterization of these cells and their ability to differentiate into multiple lineages is 
not yet known. In addition, although the commercial product Emdogain® (EMD; Institut 
Straumann AG), derived from EMP of developing pig teeth, has been used extensively to help 
re-build new periodontal tissue which supports the tooth, the effects of EMD on bone 
regeneration have been inconclusive, possibly because EMD comprises a complex mixture of 
proteins that are likely to have many diverse activities on the heterogeneous cells present in 
the PDL. However, EMD has recently been separated into two main fractions (See section 
1.4.3.2) (Mumulidu et al., 2007):  
(i) Fraction C, comprising proteins < 6 kDa and containing mainly the 43 and 45-amino 
acid tyrosine-rich peptide (TRAP), derived from proteolytic clipping of amelogenin; 
and 
(ii) Fraction A comprising EMD proteins > 6 KDa and containing the full-length 
amelogenin (18 kDa), sheathlin proteins (approximately 13-17 KDa) involved in 
formation of cementum (Kanazashi et al, 2006) and a 56-amino acid leucine-rich 
peptide (LRAP), a splicing form of amelogenin.  
 
The hypotheses of the present study are:  
(1) the heterogeneous PDL population contains precursor/progenitor/stem-like cells that have 
the capacity to differentiate into mature bone cells and possibly also a range of other 
mesenchymal and also non-mesenchymal lineages;  
(2) EMD Fraction C and Fraction A and their components can differentially modulate these 
PDL differentiation pathways in vitro; 
(3) amelogenin and amelogenin isoforms of EMD may exert their effects by direct cellular 
interaction with the PDL cell membrane followed by internalization and intracellular 
transport. 
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1.8. Aim of study 
The present study was carried out to test: 
1. the ability of adult PDL cells to undergo mesenchymal (osteogenic, adipogenic and 
chondrogenic) and non-mesenchymal (vasculogenic, angiogenic, neurogenic and 
gliogenic) differentiation in vitro; 
2. the effects of EMD and the EMD Fractions on mesenchymal and non-mesenchymal 
differentiation of PDL cells in vitro;  
3. the binding and intracellular fate of the EMD components in PDL cells.  
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Chapter 2 
 
2.1. Isolation and maintenance of primary human PDL cells 
2.1.1. Collection of PDL samples 
Human PDL was obtained from the middle third of the root surface from patients undergoing 
routine extractions of third molar teeth at the Eastman Dental Hospital. The participants 
signed informed consent, in accordance with the protocol approved by the Joint Research and 
Ethics Committee of the Eastman Dental Institute and Hospital. The PDL tissue was 
immediately placed in low glucose-Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco 
Life Technologies Ltd, Paisley, UK) containing 10% heat-inactivated foetal calf serum (FCS) 
(PAA Laboratories, Somerset, UK) (10% FCS-DMEM) supplemented with 200 U/ml 
penicillin, 200 µg/ml streptomycin, 2 mM L-glutamine and 25 µg/ml amphotericin B (all from 
Gibco). 
 
2.1.2. Isolation of cells by enzymatic digestion of the PDL tissue 
The tissue was cut into approximately 1-3 mm3 pieces and incubated for 45 min at 37oC in a 
humidified atmosphere of 5% CO2 in air with a digestion medium of low glucose-DMEM, 3 
mg/ml Collagenase type I  (Sigma Chemical Co., Poole, UK), 4 mg/ml Dispase (Sigma), 2.5 
µg/ml amphotericin B (Gibco) and 100 µg/ml streptomycin (Gibco). The suspension was 
rigorously pipetted to free any attached cells and to obtain a single cell suspension. The cells 
were centrifuged at 400 x g for 5 min and incubated in 6-well tissue culture plate (Nunc; 
Fisher Scientific, Loughborough, UK) in 3 ml of growth medium (GM), consisting of low 
glucose-DMEM, 2 mM L-glutamine (Gibco), 10% Fetal Calf Serum (FCS) (PAA 
laboratories), 100 U/ml penicillin (Gibco), 100 µg/ml streptomycin and 1% fungizone 
(Gibco), and cultured until the adherent PDL cells reached confluence. 
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2.1.3. Passage of cells 
Once the cells became confluent, the medium was aspirated and the cells washed twice with 
PBS. The cells were then treated with trypsin-ethylenediaminetetraacetic acid (EDTA) 
(0.25% trypsin, 1 mM EDTA) (Gibco) for 5 min at 37oC, followed by gentle shaking. GM 
was then added to neutralize the trypsin, the detached cells were collected in a Falcon tube 
and centrifuged at 1000 rpm for 5 min. The supernatant was discarded, the cell pellet re-
suspended in culture medium and re-cultured in tissue culture flasks at a density of 10,000 
cells/cm2. The ‘first passage’ cultures were allowed to grow until they become semi-
confluent, after which the cells were cryopreserved, as described in 2.1.5.  
 
2.1.4. Cryopreservation and recovery of cells 
Aliquots of the cells were cryopreserved at an early passage as a seed stock. After 
trypsinizing the cells, the cell pellets were re-suspended in a ‘freezing medium’ consisting of 
GM supplemented with 10% dimethyl sulfoxide (DMSO) (Sigma). Aliquots containing 
approximately 2 x 105 cells were placed into cryotubes in a pre-freezing container (Marathon, 
London, UK) at -70oC for 24 h, before transferring to liquid nitrogen for long-term storage. 
To recover the cells, the cryotubes were placed in a water bath at 37oC and the thawed cell 
suspension rapidly added to pre-warmed GM in a sterile Falcon tube, centrifuged at 100 rpm 
for 5 min and cultured in 75 cm2 tissue culture flasks as described above. In this study, three 
separate PDL cell populations from three different healthy donors (all male, aged between 18 
to 25) were pooled together and used between passages 3 and 6. PDL cell population over 
passage 6 was not used in this study in order to avoid any complications resulting from 
possible senescence and also reduction in multi-lineage differentiation potential. In addition, 
heterogeneous population (but not selected/isolated homogeneous cells) of PDL cells (pooled 
from 3 separate patients) was used in order to examine overall response of EMD and the 
EMD Fractions on range of different lineage-specific precursor/progenitor/stem cells within 
heterogeneous PDL population.    
2.1.5. Cell viability 
The cultured cells were examined by phase-contrast light microscopy to assess the 
morphological status of the cells and any possible microbial contamination. The viability of 
the cells was determined at the time of each passage by trypan blue exclusion. Briefly, the cell 
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pellet obtained after trypsinization was re-suspended in PBS and 10 µl mixed with an equal 
volume of 1% trypan blue (Sigma) for 5 min. The number of cells in 10 µl of this mixture was 
counted under the phase-contrast light microscope, using a haemocytometer (Sigma). Viable 
cells appeared bright and colourless, whereas dead cells were dark blue.  
 
2.1.6. Other cell types 
Primary human AB cells were grown from cortico-lamellar bone of the maxilla of patients 
undergoing routine extractions at the Eastman Dental Hospital, as previously described 
(Singhatanadgit et al., 2008). Briefly, the bone chips were cut into approximately 1-2 mm3 
pieces, placed in 48-well plates and incubated at 37°C in a humidified atmosphere of 5% CO2 
in air for 15 min to enable them to adhere to the culture plates. Low glucose- Dulbecco’s 
Modified Eagle’s Medium (Low glucose-DMEM) (Gibco) containing 10% FCS (PAA 
Laboratories) supplemented with 200 U/ml penicillin, 200 µg/ml streptomycin, and 2 mM L-
glutamine (all from Gibco) was then added and the explants were cultured until the outgrowth 
of the adherent cells reached confluence.   
 In addition to the PDL and AB cells, bone marrow-derived mesenchymal stem cells 
(BMSC) (Lonza, Slough, UK) and a recently isolated ‘clonogenic’ cell population from adult 
human PDL which was shown to exhibit characteristic features of a bone progenitor/stem cell 
(clone 7) (Singhatanadgit et al., 2009), were also used in the present study in order to examine 
the effects of EMD components on a range of bone-forming cells. AB, BMSC and clone 7 
were cultured in the same way as the PDL cells, described above, and used between passage 3 
and 6. Human umbilical vein endothelial cells (HUVEC) were also used for testing the effects 
of EMD components on angiogenesis. HUVEC (Lonza) were used between passage 3 and 6 
and cultured using endothelial basal medium-2 (EBM-2) (Lonza) in the same way as the PDL 
cells, described above.  
 
2.2. Semi-quantitative Reverse-Transcription polymerase chain reaction (RT-
PCR)  
Although a number of procedures exist for measuring specific mRNA transcripts in a sample 
of total cellular RNA (eg, Northern blot analysis, in situ hybridization), the reverse-
transcription polymerase chain reaction (RT-PCR) is one of the most sensitive and rapid 
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techniques currently available, being able to assess mRNA levels in samples as small as a 
single cell (Liu et al., 2004). In the present study semi-quantitative RT-PCR was used to study 
the regulation of lineage-associated genes of PDL cells when the cells were cultured under 
non-selective growth conditions and lineage-specific differentiation medium. Semi-
quantitative RT-PCR was also used here to investigate the effects of EMD and the EMD 
Fractions on genes associated with several different lineages in order to determine whether 
these proteins modulate differentiation pathways of PDL cells cultured under selective 
differentiation conditions.  
Total RNA was extracted from the cells using RNeasy® Mini Kit (Qiagen, West Sussex, 
UK), in accordance with the manufacturer’s instructions. Briefly, 350 µl of buffer RLT with 
β-mercaptoethanol (10 µl in 1 ml of RLT buffer) was added on the cell monolayer to get the 
cell lysate. The samples were then homogenized by vigorous pipetting for 1 min. Then, 350 µl 
of 70% ethanol was added to the homogenized cell lysate, after which total of 700 µl of the 
sample, including any precipitate that may have formed, were transferred to an RNeasy mini-
column placed in a 2 ml collection tube and centrifuged for 15 s at 10000 rpm. The sample 
was then washed with 700 µl of buffer RW1 and the column was centrifuged for 15 s at 
10000 rpm. The sample was washed twice with 500 µl of buffer RPE and the column 
centrifuged for 2 min at 10000 rpm. Following centrifuge, the column was transferred to a 
new 2 ml collection tube and centrifuged for another 1 min. To elute the RNA sample, the 
column was then transferred to a new 1.5 ml collection tube, 25 µl of RNase-free water was 
added directly and the column centrifuged for 1 min at 10000 rpm. The elution step was 
performed twice and the total volume of 50 µl of the RNA sample stored at -70°C until 
further analyzed.    
The initial step (i.e. RT) is the production of single-stranded complementary DNA 
(cDNA) copies of total RNA using a retroviral RT enzyme such as that from the Moloney 
Murine Leukemia Virus (MMLV). Oligo dT primers are added to hybridize with the poly-A 
tail of the mRNA, after which the enzyme, in the presence of the deoxynucleotide 
triphosphates (dNTP), extends the primer strands, resulting eventually in cDNA strands. It is 
then followed by exponential amplification of a specific cDNA of interest by PCR, as 
follows.  
The PCR reaction contains the components required for DNA amplification, i.e. a sample 
of the total cDNA sequences, the four deoxynucleotides which are utilized to produce more 
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cDNA, the primer sequences that flank specific regions of the particular gene of interest and a 
DNA polymerase. The polymerase widely used is the Taq polymerase, named for Thermus 
aquaticus from which it was isolated and invaluable because of its thermostable property. The 
first part of PCR involves heating the product of the RT reaction at 90-95oC for 30 sec in 
order to separate the cell-derived ‘parent’ mRNA strand and ensure that all of the newly-
formed cDNA is in a single-strand form.  The reaction is then cooled to 50-65oC to enable the 
specific primers to ‘anneal’ to the ends of the target cDNA strand. The final step of the 
reaction is to make a complete copy of the template in the presence of the Taq polymerase, 
which is optimally active at 72oC. The sequential addition of deoxynucleotides to the primer 
eventually makes a complementary copy of the original cDNA strand, completing one PCR 
cycle, resulting in the generation of a double-stranded DNA corresponding to the mRNA of 
interest. Beginning again with heating at 90-95oC to separate the two cDNA strands, this 
protocol can be repeated 30 or more times, each newly-synthesized cDNA sequence acting as 
a new template at each cycle. Theoretically, the amplification for a given number of cycles 
can be calculated using the formula:  
 
Y = A x 2n where A: initial number of copies; n = number of cycles  
 
The initial cycles of PCR are characterized by an exponential increase in target 
amplification in the presence of an excess of reactants and when the enzyme is fully active. 
However, when these conditions are no longer present the product stops accumulating 
exponentially and a plateau is reached at which there is little or no net increase in PCR 
product. Thus, for semi-quantitation, the PCR reaction is terminated when the products from 
both an internal ‘control’ gene sequence and a gene of interest are detectable and are being 
amplified within a linear range. Since it is usually possible to ensure that these conditions are 
met, RT-PCR is a rapid, inexpensive, simple and sensitive method for detecting and accessing 
the relative level of expression of specific genes.  
 
In the present study RT-PCR was therefore used to monitor the effects of EMD, the EMD 
fractions and components on the ability of the PDL cells to express genes associated with 
different cell phenotypes when cultured in non-selective medium. The PDL cells were 
incubated in growth medium for 4-5 days until 90% confluence, then cultured in the presence 
of the proteins for another 7 days. Total RNA was extracted from the cells using RNeasy Mini 
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Kit, in accordance with the manufacturer’s instructions. For the RT reaction, 5 µg of total 
RNA was used with 5 ng of oligo-dT (Promega; Madison, WI) in 40 µl of water. After 5 min 
at 65°C, the first stand of cDNA was synthesized in a total volume of 50 µl, containing 50 U 
of M-MuLV RT, 1x M-MuLV buffer, 40 µM of each dNTP and 40 U of RNase block (all 
Stratagene; La Jolla, CA) to stop RNase activity. After incubation at 37°C for 60 min, the RT 
enzyme was inactivated by incubation for 5 min at 90°C. 10 µl Of each cDNA sample was 
then added to a 50 µl reaction mix containing 2 U RED-Taq DNA polymerase, 1x RED-Taq 
PCR buffer, 50 µM of each dNTP (all Sigma) and 2 µM of the respective sense and antisense 
primer pair sequences (Sigma-Genosys, Pampisford, UK). The sequences of the primers for 
the lineage-specific genes are shown in Table 1.  
An initial denaturation step of 2 min at 94°C was followed by amplification cycles (30 sec 
at 94°C, 30 sec at the gene-specific annealing temperature (Table 2) and 30 s at 72°C) and 
final extension for 7 min at 72°C. The housekeeping gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was also amplified to assess the quality of the extracted RNA (Das 
and Olsen, 2001) and as the baseline gene for comparing the target genes of interest. The PCR 
products were separated by agarose gel electrophoresis on a 2% agarose gel, consisting of 2% 
agarose in 1x TAE buffer (40 mM Tris base, 40 mM acetic acid and 1 mM EDTA, pH), with 
0.5% µg/ml of ethidium bromide (all from Sigma), a fluorescent dye that intercalates between 
the nucleic acid bases and enables visulization of the PCR DNA product in the gel under UV 
light. The electrophoresis was carried out using 1x TAE buffer, with the voltage applied at 5 
volts per cm of the distance between the two electrodes of the electrophoresis tank. To obtain 
a semi-quantitative estimate of PDL gene mRNA levels, the intensities of the bands 
corresponding to the target genes were measured using the ImageJ software for analysis 
(ImageJ, NIH, USA) and compared with that of the GAPDH gene intensity, defined as 1.0. 
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* (F) Forward; (R) Reverse
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2.3. Quantitative real-time PCR (Q-PCR) 
Q-PCR was used to study the effects of EMD and the EMD Fractions on osteogenic genes 
Runx-2, osteopontin (OP), osteocalcin (OC) and bone sialoprotein (BSP) of PDL cells 
cultured in osteogenic media. 
The difference between the Q-PCR and semi-quantitative RT-PCR is that Q-PCR 
amplifies and simultaneously quantifies a target DNA molecule as it is produced directly at 
each PCR cycle. This detection and quantification of the number of copies is then normalized 
to that of an ’internal’ control DNA such as GAPDH as it is produced. This generates a rate of 
cDNA formation which is equivalent to the amount of cDNA present initially whereas semi-
quantitative RT-PCR measures the relative level of cDNA product only at one particular time 
of exponential amplification, and may be affected by reagents, non-specific binding signals 
etc. In addition, Q-PCR employs a much more sensitive detection system than ethidium 
bromide staining of gel used in RT-PCR. 
Two systems are generally used for Q-PCR: The SYBR Green I Dye-based system 
employs the SYBR Green I dye which binds to the double-stranded (ds) DNA product, 
resulting in an increase in fluorescence intensity which is proportional to the amount of 
product at each time examined and thus the rate of ds-PCR product formation. The 
disadvantage of this system is that the dye also binds to non-specific ds-DNA sequences, 
resulting in false positive signals. The Taqman probe-based system uses a fluorogenic probe 
which detects the specific PCR product as it accumulates during the PCR cycle, thus 
combining specificity of the primers and the probes and generating highly specific signals 
which are directly proportional to the initial level of the target cDNA. This Taqman Probe-
based Q-PCR system was used in present study. 
For quantification of the lineage-specific genes by RT-Q-PCR, PDL cells were cultured in 
osteogenic medium (OM) in the presence of EMD and the EMD Fractions. Total RNA was 
isolated and primers specific for Runx-2, Osteopontin, Osteocalcin, bone sialoprotein and 
GAPDH genes were used for Q-PCR (Primer sequences were obtained from Applied 
Biosystems, Foster City, CA, USA). For Q-PCR analysis, the ABI Prism® 7300 sequences 
detector (Applied Biosystems), the Taqman® Gene Expression Assay consisting of unlabelled 
specific PCR primers and Taqman® MGB probes with FAMTM dye-labelling were used. The 
PCR reactions were carried out in a 96-well plate format as recommended by the 
manufacturer. Briefly, the cDNA products were first diluted (1:2) in nuclease-free water and a 
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5 µl aliquot was used in a 25 µl reaction mixture containing 12.5 µl of 2x Taqman® Universal 
Assay mix (P/N 4304437), 1.25 µl of gene expression assay mix specific for each gene listed 
in Table 2 (all from Applied Biosystems) and 6.25 µl of nuclease-free water. Thermal cycler 
conditions were used as recommended by the manufacturer, which consisted of AmpErase® 
UNG activation at 50oC for 2 min, AmpliTaq Gold® DNA polymerase activation at 95oC for 
10 min and 40 PCR cycles, each of which was 95oC for 15 s and 60oC for 60 s. The data were 
collected and analyzed by the SDS 1.2 software (Applied Biosystems). 
All PCR reactions were performed in triplicate and each of the gene signals were 
normalized to the GAPDH signal detected simultaneously on the same plate. The data are 
presented as the mean fold-induction (± SE) compared with that of control cells cultured in 
osteogenic media in the absence of any protein additions (defined as 1.0). 
 
2.4. Flow cytometry (FCM) 
FCM is commonly used technique to measure certain physical and chemical features of 
individual cells in a cell suspension as it passes through a fixed laser beam and is based on the 
angular reflection of an incident laser (Carter and Ormerod, 2000; Shapiro, 2003). Light 
reflected by the cells at low angle (< 2°) is detected in the forward direction along the axis of 
the incident light and this “forward scatter” (FSC) is considered to be proportional to the 
relative size of the cell (Carter and Ormerod, 2000). Light reflected at more than < 2°is 
detected at 90°C or more to the light axis and is referred to as orthogonal or “side scatter” 
(SSC), which is considered to be proportional to the cytoplasmic granularity or internal 
complexity of the cell (Carter and Ormerod, 2000).  
 Using this procedure, the relative levels of cell-associated proteins can also be 
measured, by first treating the cells with a fluorochrome ‘tag’ or fluorescent-labelled tag or 
antibody which is specific for the target antigen (Carter and Ormerod, 2000). When laser light 
is applied to the cell, the fluorochrome absorbs energy from the laser and subsequently 
releases this energy by emitting fluorescence at a particular wavelength. The intensity of this 
emitted fluorescence is proportional to the amount of fluorochrome-labelled antibody, which 
is in turn proportional to the level of antigen. A FACScan flow cytometer (Becton Dickinson) 
employing an argon-ion laser for excitation was used for FCM in this study. The electronic 
system of the instrument was optimized for collection of the data and the same instrument 
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settings were used to perform all experiments. Moreover, by the use of appropriate 
concentration of a specific non-ionic detergent (such as Triton X) which permeabilised the 
cell membrane and so enables the entry of high molecular weight ‘detecting’ antibodies, it 
was possible to measure the relative levels of intracellular as well as cell surface antigen, as 
previously described (Kuru et al., 1998). Detailed protocols for preparing the cells for FCM 
are discussed in Chapters 4 and 6.   
 
2.5. Immunogold electron microscopy (EM) 
Immunogold EM is a technique that utilizes a transmission EM (TEM) to elucidate the 
precise ultrastructural localization of antigens in cells or tissue samples. This can be carried 
out by a process known as immunogold labeling, in which careful sample preparation is 
essential for preserving both the integrity of the sample and antigenicity of the protein to be 
detected. Sections are incubated with specific antibodies against the antigen of interest. Since 
these detecting antibodies are not visible in the TEM, their presence (i.e., their binding to the 
corresponding antigen) is made electron-dense and thus EM-visible by incubating with a 
second antibody conjugated to a small gold particle, which is electron-dense. The sections are 
then stained with uranyl acetate and lead citrate to enhance the contrast between intracellular 
structures of differing electron density. Despite the labour-intesive effort required for this 
work, imnmunogold EM has a significant number of advantages over light microscopic 
procedures for investigating specific subcellular structures and the precise location of antigens 
of interest.    
 
2.6. Statistical analysis 
The data are presented as the mean ± SE of measurements of three separate experiments. 
Statistical differences between the means were analyzed by one-way ANOVA, followed by 
the post-hoc Bonferroni test for multiple comparisons (p<0.05), unless otherwise stated in the 
result chapters (SPSS 11.0 software, Chicago, IL).  
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Chapter 3 
3.1. Introduction 
Stem cells are generally characterized by their ability to give rise to at least one differentiated 
cell type as well as having the unique capacity to self-renew (Collins et al., 2005). In contrast 
to the large majority of the cell populations of adult tissues that are committed to a specific 
function, stem cells are uncommitted until they receive signals to differentiate into 
progenitor/precursor cells before forming fully differentiated and functionally active cells 
(Lemoli et al., 2005). The presence of such cells is considered to be critical for tissue 
homeostasis and the replenishment of cells that have died because of apoptosis, injury and 
disease (Weissman et al., 2000; Till and McCulloch, 1961). 
Stem cell-like populations have now been identified in a number of adult human 
tissues, including the central nervous system (CNS), olfactory and dermal epithelium, blood 
vessels, skeletal muscle and adipose tissue (Johe et al., 1996; Barnett et al., 2004; Cotsarelis 
et al., 1990; Neimann et al., 2002; Asahara et al., 1997; Collins et al., 2005). While PDL cells 
have been shown to be able to differentiate along mesenchymal lineages (osteogenic, 
adipogenic and chondrogenic), their ‘non-mesenchymal’ vasculogenic, angiogenic, 
neurogenic and gliogenic lineage-associated differentiation capability is not known, despite 
the physiological and structural importance of these lineages in the PDL (Seo et al., 2004; 
Singhatanadgit et al., 2009, Xu et al., 2009). Thus, although identification, isolation and 
characterization of PDL stem cells with multi-lineage differentiation capacity is clearly highly 
relevant to periodontal regeneration, their presence within the PDL remains unclear due to 
lack of definitive phenotypic signatures and biochemical features. The present study has 
therefore examined the multi-lineage differentiation potential of adult human PDL cells using 
the conventional reverse transcription polymerase chain reaction (RT-PCR) technique to 
assess the expression of selected ‘key’ marker genes that are associated with mesenchymal 
and non-mesenchymal pathways of stem cell differentiation and, secondly, by using standard 
histological, immunological and morphological criteria to assess characteristic features of 
lineage-specific differentiation in vitro. 
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3.2. Materials and Methods 
PDL cell culture and RT-PCR were performed as described in Chapter 2; additional methods 
used in this chapter are described below. 
 
3.2.1. Analysis of lineage-associated genes using semi-quantitative RT-PCR  
Conventional RT-PCR was used to assess the expression of lineage-associated genes as 
described in Chapter 2 and in a previous report (Singhatanadgit et al., 2009). This was carried 
out by first incubating the cells in a standard non-selective growth medium (GM) to 
determine the ‘baseline’ expression of the selected genes. The cells were then cultured in 
specialized media previously shown to support the differentiation of precursor cells into 
specific lineages (differentiation medium; DM). The following genes were analyzed as ‘key’ 
markers of the different lineages which have previously been reported to be expressed by 
precursor cells at ‘early’ or ‘late’ stages of their differentiation into specific mature functional 
cells: the osteogenesis-associated marker genes Runt-related transcription factor 2 (Runx2) 
(early) and bone sialoprotein (BSP) (late); the adipogenesis-associated genes peroxisome 
proliferator activator receptor γ2 (PPARγ2) (early) and lipoprotein lipase (LPL) (late); the 
chondrogenesis-associated genes Sox-9 (early) and aggrecan (late); the myogenesis-
associated genes MyoD1 (early) and desmin (late); the vasculogenesis-associated genes 
vascular endothelial growth factor receptor 2 (Flk-1) (early) and vascular endothelial cadherin 
(VE-cadherin) (late); the neuronal differentiation marker genes nerve growth factor (NGF) 
(early) and microtubule-associated protein (MAP2) (late); the glial-associated Notch1 (early), 
glial fibril acidic protein (GFAP) (late) and myelinated oligodendrocyte basic protein 
(MOBP) (late) genes; and a house-keeping gene glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). The sequences of the forward and reverse primers (from Sigma-Genosys, 
Pampisford, UK), annealing temperature, number of amplification cycles and expected 
product sizes (bp) are shown in Chapter 2. To obtain a semi-quantitative estimate of the 
relative level of mRNA transcript expression, the cDNA intensity of the band corresponding 
to each PCR product was measured by densitometry using the ImageJ (NIH software) and 
normalized to that of GAPDH used as an internal control. 
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3.2.2. Analysis of characteristic features of cell differentiation in vitro 
In these experiments the cells were cultured in various differentiation media (DM) that 
facilitate the in vitro development of ‘mature’ cells from putative precursor/stem cells.  
 
3.2.2.1 Mesenchymal differentiation pathways 
i. Osteogenic differentiation  
PDL cells were seeded into 24-well plates at a density of 2.5 x 104 cells/well and cultured in 
GM for 3 days, then osteogenic medium (OM) added, consisting of GM supplemented with 
0.1 mM L-ascorbic acid 2-phosphate, 10 mM β-glycerophosphate and 10 nM dexamethasone 
(all from Sigma). The GM and OM were changed every 3-4 days. On days 7 and 14, total 
RNA was extracted and RT-PCR carried out on day 7 to measure the early marker gene 
Runx2 and on day 14 to measure the late marker gene BSP, as previously described (Zhou et 
al., 2008).  
The formation of mineralized nodules, a key functional aspect of terminal osteogenic 
differentiation, was determined by alizarin red S staining of calcium-containing deposits, as 
follows. Cells were cultured in GM and OM for 21 days, fixed with 10% formaldehyde for 15 
min and washed with distilled water. The samples were incubated with 2% Alizarin Red S 
(pH 4.2) (Sigma) for 15 min at room temperature, then washed with ice cold methanol, air-
dried and photographed. The level of alizarin red staining was quantified by absorbance at 
562 nm (A562), after eluting the stain for 2 h with 10% cetylpyridinium chloride in 10 nM 
sodium phosphate buffer, pH 7.0. 
 
ii. Adipogenic differentiation  
PDL cells were cultured in GM as above, then adipogenic medium (AM) added, consisting of 
GM supplemented with 10 nM dexamethasone, 0.5 µM 3-isobutyl-1-methylxanthine and 50 
µM indomethacine (all from Sigma). The GM and AM were changed every 3-4 days. After 
culture in AM for 3 and 5 weeks, total RNA was extracted in order to measure the early 
adipogenic marker gene PPARγ2 (week 3) and the late marker gene LPL (at week 5), as 
described previously (Zhou et al., 2008).  
 Oil red O staining was carried out after 5 weeks of culture in GM or AM to assess 
terminal adipogenic differentiation, as follows. The cells were fixed with 10% formalin for 30 
min, incubated with 60% propan-2-ol for 5 min and then stained with 0.2% Oil Red O in 
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propan-2-ol for 5 min. After washing with tap water, the samples were counterstained with 
Harris Hematoxylin. For quantification of Oil Red O, the samples (without counter staining) 
were extracted into 100% propan-2-ol and the absorbance measured at 490 nm (A490). 
 
iii. Chondrogenic differentiation  
Cells were trypsinized and 2.5x105 cells suspended in 0.5 ml of serum-free chondrogenic 
medium (CM) containing low glucose-DMEM, 100 ng/ml transforming growth factor-β3 
(TGF-β3), 100 nM dexamethasone, 0.1 mM L-ascorbate2-phosphate, 100 µg/ml sodium 
pyruvate, 40 µg/ml L-proline and 6.25/6.25/6.25 µg/ml insulin/transferrin/selenium and 
placed in 15 ml conical polypropylene centrifuge tubes (Nunc). After centrifugation at 200g 
for 5 min, the pellets were incubated at 37°C for 2 weeks, with caps loosened to allow gas 
exchange, then total RNA extracted for RT-PCR analysis of the early chondrogenic marker 
gene Sox-9 (after 1 week) and the late marker aggrecan (after 2 weeks), as previously 
described (Narukawa et al., 2006).   
 Alcian blue staining for acid mucopolysaccharides and glycosaminoglycans was also 
carried out, after 3 weeks, to assess terminal chondrogenic differentiation as follows. Cell 
pellets were fixed in 10% formalin at 4˚C for 24 h, dehydrated in an ascending series of 
ethanol (50 to 100%) and embedded in paraffin. Sections (3 µm) were cut, stained with 1% 
Alcian blue (pH 2.5) (Sigma) for 5 min. The deposition of mucopolysaccharide and 
glycosaminoglycan was visualized as blue staining of the extracellular matrix (ECM). Nuclei 
were stained purple using Harris Hematoxylin.  
 
iv. Myogenic differentiation 
PDL cells were cultured on 1% gelatin (Sigma) coated 24-well tissue culture plates in GM for 
2-3 days, then myogenic medium (MM) added, consisting of high glucose-DMEM 
supplemented with 2% horse serum (PAA laboratories), 2% chick embryo extract (EggTech, 
Salisbury, UK) and 100 ng/ml IGF-1 (Sigma). The GM and MM were changed every 3-4 
days. After culture in MM for 3 and 5 weeks, total RNA was extracted in order to measure the 
early myogenic marker MyoD1 (week 3) and the late marker desmin (at week 5), as described 
previously (Sinanan et al., 2004).  
 Immunostaining for desmin (after 5 weeks) was also carried out, as previously described 
(Singhatanadgit et al., 2008). Briefly, cells were fixed with 4% paraformaldehyde (Merck, 
Poole, UK) for 15 min at room temperature (RT) and permeabilised using 0.1% Triton X 
(Sigma) for 15 min at RT. They were then treated with a blocking solution containing 10% 
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normal goat serum (NGS) in PBS for 1 h and incubated for 1 h at RT with primary mouse 
monoclonal anti-desmin antibody (Sigma) diluted 1:500 in PBS containing 1% NGS. 
Incubation was then carried out with goat anti-mouse Alexa Fluor secondary antibody 
(Invitrogen, Paisley, UK) diluted 1:200 in PBS containing 1% NGS for 1 h at RT. The 
desmin-positive myotube-like structures were visualized as green fluorescent stained cells. 
Nuclei were stained blue using Hoechst dye. The proportion of desmin-positive cells was 
determined by manual counting of 5 separate fields of each culture. 
 
3.2.2.2. Non-mesenchymal differentiation pathways 
i. Vasculogenic and angiogenic differentiation 
In order to assess the potential of PDL cells to undergo vasculogenesis, a process by which 
stem cells differentiate into endothelial precursors (Damir et al., 2007), and angiogenesis, a 
process by which endothelial cells form morphologically distinct tubular blood vessel-like 
networks (Damir et al., 2007), the PDL cells were cultured in GM as described above and 
then endothelial basal medium-2 (Lonza, Wokingham, UK) (EBM-2) was then added, 
consisting of vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF). 
Total RNA was extracted to measure the early vasculogenesis-associated marker gene (Flk-1; 
at week 2) and a late marker gene (VE-cadherin; at week 5) associated with this process, as 
described previously (Lee et al., 2009).  
Further assessment of terminal vasculogenic differentiation was also carried out by 
immunostaining for VE-cadherin (after 5 weeks), as previously described (Singhatanadgit et 
al., 2008). Briefly, cells were fixed with 4% paraformaldehyde (Merck, Poole, UK) for 
15 min at room temperature (RT) and permeabilised using 0.1% Triton X (Sigma) for 15 min 
at RT. They were then treated with a blocking solution containing 10% NGS in PBS for 1 h 
and incubated for 1 h at RT with primary mouse monoclonal anti-VE-cadherin antibody 
(Insight Biotechnology, Wembley, UK) diluted 1:100 in PBS containing 1% NGS. Incubation 
was then carried out with goat anti-mouse Alexa Fluor secondary antibody (Invitrogen, 
Paisley, UK) diluted 1:200 in PBS containing 1% NGS for 1 h at RT. The vasculogenic VE-
cadherin-positive endothelial cell-like population was visualized as green fluorescent stained 
cells. Nuclei were stained blue using Hoechst dye. The proportion of VE-cadherin-positive 
cells was determined by manual counting of 5 separate fields of each culture.  
Angiogenic differentiation of PDL cells was performed using an in vitro angiogenesis 
assay kit (Millipore, Billerica, MA, USA). Briefly, 104 cells were plated on ECMatrix gel 
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coated 96-well plates and cultured in the presence of EBM-2. After 6 h, digital images were 
obtained using bright-field microscopy to visualize morphological evidence of angiogenic 
structures, which were scored from 0 to 5, as previously described (Schlueter et al., 2007), 
based on the progressive appearance of morphological features associated with angiogenic 
structures: individual cells, (0); aligned cells, (1); capillary tubes without sprouting, (2); 
sprouting of new capillaries, (3); the formation of closed polygonal structures, (4); and 
complex-mesh-like structures, (5). Each condition for each culture was scored using 5 
separate fields. 
 
ii. Neural differentiation 
In order to assess the ability of PDL cells to undergo neurogenesis, the process by which 
nerve cells are generated from stem cells/neuronal precursors, 2 x 104 cells/well were cultured 
in poly-L-lysine/laminin coated 8-well chamber slides (Nunc) in GM for 2 days and neural 
differentiation medium (NM) then added, consisting of 20 ng/ml EGF, 50 ng/ml bFGF, 4 µM 
forskolin, 10 µM retinoic acid, 50 ng/ml brain derived neurotrophic factor (BDNF) and 50 
ng/ml neurotrophin-3 (NT-3) (all from Sigma). Total RNA was extracted and the early 
neuronal marker gene NGF (day 2) and late gene MAP-2 (day 7) were measured, as 
previously described (Coura et al., 2008).  
Immunostaining for neuron-specific βIII tubulin was carried out as previously 
described (Singhatanadgit et al., 2009). Briefly, cells were fixed with 4% paraformaldehyde 
(Merck, Poole, UK) for 15 min at RT and permeabilised using 0.1% Triton X (Sigma) for 
15 min at RT. They were then treated with a blocking solution containing 10% NGS in PBS 
for 1 h and incubated for 1 h at RT with primary mouse monoclonal anti-βIII tubulin diluted 
1:1000 in PBS containing 1% NGS. Incubation was then carried out with goat anti-mouse 
Alexa Fluor secondary antibody (Invitrogen, Paisley, UK) diluted 1:200 in PBS containing 
1% NGS for 1 h at RT. Neuron-like cells were visualized by their green fluorescent staining 
and long axonal projections. Nuclei were stained blue using Hoechst dye. The proportion of 
neuron-specific βIII tubulin-positive cells was determined by manual counting of 5 separate 
fields of each culture. 
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iii. Glial differentiation 
The capacity of PDL cells to undergo glial differentiation, the process by which three distinct 
types of myelinating cells (astrocytes and oligodendrocytes found in the central nervous 
system and Schwann cells found in the peripheral nervous system (PNS)) are generated, 2 x 
104 cells/well were cultured in 8-well chamber slides (Nunc) in GM for 2 days and glial 
differentiation medium (GDM) then added, consisting of DMEM/F-12, 2% FCS and 4 µM 
forskolin in order to facilitate astrocytic differentiation. The GDM was further supplemented 
with 10 ng/ml heregulinβ2 to enable oligodendrocyte and Schwann cell differentiation. Total 
RNA was extracted and Notch1 (day 4) (a common marker of all three gliogenic lineages), 
GFAP (day 10) (a late marker specific for the astrocytic lineage) and MOBP (day 10) (an 
oligodendrocytic and Schwann cell-associated marker gene) were measured as previously 
described (Coura et al., 2008).  
Immunostaining was carried out for GFAP and O4, markers of astrocytes and of 
oligodendrocytes and Schwann cells, respectively, as previously described18. Briefly, cells 
were fixed with 4% paraformaldehyde (Merck, Poole, UK) for 15 min at RT and 
permeabilised using 0.1% Triton X (Sigma) for 15 min at RT. They were then treated with a 
blocking solution containing 10% NGS in PBS for 1 h and incubated for 1 h at RT with 
primary mouse monoclonal anti-GFAP (R&D Systems, Minneapolis, MN, USA) and anti-
oligodendrocyte O4 (R&D Systems, Minneapolis, MN, USA) diluted 1:500 in PBS 
containing 1% NGS. Incubation was then carried out with goat anti-mouse Alexa Fluor 
secondary antibody (Invitrogen, Paisley, UK) diluted 1:200 in PBS containing 1% NGS for 
1 h at RT. Astrocyte-like cells were visualized by their red fluorescent staining and 3-10 long 
dendritic projections, and oligodendrocyte-like cells were visualized by their yellow 
fluorescent staining and 20-30 dendritic projections. Schwann-like cells were visualized by 
the yellow fluorescent staining of their small cell body (soma) and two myelinating dendrites 
on opposite sides of the soma. Nuclei were stained blue using Hoechst dye. The proportions 
of astrocyte-specific GFAP-positive cells and of oligodendrocyte and Schwann cell-
associated O4-positive cells were determined by manual counting of 5 separate fields of each 
culture. 
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3.2.3. Statistical analysis 
The RT-PCR data are presented as the mean of the triplicate measurements of cells cultured 
in DM compared with that of control cells cultured in GM (defined as 1.0). Student’s paired T 
test was used for statistical comparison of the test and control conditions (SPSS 12.0 
software, Chicago, IL). 
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3.3. Results 
3.3.1. Mesenchymal lineage-specification of PDL cells  
The expression of mesenchymal lineage-associated genes of PDL cells cultured in non-
differentiation-inducing GM was examined. Figure 3.1 shows that the PDL cells cultured in 
GM constitutively expressed the bone-associated genes Runx2 and BSP, the adipogenic genes 
PPARγ2 and LPL, the chondrogenic genes Sox-9 and Aggrecan and the myogenic genes 
MyoD1 and desmin, suggesting that even when incubated in medium that was not optimized 
to elicit any specific pathway of ‘terminal’ cell differentiation in vitro, at least some cells in 
the PDL cell population expressed basal levels of genes associated with a number of different 
mesenchymal lineages.  
The differentiation potential of PDL cells into mesenchymal lineages when cultured in 
various differentiation media (DM) that facilitate the in vitro development of ‘mature’ cells 
from putative precursor/stem cells was examined. Thus, in OM, which facilitates 
osteogenesis, the early osteogenic transcription factor Runx2 and the late osteogenic gene 
BSP were found to be significantly up-regulated (1.4- and 2.2-fold, respectively; p<0.05) 
compared with cells cultured in GM alone. When cultured in adipogenesis-inducing AM, 
there was a 3.3-fold increase in expression of the early transcription factor PPARγ2 gene and 
a 4.9-fold increase in the late adipogenic gene LPL compared with GM alone, as shown in 
Figure 3.1 (B) (p<0.05). After culture in CM, the early chondrogenic gene Sox-9 and the late 
chondrogenic gene Aggrecan were significantly up-regulated (3.2- and 1.7-fold, respectively; 
p<0.05). When PDL cells cultured under myogenesis-inducing MM, although no significant 
change in the early myogenic gene myoD1 was observed (1.2-fold), the late gene desmin was 
significantly up-regulated (1.6-fold increase; p<0.05) compared with GM alone. These results 
thus demonstrate that at least some cells present in the adult PDL are capable of expressing 
significantly elevated levels of genes that delineate terminal differentiation to several distinct 
mesenchymal lineages (osteogenic, adipogenic, chondrogenic, myogenic). When the PDL 
cells were cultured in GM alone, there was little evidence of any terminal differentiation to 
mesenchymal lineages, on the basis of cell function and morphology in vitro as described in 
the Section 3.2 (Fig. 3.1). However, when cultured in osteogenesis-inducing OM, the cells 
formed higher amounts of distinct bone-like nodules compared with cells cultured under 
baseline conditions (in GM), exhibiting significantly higher alizarin red staining intensity 
(1.14 compared with 0.57; p<0.05) (Fig. 3.1 (A)). Similarly, when cultured in adipogenic 
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AM, the PDL cells produced significantly greater amounts of oil red O-positive lipid-like 
droplets, a functional characteristic of mature adipocytes (staining intensity of 1.32 compared 
with 0.50 in GM alone; p<0.05) (Fig. 3.1 (B)). In CM, the PDL cell pellet cultures were found 
to exhibit higher levels of Alcian blue staining of the ECM, indicating greater amounts of acid 
mucopolysaccharides and glycosaminoglycans characteristic of chondrogenic differentiation 
in vitro compared with GM (Fig. 3.1 (C)), and in MM the PDL cells produced 11.9% desmin-
positive myotube-like structures compared with cells cultured in the baseline non-selective 
GM (0.0%). However, no multinucleated myotubes (containing three or more nuclei), a 
characteristic feature of terminally differentiated muscle cells, were detected (Fig. 3.1 (D)) 
(Collins et al., 2005).  
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Figure 3.1. Differentiation of PDL cells to mesenchymal lineages in vitro.  
(I) Representative RT-PCR gels of the expression of lineage-associated genes by PDL cells 
cultured in non-selective GM and in lineage-specific differentiation media (DM). The values 
are the changes in PCR product band intensity (relative to GAPDH) obtained in DM 
compared with GM, defined as 1.0;  
(II) Terminal differentiation characteristics. (A) Osteogenic differentiation: Alizarin red 
staining of PDL cells cultured for 3 weeks in GM and in DM. The black arrows show the 
alizarin red positive bone-like nodules, and the numbers are the alizarin red staining 
intensities. Magnification x10; (B) Adipogenic differentiation: Oil red O staining of the PDL 
cells cultured for 5 weeks in GM and in DM. Nuclei are counter-stained purple with Harris 
Hematoxylin, and the back arrows show lipid-like droplets stained red with Oil red O, and the 
numbers are the Oil red O staining intensities. Magnification x20; (C) Chondrogenic 
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differentiation: Alcian blue staining of paraffin sections of pellet cultures maintained for 3 
weeks in GM and in CM. Nuclei are counter-stained purple with Harris Hematoxylin, and the 
red arrows show the ECM stained with Alcian blue. Magnification x40; (D) Myogenic 
differentiation: Immunostaining of desmin after 5 weeks of culture in GM and in MM. The 
numbers are the % of desmin-positive cells. Nuclei are stained blue with Hoechst dye, and the 
white arrows show the green fluorescence-stained myotube-like structures that were devoid of 
multiple nuclei. Magnification x40. The values are the means ±SE of triplicate measurements. 
*Indicates statistically significant difference compared with GM alone (p<0.05).  
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3.3.2. Non-mesenchymal lineage-specification of PDL cells 
The expression of non-mesenchymal pathways of vasculogenesis/angiogenesis, neurogenesis 
and gliogenesis-associated genes was first examined when the PDL cells were cultured in 
non-selective GM. The results in Figures 3.2 and 3.3 show that the PDL cells constitutively 
expressed genes associated with all of these lineages. Thus, the vasculogenesis/angiogenesis-
associated gene Flk-1, the neurogenesis-associated genes NGF and MAP-2 and the 
gliogenesis-associated genes Notch1, GFAP and MOBP were constitutively expressed by the 
PDL cells cultured in non-differentiation-inducing GM (Figs. 3.2 and 3.3). However, lineage-
specific gene expression was nevertheless selective, as the late-vasculogenic/angiogenic 
marker VE-cadherin was not detected.  
The vasculogenic, neurogenic and gliogenic differentiation potential was also 
examined after the PDL cells were cultured in lineage-specific differentiation media (DM). 
Thus, PDL cells cultured in vasculogenic/angiogenic differentiation media (EBM-2) appeared 
to exhibit elevated levels of vasculogenesis-associated early gene Flk-1 and late gene VE-
cadherin expression compared with PDL cells cultured in GM (1.6- and 15.5-fold increase; 
p<0.05) (Fig. 3.2). Similarly, after culture in NM, neuronal genes NGF and MAP-2 were 
significantly up-regulated compared with GM (2.2 and 1.8-fold increase; p<0.05) (Fig. 3.3). 
The astroglial genes Notch1 and GFAP were found to be markedly stimulated when PDL 
cells cultured in GDM (1.9 and 2.8-fold increase; p<0.05). Moreover, when GDM was 
supplemented with heregulinβ2, the early oligodendrocytic gene Notch1 and the late MOBP 
were both up-regulated compared with cells cultured in GM alone (2.0- and 3.3-fold increase, 
respectively; p<0.05) (Fig. 3.3). These results thus demonstrate that, under the appropriate 
conditions, PDL cells can express significantly elevated levels of vasculogenic/angiogenic, 
neurogenic and gliogenic genes.  
Analysis of vasculogenic differentiation showed that, in EBM-2, 8.5% of the PDL 
cells were VE-cadherin-positive, morphologically appearing as blood vessel-like structures as 
shown in Figure 3.2 (A). Furthermore, cells cultured on an ECMatrix substrate in EBM-2 
formed a tubular network, morphologically characteristic of angiogenesis in vitro, and had an 
angiogenic score of 2.6, while PDL cells cultured on the ECMatrix in the baseline GM alone 
were individual cells without any apparent tubule formation (mean score of 0.0) (Fig. 3 (ii); 
p<0.05).  
Examination of the neurogenic pathway showed that, when cultured in NM, the PDL 
cells formed significantly more neuron-specific βIII tubulin-positive neuron-like structures 
exhibiting long axonal projections and neuronal dendrites, compared with GM (14.9% 
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compared with 0.0%; p<0.05) (Fig. 3.3 (A)). When cultured in GDM, 36.2% of the cells 
expressed the astrocyte-associated marker protein GFAP and exhibited astrocyte-like 
morphology (Fig. 3.3 (B)), similar to those previously observed (Chi et al., 2010). Moreover, 
when the GDM was supplemented with heregulinβ2, 7.4% of PDL cells expressed the 
oligodendrocyte and Schwann cell-specific marker O4 and exhibited oligodendrocyte-like 
morphology with 20-30 dendritic projections and Schwann cell-like morphology as evidenced 
by a small cell body with two myelinating dendrites (Fig. 3.3 (C); p<0.05), similar to those 
previously observed (Chi et al., 2010). 
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Figure 3.2. Vasculogenic/angiogenic differentiation of PDL cells in vitro.  
(I) Representative RT-PCR gels of the expression of vasculogenesis/angiogenesis-associated 
genes by PDL cells cultured in GM and in vasculogenic/angiogenic DM. The values are the 
changes in PCR product band intensity obtained in the presence of DM compared with GM, 
defined as 1.0. 
(II) (A) Immunostaining of VE-cadherin after 5 weeks of culture in GM and in DM. The 
numbers are the % of VE-cadherin-positive cells. Nuclei are stained blue with Hoechst dye, 
and the white arrows show the green fluorescence-stained vasculogenic tube-like structures 
in the DM cultures. Magnification x40. (B) In vitro angiogenic structure formation by PDL 
cells cultured for 5 h in GM and in DM. The numbers are the angiogenic scores, and the 
black arrows show the closed polygonal structures formed in DM cultures. Magnification 
x10. The values are the means ±SE of triplicate measurements. *Indicates statistically 
significant difference compared with GM alone (p<0.05).  
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Figure 3.3. Neurogenic and gliogenic differentiation of PDL cells in vitro.  
(I) Representative RT-PCR gels of the expression of neurogenesis and gliogenesis-associated 
genes by PDL cells cultured in GM and in neurogenic or gliogenic differentiation medium 
(DM). The values are changes in PCR product band intensity obtained in the presence of DM 
compared with GM, defined as 1.0.  
(II) Immunostaining of (A) βIII-tubulin, (B) GFAP, and (C) oligodendrocyte-specific O4, in 
PDL cells cultured for 7 and 10 days in GM, in NM and GDM, respectively. The numbers are 
the % of βIII-tubulin, GFAP and O4-positive cells. Nuclei are stained blue with Hoechst dye, 
and the white arrow in (A) shows a green fluorescence-stained neuron-like cell, the white 
arrow in (B) shows a red fluorescence-stained astrocyte while, the white arrow in (C) shows 
the yellow fluorescence-stained oligodendrocyte-like cell blue arrow shows yellow 
fluorescence-stained Schwann-like cell. Magnification 40x. Nuclei are stained blue with 
Hoechst dye.  
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3.4. Discussion 
A number of previous studies have suggested that the PDL may contain mesenchymal stem 
cell-like population capable of expressing a range of phenotypic markers such as STRO-1, 
CD29, CD44, CD105, CD106 and CD146 (Singhatanadgit et al., 2009; Tomokiyo et al., 
2008; Xu et al., 2009; Cheng et al., 2009). However, these surface antigens are not definitive 
as they are also expressed by several other types of adult human cells, in addition to PDL 
cells, such as bone marrow-derived mesenchymal stromal cells, keratinocytes, T-lymphocytes 
and fibroblasts (Singhatanadgit et al., 2009; Mareddy et al., 2007; Staquet et al., 1989; 
Weninger et al., 2000; Pickl et al., 1997). Thus, the identification of PDL stem cells with 
multiple tissue regenerative capabilities has been limited partly due to the lack of definitive 
phenotypic markers of such cells. In addition, even though the complex process of 
homeostasis, repair and regeneration of PDL not only involves formation of mesenchymal 
tissues such as new bone and connective tissue architecture, but also the production of new 
BV, neurovascular channels and proprioceptive sensory nerve innervations, pivotal non-
mesenchymal tissues present in the PDL (Maeda et al., 1999), the examination of the 
differentiation potential of these putative cell population has been limited to only 
mesenchymal (osteogenic, adipogenic and chondrogenic) lineages in previous studies 
(Singhatanadgit et al., 2009; Tomokiyo et al., 2008; Xu et al., 2009; Cheng et al., 2009). 
Thus, the present study investigated for the first time the multi-lineage (osteogenic, 
adipogenic, chondrogenic, myogenic, vasculogenic, angiogenic, neurogenic and gliogenic) 
differentiation potential of the heterogeneous primary PDL cell population in vitro.  
Our findings showed that at least some cells obtained from PDL tissue, even after 
culture under non-selective growth conditions, constitutively expressed basal levels of all of 
the genes examined, except the vasculogenic/angiogenic VE-cadherin gene, indicating that 
‘mature’ endothelial-like cells were unlikely to have been present in the population. In 
addition, under differentiation-inducing conditions we also showed that the adult PDL cells 
are capable of terminal osteogenic, adipogenic and chondrogenic differentiation in vitro. 
Similar observations were also reported using the adult human PDL clonal populations, which 
showed that the colony-forming cells within PDL have the ability to undergo osteogenesis, 
adipogenesis and chondrogenesis in vitro (Singhatanadgit et al., 2009). Moreover, CD146 and 
STRO-1-positive cells isolated from the heterogeneous PDL cell population were shown to be 
able to differentiate into the above mesenchymal lineages (Xu et al., 2009; Cheng et al., 
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2009). In contrast, although under muscle-inducing conditions, PDL cells expressed a higher 
level of the late marker gene desmin and exhibited desmin-positive tube-like structures, these 
cells failed to express elevated levels of the pivotal early myogenic transcription factor 
MyoD1 and also the desmin-positive tube-like structure were found to be mononucleated. The 
reason for the lack of up-regulation of MyoD1 and the absence of multi-nucleated myotube-
like structures is not yet clear, although similar observations have also been reported using 
BC3H1 cells, a skeletal muscle cell line characterized by the lack of MyoD1 gene up-
regulation, inability to fuse with surrounding cells and a non-multinucleated myotube 
phenotype (Brennan et al., 1990). The present results thus demonstrate that the PDL 
compartment contains progenitor/stem cell population capable of osteogenic, adipogenic and 
chondrogenic differentiation, although the presence of precursors capable of myogenic 
differentiation is less clear.   
 As with many other tissues (Nomi et al., 2002; Lammert et al., 2001; Matsumoto et al., 
2001), vasculogenic and angiogenic differentiation processes are pivotal and indispensable 
features of tissue healing and regeneration, but have not previously been described for PDL 
cells. The results here have shown that transcripts of the Flk-1 and VE-cadherin genes, 
previously shown characteristics of endothelial cells (Heydarkhan-Hagvall et al., 2008), were 
both up-regulated when PDL cells were cultured in EBM-2 and, furthermore, that the PDL 
cells formed VE-cadherin-positive blood vessel-like structures, characteristics of 
vasculogenesis in vitro, similar to those previously reported observation using human 
adipose-derived stem cells and human umbilical cord-derived endothelial cells (HUVEC) 
(Heydarkhan-Hagvall et al., 2008; Ning et al., 2009). Moreover, although endothelial-like 
cells, a prerequisite for the process of angiogenesis, were not detected in the PDL cell 
population (based on the absence of VE-cadherin-positive cells in PDL cultures under non-
differentiation-inducing conditions as noted above and also by the lack of expression of the 
endothelial cell surface marker CD34 shown previously (Singhatanadgit et al., 2009; 
Tomokiyo et al., 2008; Xu et al., 2009; Cheng et al., 2009)), when cultured on Matrigel the 
PDL cells were able to form angiogenic capillary-like tubules with minimal sprouting. Similar 
findings have also been reported using mesenchymal cell populations derived from human 
adipose tissue, murine embryo and human umbilical cord (Ning et al., 2009; Wang et al., 
2010; Gang et al., 2006). The precise cellular origin of such capillary-like structures is not yet 
certain, since other reports have suggested that a fibroblastic cell population rather than the 
endothelial cells precursors might also be involved in the morphological appearance of 
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organized tubule network (Auerbach et al., 2003; Obeso et al., 1990). Thus, while the present 
findings provide evidence that the PDL contains precursor cells capable of undergoing 
vasculogenesis, it is possible that angiogenic structure formation in vitro by the heterogeneous 
PDL cell population could in part be due to the presence of fibroblastic-type cells.  
PDL tissue has also been reported to contain dense proprioceptive sensory nerve 
innervations by the peripheral nervous system (Byers et al., 2004; Maeda et al., 1999; 
Johansson et al., 1991). Moreover, unlike the CNS in which oligodendrocytes and astrocytes 
are responsible for nerve myelination, sensory nerve innervations found in PDL tissue are 
myelinated by specialized glial (Schwann) cells as well as astrocytes (Byers et al., 2004; 
Maeda et al., 1999; Johansson et al., 1991). The present findings that, under neural-inductive 
conditions in vitro the neuronal marker genes NGF and MAP-2 were both up-regulated and 
cells were detected which exhibited a morphological appearance similar to bipolar peripheral 
sensory neurons containing an axon and one dendritic projection on opposite ends of the cell 
body (soma) (Kriegstein et al., 1983), indicates that the PDL cells might contain neuronal 
precursor cells. Similar findings were also reported using rat and human PDL cells in a 
neurosphere culture system (Techawattanawisal et al., 2007; Widera et al., 2007). In addition, 
PDL cells cultured under glial differentiation conditions were found here to have elevated 
levels of the astrocytic marker genes Notch1 and GFAP and the oligodendritic and Schwann 
cell-associated marker gene MOBP, to exhibit a GFAP-positive astrocyte-like cell 
morphology and, when supplemented with heregulinβ2, to exhibit O4 positive-
oligodendrocyte and Schwann cell-like morphology (Maeda et al., 1999; Techawattanawisal  
et al., 2007; Widera et al., 2007). Astrocytic differentiation of these cells has previously been 
reported (Techawattanawisal et al., 2007; Widera et al., 2007), while the ability of PDL cells 
to form oligodendrocytes and Schwann cells has been shown here for the first time. It is 
notable that despite the histological absence of oligodendrocytes within PDL tissue (Byers et 
al., 2004), PDL cells in vitro nevertheless formed oligodendrocyte-like cells under 
appropriate differentiation conditions, suggesting that the PDL may contain primitive cells 
capable of undergoing all three types of glial cell differentiation in vitro. These results thus 
demonstrate that the PDL cells contain neuronal and glial precursor/stem cells capable of 
forming bipolar nerves and astrocytes, oligodendrocytes and Schwann cells under the 
appropriate differentiation conditions in vitro.   
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The summary of the results in Figure 3.4 shows that the adult human primary PDL 
cell population is capable of osteogenic, adipogenic and chondrogenic differentiation under 
the appropriate mesenchymal differentiation conditions in vitro. Such cells may possibly have 
a crucial role in PDL and AB regeneration during periodontal therapy. Moreover, PDL cells 
were also capable of undergoing vasculogenic differentiation indicating the presence of a 
primitive cell population capable of producing new blood vessels during the time of 
healing/repair/regeneration. The PDL compartment was also found to contain cells capable of 
producing bipolar nerve-like cells, one of the key elements of PDL proprioceptive function, 
and notably, these cells were also capable of producing all three types of glial cells which 
myelinate nerve axons.  
 
  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4. Summary of multi-lineage differentiation potential of PDL cells. The representative 
micrograph in the centre shows adult human PDL cells, obtained originally from the PDL of 
the tooth (black arrows), during culture in non-selective conventional GM. 
(no multinucleated myotubes) 
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Chapter 4 
4.1. Introduction 
Amelogenins are a family of proline-rich peptides formed from the amelogenin gene by 
alternative splicing and post-translational modifications (Fincham et al, 1993), and include the 
5 kDa tyrosine-rich (TRAP) and 6-8 kDa leucine-rich (LRAP) isoforms (Fincham et al, 
1993). They are the constituents of crude preparation EMP and commercially available heat-
treated EMD and have been extensively studied partly because of their effect on osteogenic 
differentiation in vitro and bone regeneration in vivo (Lossdorfer et al, 2007; Sculean et al, 
2008; Reseland et al, 2006; Keila et al, 2004; Sculean et al, 2004; Donos et al., 2003).  Thus, 
EMP and EMD have been reported to promote osteogenesis by up-regulating bone-associated 
genes such as alkaline phosphatase (ALP), osteopontin (OP), osteocalcin (OC) and bone 
sialoprotein (BSP), and by stimulating the production of bone-like mineralized nodules in 
vitro (Lossdorfer et al, 2007; Keila et al, 2004). However, other studies have shown that these 
preparations down-regulated these bone-associated markers and terminal osteogenic 
differentiation of human periodontal ligament (PDL) cells, osteoblasts and bone marrow 
derived mesenchymal stem cells (BMSC) (Wada et al, 2008; Hama et al, 2008). Similarly, 
while some experimental models and clinical studies have demonstrated that, in vivo, EMP 
and EMD promote regeneration of periodontal ligament (PDL) and root cementum, its effect 
on new bone growth has often been inconsistent and unpredictable (Donos et al, 2005; Donos 
et al., 2003; Heijl et al, 1997). Although the reason for these discrepancies is not yet clear, it 
may be due at least partly to the use of different preparations of EMP and EMD, some of 
which have been reported to contain BMP- and TGFβ-like activities (Johnson et al, 2009; 
Suzuki et al, 2005). In addition, such preparations are highly heterogeneous and contain 
several different proteins and their isoforms, as noted above, which are likely to differ both 
qualitatively and quantitatively between different preparations.  
Recent analysis of a commercially available heat-treated form of EMP (Emdogain®; 
EMD, Institut Straumann, Basel, Switzerland) has demonstrated the presence of two main 
sub-fractions (Mumulidu et al, 2007). One comprises mainly the amelogenin-derived TRAP 
peptide and the other contains > 6 kDa peptides, including the amelogenin peptide LRAP, 
sheathlin and full-length amelogenin (Fincham et al, 1993). While sheathlin has been shown 
to have a role in cementum development and repair (Kanazashi et al., 2006), the effects of 
these amelogenin peptide-containing sub-fractions of EMD on osteogenesis have not been 
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investigated. The present study has therefore examined the response of bone-forming cells to 
EMD components under conditions that facilitate terminal osteogenic differentiation in vitro. 
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4.2. Materials and methods 
PDL cell culture and RT-PCR were performed as described in Chapter 2; additional methods 
used in this chapter are described below. 
 
4.2.1. Isolation of primary human alveolar bone (AB) cells 
Primary human bone cells (AB) were grown from cortico-lamellar bone of the maxilla of 
patients undergoing routine extractions at the Eastman Dental Hospital, as previously 
described (Singhatanadgit et al, 2006). Briefly, the bone chips were cut into approximately 1-
2 mm3 pieces, placed in 48-well plates and incubated at 37°C in a humidified atmosphere of 
5% CO2 in air for 15 min to enable them to adhere to the culture plates. Low glucose- 
Dulbecco’s Modified Eagle’s Medium (Low glucose-DMEM) (Gibco) containing 10% FCS 
(PAA Laboratories) supplemented with 200 U/ml penicillin, 200 µg/ml streptomycin, and 2 
mM L-glutamine (all from Gibco) was then added and the explants were cultured until the 
outgrowth of the adherent cells reached confluence. Cells were used between passage 2 and 5 
in the experiments.  
 In addition to the PDL and AB cells, bone marrow-derived mesenchymal stem cells 
(BMSC) (Lonza, Slough, UK) and a recently isolated ‘clonogenic’ cell population from adult 
human PDL which was shown to exhibit characteristic features of a bone progenitor/stem cell 
(clone 7; Singhatanadgit et al, 2009), were also used in the present study in order to examine 
the effects of EMD components on a range of bone-forming cells. BMSC and clone 7 were 
cultured in the same way as the PDL and AB cells, described above, and used between 
passage 3 and 6.  
 
 
4.2.2. Treatment of cells with EMD and the EMD Fractions  
EMD, the EMD-derived sub-fraction < 6 kDa (Fraction C) and the EMD-derived > 6 kDa 
sub-fraction (Fraction A) were diluted in 0.1% acetic acid and added directly to the cells 
when they reached approximately 90% confluence. EMD and Fractions C and A were used at 
a final concentration of 100 µg/ml throughout the experiments, unless otherwise noted. These 
concentrations were determined from their dose effects on terminal PDL cell osteogenesis in 
vitro, as described below. 
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4.2.3. Effects of the EMD, Fraction C and Fraction A on terminal differentiation of 
bone-forming cells 
PDL cells were seeded into 24-well plates at a density of 2.5 x 104 cells/well and cultured in 
non-selective growth medium (GM) containing low glucose-DMEM supplemented with 10% 
FCS, 200 U/ml penicillin and 200 µg/ml streptomycin) for 3 days. Osteogenic medium (OM) 
was then added, consisting of GM supplemented with 0.1 mM L-ascorbic acid 2-phosphate, 
10 mM β-glycerophosphate and 10 nM dexamethasone (all from Sigma). 1, 3, 10, 30 and 100 
µg/ml concentrations of EMD, Fraction C and Fraction A were added to the cultures and the 
medium was changed every 3 days.  
Similarly, AB, BMSC and clone 7 were also seeded into 24-well plates at a density of 
2.5 x 104 cells/well and cultured in GM for 3 days until 90% confluent, the medium then 
replaced with OM containing EMD, Fraction C and Fraction A (all 100 µg/ml) and was 
changed every 3 days. Control cultures were incubated with OM alone.  
The formation of mineralized nodules, a measure of terminal osteogenic 
differentiation, was determined by alizarin red S staining of calcium-containing deposits, as 
follows. After 3 weeks of culture in OM in the presence of EMD, Fraction C and Fraction A 
cells were fixed with 10% formaldehyde for 15 min and washed with distilled water. The 
samples were then incubated with 2% Alizarin Red S (pH 4.2) (Sigma) for 15 min at room 
temperature, washed with ice-cold methanol, air-dried and photographed. The level of alizarin 
red staining was quantified by absorbance at 562 nm (A562), after eluting the stain for 2 h with 
10% cetylpyridinium chloride in 10 nM sodium phosphate buffer, pH 7.0. 
 
4.2.4. Quantitative-polymerase chain reaction (Q-PCR) analysis of osteogenesis-
associated genes  
PDL cells were seeded into 24-well plates at a density of 2.5 x 104 cells/well and cultured in 
GM for 3 days. GM was then replaced with OM and the cells cultured in the presence of 
EMD, Fraction C and Fraction A, and the medium changed every 3 days. On days 4, 7, 10 
and 14, total RNA was extracted and Q-PCR carried out to measure the ‘early’ osteogenic 
marker gene runt-related transcription factor-2 (Runx2) (day 4), the ‘intermediate’ osteogenic 
marker gene osteopontin (OP) (day 7) and the ‘late’ osteocalcin (OC) (day 14) and bone 
sialoprotein (BSP) (day 14) genes, as described below.  
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 Total RNA was isolated from PDL cells using the RNeasy Mini Kit (Qiagen, Crawley, 
UK) according to the manufacturers instructions. For reverse transcription first strand cDNA 
was synthesized using 1 µg of total RNA, as previously described (Singhatanadgit et al, 
2009), with primers obtained from Applied Biosystems (Applied Biosystems, Foster City, 
CA). Q-PCR analysis was carried out using the ABI Prism® 7300 sequence detector (Applied 
Biosystems), the Taqman® Gene Expression Assay consisting of the unlabelled specific PCR 
primers and Taqman® MGB probes with FAMTM dye labeling in a 96-well plate format. 
Thermal cycler conditions were used as recommended by the manufacturer and the data were 
collected and analyzed by the SDS 1.2 software (Applied Biosystems). All PCR reactions 
were performed in triplicate and each of the gene cycle threshold (ct) value normalized to the 
GAPDH ct values detected simultaneously on the same plate.  
 
4.2.5. ALP activity assay  
PDL cells were cultured in OM with and without EMD, Fraction C and Fraction A, with the 
medium changed every 3 days. Since ALP is involved in a late phase of mineralization 
(Singhatanadgit et al., 2006) it’s activity in PDL cells was measured on day 14, as described 
previously (Singhatanadgit et al, 2006). Briefly, triplicate wells were washed with PBS and 
the cells incubated with 200 µl of 5 mM p-nitrophenyl phosphate in 50 mM glycine, 1 mM 
MgCl2 and 150 mM 2-amino-2-methyl-1-propanol buffer, pH 10.5, at 37oC for 1 h. A 50 µl 
aliquot of 3 M NaOH was added to stop the enzymatic reaction and the absorbance measured 
at 405 nm (A405).  
 
4.2.6. Effects of a BMP-antagonist noggin and a TGFβ-antagonist UB-505124 on EMD, 
Fraction C and Fraction A-mediated PDL osteogenesis  
To determine whether EMD, Fraction C and Fraction A act via a BMP and/or TGFβ-
dependent pathway, the effects of noggin, a BMP pathway inhibitor (Chen et al., 2004; 
Miyazono, 2000), and UB-505124, a TGFβ pathway inhibitor (DaCosta et al., 2004; 
Miyazono, 2000), on PDL osteogenesis was measured, as described below. PDL cells were 
plated and cultured in OM for 2 weeks in the presence of EMD, Fraction C and Fraction A. 
Replicate test cultures also contained 100 ng/ml of noggin (Peprotech, London, UK) or 1 µM 
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UB505124. After 2 weeks, the cultures were stained with alizarin red S and the formation of 
mineralized nodules measured as described above. 
 
4.2.7. Effects of EMD, Fraction C and Fraction A on the Smad pathway of osteogenic 
regulation  
Smad1/5/8 is an inactive cytoplasmic protein complex that is activated by phosphorylation to 
p-Smad1/5/8 and then translocated to the nucleus where it acts as a transcription factor for the 
BMP gene, thereby stimulating osteogenic activity (Rider et al., 2010; Miyazono, 2000). To 
determine the effects of EMD, Fractions C and Fraction A on Smad1/5/8 activation to p-
Smad1/5/8, flow cytometry (FCM) was used to examine changes in the relative levels of p-
Smad1/5/8 and immunocytochemistry was carried out to examine changes in intracellular 
localization, as described previously (Amin et al., 2011; Singhatanadgit et al, 2006).  
Briefly, PDL cells were incubated in 24-well plates in GM for 3 days, GM was then 
replaced with low glucose-DMEM with 1% FBS for a further period of 48 h in order to 
reduce the levels of endogenous growth factors. In order to eliminate the presence of any 
exogenous growth factors, the culture medium was replaced with (1) completely serum-free 
OM containing low glucose-DMEM, 0.1 mM L-ascorbic acid 2-phosphate, 10 mM β- 
glycerophosphate and 10 nM dexamethasone (all from Sigma), (2) serum-free OM + EMD 
(100 µg/ml), (3) serum-free OM + Fraction C (100 µg/ml) and (4) serum-free OM + Fraction 
A (100 µg/ml), and further cultured for 1 h. For the FCM, after treatment of the PDL cells 
with EMD, Fraction C and Fraction A as above, the cells were detached with 0.05% (w/v) 
trypsin and 0.05 mM (w/v) EDTA (trypsin-EDTA) for 5 min at RT, fixed with 1% 
paraformaldehyde, permeabilised with 0.1% Triton X and blocked for 20 min using 10% 
NGS. Cells were then incubated with 1:100 rabbit polyclonal anti-p-Smad1/5/8 (Insight 
Biotechnology, London, UK) for 1 h. After washing, the cells were further incubated with 
FITC-conjugated goat anti-rabbit (1:200) for 1 h at RT. FITC- conjugated normal rabbit IgG 
was used as a negative control. The cells were centrifuged and re-suspended in 200 µl of PBS 
and the fluorescence intensity of 10,000 individual cells measured using a flow cytometer 
(FACScan; Becton-Dickinson, Cowley, UK). Data analysis was carried out using the 
WinMDI 2.8 software program. 
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For immunocytochemistry, after treatment of the PDL cell monolayers with EMD, 
Fraction C and Fraction A as above, the cells were fixed with 4% paraformaldehyde for 
15 min at RT and permeabilised using 0.1% Triton X (Sigma) for 15 min at RT. They were 
then treated with 10% NGS in PBS for 1 h, followed by incubation for 1 h at RT with 1:100 
rabbit polyclonal anti-p-Smad1/5/8 (Insight Biotechnology). After washing, FITC-conjugated 
goat anti-rabbit was added (1:200) for 1 h at RT. Nuclei were stained with Hoechst stain, and 
p-Smad1/5/8-positive cells were visualized by their green fluorescent staining.  
 Smad6 is a negative regulator of BMP-mediated osteogenic differentiation, exerting its 
activity by binding to and inhibiting the phosphorylation of the Smad1/5/8 complex (Wu et 
al., 2004). This prevents translocation to the nucleus and thereby blocks its function as a BMP 
transcription factor, as noted above (Chen et al., 2004). To examine the effects of EMD, 
Fraction C and Fraction A on the Smad6 gene, the PDL cells were cultured in OM in the 
presence of these proteins (all used at 100 µg/ml) and gene expression assessed by 
conventional PCR on day 4, as previously described (Amin et al, 2011). Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), a housekeeping gene was used as an endogenous 
control. The sequences of the forward and reverse primers (from Sigma-Genosys, 
Pampisford, UK): Smad6 forward: AAAGACGCACTTTGGCTTA, reverse: 
CGAATACTTTATTATCGAGTGACTG; GAPDH forward:  
CCACCCATGGCAAATTCCCATGGCA, reverse: CTGGACGGCAGGTCAGGTCCACC. 
Smad6 primers were used at an annealing temperature of 57oC for 30 cycles and GAPDH 
primers were used at an annealing temperature of 55oC for 25 cycles.  
 
4.2.8. Identification of the bioactive components of EMD, Fraction C and Fraction A 
As noted above, TRAP is a naturally-occurring 45-amino acid proteolytic product of the full-
length amelogenin protein, and is the major component of Fraction C (Mumulidu et al., 2007; 
Fincham et al., 1993). LRAP is a naturally-occurring 56-amino acid spliced form of 
amelogenin, and is a major component of Fraction A, as previously reported (Mumulidu et 
al., 2007; Fincham et al., 1993). We have identified that TCT is the unique 12-amino acid C-
terminal sequence present in TRAP, while LCT is the unique 23-amino acid C-terminal 
sequence present in LRAP. TCT and the parent peptide TRAP, and LCT and the parent 
peptide LRAP were chemically synthesized (Insight Biotechnology) (Table 4), diluted in cell 
culture grade water (Thermo Scientific, Basingstoke, UK) and 1 µg/ml of each added directly 
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to the PDL cells, clone 7, AB cells and BMSC when they reached approximately 90% 
confluence. These concentrations were determined from their dose effects (from 0.1-100 
µg/ml) on terminal osteogenesis on PDL cells in vitro, as described above.  
 
4.2.9. Statistical analysis 
The PCR data are shown as the mean fold-change ± standard error (± SE) of three separate 
experiments compared with that of control cells cultured in OM alone (defined as 1.0). 
Alizarin red staining intensity is shown as the relative staining intensity ± SE of three separate 
experiments compared with OM alone (defined as 1.0). FCM data is presented as the mean 
average fluorescence intensity (AFI ± SE) of three separate experiments. One-way ANOVA 
was used to assess statistical significant difference followed by the post-hoc Bonferroni test 
for multiple comparisons between the means (p<0.05) (SPSS 11.0 software, Chicago, IL).  
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4.3. Results 
4.3.1. Effects of EMD and the EMD Fractions on terminal differentiation of bone-
forming cells 
Increasing concentrations of the EMD preparation used in the present study were found to 
progressively stimulate the formation of bone-like mineralized nodules by PDL cells, a key 
indicator of their ability to undergo terminal osteogenic differentiation in vitro (Fig. 4.1), with 
100 µg/ml of EMD resulting in a 430% increase in alizarin red staining intensity compared 
with control PDL cells cultured in OM alone (p<0.05). In marked contrast, increasing 
concentrations of Fraction C decreased alizarin red staining, with 100 µg/ml resulting in a 
30% reduction in staining intensity (p<0.05; Fig. 4.1). Notably, as with EMD, increasing 
concentrations of Fraction A progressively increased terminal osteogenic differentiation of 
the PDL cells, with 100 µg/ml resulting in a level that was 680% higher than found when the 
cells were cultured in OM alone, as shown in Figure 4.1 (p<0.05). These results thus show 
that 100 µg/ml of EMD and Fraction A are stimulatory, whereas 100 µg/ml of Fraction C is 
inhibitory to terminal osteogenic differentiation of PDL cells. Since EMD and the EMD 
Fractions were found to have the most pronounced effect on PDL osteogenesis at 100 µg/ml, 
this concentration was used throughout the experiments reported below.  
EMD and the EMD Fractions were also found to have similar effects on other bone-
forming cells, as shown in Fig. 4.1. Thus, when PDL clone 7 (an osteogenic precursor/stem 
cell-like clone isolated from adult human PDL; Singhatanadgit et al., 2009) was cultured in 
OM in the presence of 100 µg/ml of EMD, there was a significant increase (220%; p<0.05) in 
alizarin red staining intensity observed compared with OM alone. In contrast, in the presence 
of Fraction C the staining intensity decreased by 40% compared with OM alone (p<0.05) 
while, as with EMD, the presence of Fraction A resulted in a 450% increase in staining 
intensity (Fig. 4.1). Similar effects on mineralization were also observed with both AB and 
BMSC cells, which were stimulated by EMD  (staining intensity 2.6 and 2.0, respectively; 
p<0.05) and also by Fraction A (370% and 280% increase, respectively; p<0.05) compared 
with OM alone. In contrast, Fraction C reduced the staining intensities of these two types of 
bone-forming cell by 30% and 40%, respectively, compared with OM alone (p<0.05). Thus 
the differential effects of the EMD Fractions were exerted not only on the heterogeneous PDL 
cell population but also on the isolated osteogenic clone, AB cells and the BMSC. 
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Figure 4.1. Effects of EMD, Fraction C and Fraction A on terminal osteogenic differentiation 
of PDL and other bone-forming cells. Alizarin red staining of the cells cultured for 3 weeks in 
OM in the presence of EMD, Fraction C and Fraction A at concentrations 1, 3, 10, 30 and 
100 µg/ml for the PDL cells and 100 µg/ml for the PDL clone 7, AB and BMSC. The numbers 
are the relative staining intensities compared with OM alone, defined as 1.0.  
*Indicates statistically significant difference compared with OM alone p<0.05. 
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4.3.2. Effects of EMD, Fraction C and Fraction A on the expression of bone-associated 
markers  
The results in Table 3 show that EMD significantly up-regulated the expression of the ‘early’ 
osteogenic transcription factor Runx2 after 4 days (approximately 2-fold), whereas the 
presence of Fraction C had no effect compared with OM alone. As with EMD, Fraction A 
also up-regulated Runx2 nearly 2-fold (p<0.05) (Table 3). Similarly, the intermediate OP and 
late osteogenic marker genes OC and BSP, and ALP activity were all found to be 
significantly up-regulated by both EMD and Fraction A, whereas Fraction C significantly 
down-regulated all of these genes except for OP (Table 3). These results thus demonstrate that 
although Fraction C had no effect on the early Runx2 and intermediate OP genes, it 
nevertheless suppressed the key late markers OC, BSP and ALP, and it also suppressed the 
terminal osteogenic differentiation of PDL and other bone-forming cells as described above. 
Moreover, it also suggests that Fractions C and A, two different components of EMD, have 
completely opposite effects on bone-forming cells. 
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4.3.3. Effects of noggin and UB505124 on EMD, Fraction C and Fraction A-mediated 
osteogenesis 
To determine whether EMD and the EMD Fractions act by modulating the BMP- and TGFβ-
mediated pathways of osteogenic differentiation, the PDL cells were incubated in OM in the 
absence and presence of noggin, a BMP pathway inhibitor, and UB505124, a TGFβ pathway 
inhibitor. The results in Figure 4.2 show that the presence of noggin or of UB505124 alone 
had no effect on the alizarin red staining intensity of control PDL cells cultured in OM. As 
before, when the cells were cultured in the presence of EMD the staining intensity 
significantly increased to 2.1. However, the concurrent presence of noggin or UB505124 in 
the EMD cultures markedly reduced the alizarin red levels compared with cultures incubated 
with EMD alone (from 2.1 to 1.0 and 1.4, respectively; p<0.05) (Fig. 4.2). Moreover, the 
presence of noggin and UB505124 similarly further reduced the low mineralization activity 
obtained in the presence of Fraction C alone (0.1 and 0.3, respectively, compared with 0.6; 
p<0.05). Notably, the high level of mineralization observed in the presence of Fraction A 
(3.5) was unaffected by noggin and UB505124 (3.1 and 3.1, respectively). These results thus 
suggest that the osteogenic activity of EMD and Fraction C, but not of Fraction A, is 
mediated via BMP and TGFβ-dependent pathways. 
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Figure 4.2. Alizarin red staining of PDL cells cultured for 14 days in OM in the presence of 
EMD (100 µg/ml), Fraction C (100 µg/ml) and Fraction A (100 µg/ml) with and without 
noggin and UB505124. The numbers are the alizarin red staining intensity. *Indicates 
statistically significant difference between noggin-treated verses untreated (p<0.05); 
§Indicates statistically significant difference between UB505124-treated verses untreated 
(p<0.05).  
 
 
 
 
 
 
 
 
Chapter 4                                            Effects of EMD and the EMD Fractions on osteogenesis 
  102 
4.3.4. Effects of EMD, Fraction C and Fraction A on the Smad pathway of osteogenic 
regulation 
The Smad pathway has previously been shown to modulate BMP-mediated osteogenic 
differentiation (Singhatanadgit et al., 2006; Miyazozo, 2000). In view of the apparent effect of 
EMD and the EMD Fractions on the BMP pathway, shown above, the effect of these proteins 
on the relative level of p-Smad1/5/8, the active form of the BMP transcription factor, was 
examined by FCM.  As shown in Figure 4.3, EMD and Fraction A were found to have no 
effect on p-Smad1/5/8 compared with serum-free OM alone, whereas the presence of Fraction 
C significantly reduced this activated complex by 42% (p<0.05). Moreover, 
immunocytochemical studies demonstrated that approximately 50% of the cells in the 
presence of serum-free OM alone and with EMD and Fraction A expressed p-Smad1/5/8, 
whereas in the presence of Fraction C no p-Smad1/5/8-positive cells were detected (Fig. 4.4). 
These results thus indicate that Fraction C inhibits osteogenic differentiation via suppression 
of activated p-Smad1/5/8.  
Smad6 has previously been shown to be a negative regulator of BMP-mediated 
osteogenesis that exerts its activity by binding to and preventing the phosphorylation and 
subsequent nuclear translocation of Smad1/5/8. To determine whether the apparent inhibitory 
effect of Fraction C on the level of p-Smad1/5/8, as shown above, was mediated via Smad6, 
the expression of the Smad 6 gene was examined in the absence and presence of EMD and the 
EMD Fractions. The results in Figure 4.5 show that while EMD and Fraction A did not cause 
any marked change in Smad6 gene expression, in the presence of Fraction C the Smad6 gene 
was significantly up-regulated (2-fold; p<0.05) compared with OM alone, These results thus 
suggest that Fraction C may inhibit osteogenic activity via stimulating Smad6, a negative 
regulator of the BMP pathway.  
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Figure 4.3.  FCM analysis of the effects of EMD and the EMD Fractions on intracellular 
levels of p-Smad1/5/8. Cells were immunostained for p-Smad1/5/8 after 1 h of incubation in 
the presence of 100 µg/ml of EMD, Fraction C and Fraction A. The numbers show the AFI of 
10,000 cells cultured in the presence of serum free OM alone and in the presence of EMD, 
Fraction C and Fraction A, as described in Materials and methods. *Indicates a statistically 
significant decrease of 42% compared with OM alone (p<0.05) 
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Figure 4.4. Effects of EMD and the EMD Fractions on p-Smad1/5/8 localization. 
Immunostaining of p-Smad1/5/8 after 60 min of incubation of PDL cells in serum free OM in 
the absence and presence of 100 µg/ml of EMD, Fraction C and Fraction A. Nuclei are 
stained blue with Hoechst dye, and the white arrows show the green fluorescence-stained 
PDL cells positive for p-Smad1/5/8. Note the nuclear localization of p-Smad1/5/8.  
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Figure 4.5. Effects of EMD and the EMD Fractions on Smad6 gene expression. 
Representative RT-PCR gel showing the expression of Smad6 transcripts of PDL cells 
cultured in OM in the presence of 100 µg/ml of EMD, Fraction C and Fraction A. GAPDH 
was used as an endogenous control to normalize the gene expression. The numbers below the 
representative electrophoresis gels show the fold induction of the EMD and the EMD 
Fractions treated cells compared with control cells cultured in OM alone, defined as 1.0. 
*Indicates statistically significant difference compared with OM alone (p<0.05) 
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4.3.5. Effects of synthetic amelogenin peptides on bone-forming cells 
The TRAP and LRAP peptides are major components of Fractions C and A, respectively, as 
noted above. In view of the effects of these Fractions on osteogenic differentiation, 
chemically synthesized TRAP and LRAP were obtained and examined for their effect on the 
terminal osteogenic differentiation of bone-forming cells. As with Fraction C, synthetic 
TRAP (1 µg/ml) significantly reduced bone-like nodule formation and the alizarin red 
staining intensity of the PDL cells, clone 7, AB cells and BMSC (40-60% reduction; p<0.05) 
compared with OM alone (Figure 4.6). In contrast, as with Fraction A, 1 µg/ml of LRAP 
markedly stimulated bone-like nodule formation and increased the staining intensity of the 
PDL cells, clone 7, AB cells and BMSC (between 250 and 440% increases; p<0.05) 
compared with OM alone. These results thus demonstrate that the chemically synthesized 
amelogenin isoforms TRAP and LRAP exhibit activities that are similar to EMD Fractions C 
and A and further, these data suggest that TRAP and LRAP are the active components of 
EMD that differentially regulate osteogenic differentiation. 
Alignment of the TRAP and LRAP isoforms shows that the 33-amino acid sequence at 
the N-terminal of TRAP and of LRAP are common to each other (Table 4).  In view of the 
differential activities of TRAP and LRAP, it was considered that this overlapping sequence is 
likely to be devoid of the specific bone-modulating activity exhibited by TRAP and LRAP. In 
experiments not reported here, we found that concentrations between 0.1-100 µg/ml of this 
‘null’ peptide had no effect on cell mineralization in vitro (Appendix Material 1.1). In marked 
contrast, however, the 12-amino acid C-terminal peptide (TCT) unique to the osteogenesis-
inhibitory TRAP, and the 23-amino acid C-terminal peptide (LCT) unique to the 
osteogenesis-stimulatory LRAP, were found to have potent but opposite osteogenic effects, as 
shown in Figure 4.6. Thus, 1 µg/ml of TCT was found to strongly inhibit (between 30 and 
50% reduction; p<0.05), whereas 1 µg/ml of LCT strongly stimulated, terminal osteogenic 
differentiation of PDL cells, clone 7, AB cells and BMSC (between 240 and 590% increases; 
p<0.05), compared with OM alone (Fig. 4.6). These results indicate that the unique C-
terminal amino acid sequences of TRAP and LRAP, TCT and LCT respectively, are the 
bioactive sequences responsible for the differential activities of the parent amelogenin 
isoforms.    
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Figure 4.6. Effects of synthetic amelogenin isoforms and peptides on bone-forming cells. 
Alizarin red staining intensity of the PDL cells, clone 7, AB cells and BMSC cultured for 3 
weeks in OM in the presence of synthetic TRAP (1 µg/ml), LRAP (1 µg/ml), TCT (1 µg/ml) and 
LCT (1 µg/ml). The numbers are the relative staining intensity compared with OM alone, 
defined as 1.0. *Indicates statistically significant difference compared with OM alone 
(p<0.05) 
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4.4. Discussion 
A number of studies, including the present, have demonstrated that commercial preparation of 
EMD and crude preparation of EMP stimulate bone-associated markers and bone-like nodule 
formation of PDL and other bone-forming cells (Gestrelius et al., 1997; Van der pauw et al. 
2000; Nagano et al. 2004). In contrast, EMD and EMP have also been reported to inhibit the 
expression of osteogenic genes and mineralized bone-like nodule formation in vitro (Hamma 
et al., 2008; Hakki et al., 2001) and also in vivo (Donos et al, 2005; Donos et al., 2003; Heijl 
et al, 1997). At least some of these discrepancies may be due to qualitative as well as 
quantitative differences in the multiple components between EMD and EMP, and several 
attempts have therefore been made to fractionate freshly isolated non-heat treated porcine 
EMP, in order to delineate the putative osteomodulatory components (Suzuki et al., 2005; 
Johnson et al., 2009). However, such partially purified preparations often contain growth 
factors such as BMP-2 and TGF-β1 that are likely to have pronounced effects on bone cell 
activity (Suzuki et al., 2005; Johnson et al., 2009; Nagano et al., 2006). In addition, these 
fractions have also been reported to contain components of differing molecular sizes, 
including low-molecular (< 6 kDa) weight proteins (Suzuki et al., 2005; Johnson et al., 2009; 
Nagano et al., 2006). 
The present study has used two fractions of EMD (Fraction C and Fraction A) that 
have recently been isolated from a commercially available heat-treated extract of EMP 
(Emdogain®; EMD, Institut Straumann, Basel, Switzerland) using industrial scale protein 
fractionation methodologies (Mumulidu et al., 2007). The results obtained here demonstrated 
that 100 µg/ml of Fraction C, which comprises < 6 kDa EMD proteins, mainly TRAP, 
strongly suppressed the mineralization of PDL as well as other bone-forming cells, including 
osteogenic precursor/stem cell clone 7, AB cells and BMSC. Although Fraction C did not 
have any apparent effect on the early and intermediate osteogenic markers Runx2 and OP, 
respectively, the late markers OC, BSP and ALP were strongly inhibited by this fraction. In 
contrast, the presence of Fraction A, which comprises > 6 kDa EMD proteins and is devoid of 
Fraction C components, strongly stimulated the expression of early, intermediate and late 
osteogenic marker genes and also the terminal differentiation of the bone-forming cells. Thus, 
the variable outcomes of osteogenic differentiation in vitro and bone regeneration in vivo 
observed in the presence of non-fractionated EMD (Donos et al, 2005; Donos et al., 2003; 
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Heijl et al, 1997; Gestrelius et al., 1997; Van der pauw et al. 2000; Nagano et al. 2004; Hakki 
et al., 2001) may reflect at least partly differences in the relative proportions of these two 
fractions between different preparations of EMD and EMP.  
It has previously been shown that the BMP-2 and TGF-β1 pathways are involved in 
the regulation of bone-forming cell activity (DaCosta et al., 2004; Miyazono, 2000; Alliston 
et al., 2001; Elford et al., 1987; Katagiri et al., 1994; Singhatanadgit et al., 2006). To 
determine whether EMD and the EMD Fractions acted via one or both of these signaling 
pathways, the present study used noggin, a BMP-2 pathway inhibitor, and UB-505124, a 
TGF-β1 pathway inhibitor, to examine if the presence of these inhibitors abrogated the 
osteogenic effects of EMD and the Fractions. The results showed that in the presence of these 
inhibitors the mineralization of the cells was further reduced, suggesting that Fraction C 
inhibits osteogenic differentiation at least partly via BMP-2- and TGF-β1-induced 
intracellular messengers, consistent with a previous report that, in mouse C2C12 cell line, low 
molecular weight components in EMP were able to suppress BMP-2 and TGF-β1-dependent 
osteogenesis (Suzuki et al., 2005). In addition, the results reported here demonstrate that 
Fraction C reduced the intracellular level of the activated BMP-2 transcription factor complex 
p-Smad1/5/8 in PDL cells and it also stimulated the expression of the Smad6 gene, which is 
known to act as a BMP-2 pathway negative regulator (Wu et al., 2004). Taken together these 
data indicate that Fraction C in EMD suppresses osteogenesis by up-regulating the inhibitory 
Smad6 that binds to and blocks the phosphorylation and subsequent nuclear translocation of 
the Smad1/5/8 complex.   
In contrast to previous reports that BMP-2 and TGF-β1 growth factors may be present 
in a high molecular weight EMP fraction (e.g., 10-20 kDa) (Nagano et al., 2004; Suzuki et al., 
2005; Johnson et al., 2009), in the present investigation it was observed that the stimulatory 
effects of Fraction A were unaffected by the BMP-2 and TGF-β1 inhibitors, suggesting that 
this Fraction (6 to 20 kDa components) is unlikely to contain BMP-2- and TGF-β1-like 
activities. Moreover, it further indicates that Fraction A stimulates bone via signaling 
pathway(s) independent of BMP-2 and TGF-β1, possibly such as those mediated by 
parathyroid hormone and the hedgehog and Wnt families (Williams et al., 2009; Wu et al., 
2004).  
Since TRAP and LRAP are major components of Fractions C and A, respectively, the 
present study also investigated the effects of chemically-synthesized TRAP and LRAP on 
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bone-forming cells. As with Fraction C, synthetic TRAP suppressed whereas, as with Fraction 
A, synthetic LRAP stimulated the osteogenic differentiation of the PDL cells. Although a 
previous report has suggested that the C-terminal amino acid sequence of LRAP might be 
responsible for the bioactivity of the parent protein (Veis et al., 2000), hitherto there has been 
no definitive evidence for the molecular identities of the active peptides. To delineate the 
specific sequences that are most likely to modulate osteogenic differentiation we compared 
the TRAP and LRAP amino acid sequences, which revealed that while the 33-amino acid 
sequence at the N-terminal of both the peptides are identical, the 12-amino acid (TCT) and 
the 23-amino acid (LCT) sequences at the C-terminals of TRAP and LRAP, respectively, are 
unique to each. These sequences were therefore chemically synthesized and examined for 
osteogenic activity, and found to inhibit and stimulate bone-forming cells, respectively. 
Moreover, protein homology analysis of the TRAP and LRAP amino acid sequences, using 
the National Centre for Biotechnology Information (NCBI) protein database and BLAST 
software (NCBI, Bethesda, MD), showed that these TCT and LCT amino acid sequences 
were the domains that were the most ‘conserved’ TRAP and LRAP sequences of > 100 
different animal species, further indicating the possible physiological importance of these 
small unique C-terminal amino acid sequences in modulating the process of bone formation. 
These findings thus demonstrate, for the first time, that the C-terminal TCT and LCT peptide 
sequences exhibit the osteogenic bioactivities of the respective TRAP and LRAP amelogenin-
derived parent peptides. 
Although a number of techniques and materials are available for achieving bone 
regeneration, including the use of different types of bone graft as well as the FDA-approved 
BMP-2/INFUSE, their predictability and efficacy in terms of clinical outcome remain 
uncertain. The novel bioactive 23-amino acid LCT amelogenin sequence identified here can 
be produced synthetically in large quantities and with high purity, and may have the potential 
to significantly improve therapeutic options for periodontal disease, while the novel 12-amino 
acid TCT peptide might prove to be a valuable tool for limiting pathological bone cell 
growth.     
In conclusion, two main fractions of EMD, Fraction C and Fraction A, which contain 
the amelogenin isoforms TRAP and LRAP, respectively, elicited differential bone-forming 
responses in vitro. Furthermore, while naturally occurring Fraction C and the synthetically 
produced TRAP and its unique C-terminal TCT sequence all strongly suppressed bone-
forming cells, the naturally-occurring Fraction A and the synthetically produced LRAP and its 
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unique C-terminal LCT sequence strongly induced terminal differentiation of bone-forming 
cells.  
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Chapter 5 
5.1. Introduction 
A number of reports, including the present (Chapter 3), have shown that despite the absence 
of adipocytes in PDL tissue at least some cells in adult human PDL are nevertheless capable 
of adipogenic differentiation (Amin et al., 2011; Huang et al., 2009; Singhatanadgit et al., 
2009; Kawanabe et al., 2010; Xu et al., 2009; Fujii et al., 2008). PDL also comprises a cell 
population capable of undergoing chondrogenesis in vitro, even though the maxilla and 
mandibular bones of the facial skeleton are considered to develop from MSC directly via 
intramembranous ossification (Chapter 1). Chondrogenic precursors are thus also unlikely to 
be present in the periodontium or to be involved in periodontal regeneration (Lee et al., 2001; 
Huang et al., 2009; Singhatanadgit et al., 2009; Kawanabe et al., 2010; Xu et al., 2009; Fujii 
et al., 2008). 
Adipogenic and chondrogenic differentiation are two major pathways of mesenchymal 
differentiation and consequently widely studied in delineating mesenchymal stem cell-like 
populations. In addition, previous studies have shown that EMD can modulate these pathways 
in the mouse mesenchymal C2C12 and C3H10T1/2 and chondrogenic ATDC5 cell lines in 
vitro (Narukawa et al., 2006; Narukawa et al., 2007; Ohyama et al., 2002). Although EMD 
appeared to inhibit adipogenic differentiation and stimulate chondrogenic differentiation of 
these cells (Narukawa et al., 2006; Narukawa et al., 2007; Ohyama et al., 2002), it is not yet 
known which component(s) in EMD exhibit these (differential) modulatory activities. The 
present study therefore examined the effects of the various EMD components on the 
adipogenic and chondrogenic capabilities of PDL cells in vitro. 
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5.2. Materials and methods  
PDL cell culture and RT-PCR were performed as described in Chapter 2; additional methods 
used in this chapter are described below. 
 
5.2.1. Treatment of cells with EMD and the EMD Fractions 
EMD, Fraction A and Fraction C were diluted in 0.1% acetic acid and added directly to the 
cells when they reached approximately 90% confluence. EMD and Fraction A were used at a 
final concentration of 100 µg/ml, whereas Fraction C was used at a final concentration of 10 
µg/ml throughout the experiments, unless otherwise stated. These concentrations were 
determined from the dose effects of EMD, Fraction A and Fraction C on terminal PDL cell 
adipogenesis and chondrogenesis in vitro, as described below. 
 
5.2.2. Effects of EMD and the EMD Fractions on adipogenic differentiation  
The cells were cultured in GM and then adipogenic medium (AM) added, consisting of GM 
supplemented with 0.5 µM 3-isobutyl-1-methylxanthine, 50 µM indomethacine and 10 nM 
dexamethasone (all from Sigma) in the absence (control sample) and presence (test samples) 
of 1, 3, 10, 30 and 100 µg/ml of EMD, Fraction A and Fraction C to assess the effects of 
different doses on adipogenic differentiation, as follows (Amin et al., 2011). After 5 weeks, 
the cell monolayers were fixed with 10% formalin for 30 min, incubated with 60% propan-2-
ol for 5 min and then stained with 0.2% Oil Red O in propan-2-ol for 5 min. After washing 
with tap water, the samples were counterstained with Harris Hematoxylin. For quantification 
of Oil Red O, the samples (without counter staining) were extracted into 100% propan-2-ol 
and the absorbance measured at 490 nm (A490).  
 Total RNA was extracted from replicate cultures after 3 and 5 weeks for PCR analysis 
of the early adipogenic marker PPARγ2 (week 3) and the late marker LPL (week 5), as 
described in Chapter 2. 
 
 
5.2.3. Effects of EMD and the EMD Fractions on chondrogenic differentiation  
The PDL cells were trypsinized and 2.5x105 cells suspended in 0.5 ml of serum-free 
chondrogenic medium (CM) (Lonza, Wokingham, UK) (low glucose-DMEM containing 
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insulin, transferrin, selenious acid, bovine serum albumin, linoleic acid, dexamethasone, 
ascorbate-phosphate, proline, pyruvate and TGF-β3) and placed in 15 ml conical 
polypropylene centrifuge tubes (Nunc). After centrifugation at 200g for 5 min, the pellets 
were incubated in CM in the absence (control sample) and presence (test sample) of 1, 3, 10, 
30 and 100 µg/ml of EMD and the EMD Fractions at 37°C for 3 weeks, with caps loosened to 
allow gas exchange, then Alcian blue staining for acid mucopolysaccharides and 
glycosaminoglycans was also carried out to assess terminal chondrogenic differentiation as 
follows (Amin et l., 2011). Cell pellets were fixed in 10% formalin at 4˚C for 24 h, 
dehydrated in an ascending series of ethanol and embedded in paraffin. Sections (3 µm) were 
cut, stained with 1% Alcian blue (pH 2.5) (Sigma) for 5 min. The deposition of 
mucopolysaccharides and glycosaminoglycans was visualized as blue staining of the 
extracellular matrix. Nuclei were stained purple using Harris hematoxylin. Total RNA was 
extracted from the replicate cultures for PCR analysis of the early chondrogenic marker gene 
Sox-9 (after 1 week) and the late markers aggrecan and Col2a1 (after 2 weeks).    
   
   
5.2.5. Statistical analysis 
The RT-PCR data are presented as the mean of the triplicate measurements of cells cultured 
in AM or CM in the presence of EMD and the EMD Fractions compared with that of cell 
cultured in AM or CM alone (defined as 1.0). One-way ANOVA followed by post-hoc 
Bonferroni test (for multiple comparison) was used for statistical analysis (SPSS 12.0 
software, Chicago, IL). 
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5. 3. Results 
5.3.1. Dose-effects of EMD and the EMD Fractions on PDL cell adipogenesis 
It was shown in Chapter 3 that PDL cells cultured in AM alone produced Oil red O- positive 
lipid-like droplets and that the Oil red O staining intensity was significantly higher in cells 
cultured in AM alone (1.3) compared with the cells cultured in non-differentiation-inducing 
GM (0.5). To examine the effects of EMD and the EMD Fractions on terminal adipogenesis, 
the PDL cells were cultured in AM in the absence and presence of varying concentrations 
(from 1-100 µg/ml) of EMD, Fraction A and Fraction C for 5 weeks, stained with the Oil red 
O and the Oil red O staining intensities measured as described in Section 5.2. The results in 
Figure 5.1 (i, ii) show that the addition of EMD, Fraction A and Fraction C at all 
concentrations (1 to 100 µg/ml) significantly reduced the formation of Oil red O-positive 
lipid-like droplets and the corresponding staining intensities of the PDL cells compared with 
the control cells cultured in AM alone (p<0.05). It is notable that the staining intensities of the 
cells cultured in the presence of EMD and the EMD Fractions were similar to that of the cells 
cultured in non-differentiation-inducing GM alone. 
 Moreover, representative PCR bands in Figure 5.2 (i) show that the cells cultured in 
AM with EMD and the EMD Fractions (all at 100 µg/ml) also expressed significantly reduced 
levels of the early and late adipogenic genes PPARγ2 and LPL, respectively, compared with 
cells cultured in AM alone (p<0.05) (Fig. 5.2 (ii)). These results thus suggest that EMD, 
Fraction A and Fraction C all suppress adipogenic differentiation of the PDL cells.       
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Figure 5.1. Effects of varying concentrations of EMD, Fraction A and Fraction C on terminal 
adipogenic differentiation of PDL cells. (i) Oil red O staining intensity of the PDL cells 
cultured in AM in the presence of 1, 3, 10, 30 and 100 µg/ml EMD, Fraction A and Fraction 
C for 5 weeks. The values are the mean ±SE of triplicate measurements *Indicates 
statistically significant difference compared with GM alone (p<0.05); §Indicates statistically 
significant difference compared with AM alone (p<0.05). (ii) Representative Oil red O 
staining of PDL cells cultured in AM in the presence of EMD and the EMD Fractions for 5 
weeks. Nuclei are counter-stained purple with Harris Hematoxylin, and the back arrows show 
lipid-like droplets stained red with Oil red O. Magnification x20.   
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Figure 5.2. Effects of EMD and the EMD Fractions on adipogenic genes of PDL cells. (i) A 
representative RT-PCR gel showing the expression of the adipogenic genes PPARγ2 and LPL 
by PDL cells cultured for 3 and 5 weeks, respectively, in AM in the presence of EMD, 
Fraction A and Fraction C. (ii) The values are the changes in PCR product band intensity 
relative to GAPDH of cells cultured in the presence of EMD and the EMD Fractions 
compared with AM alone, defined as 1.0. The values are the means ±SE of triplicate 
measurements. *Indicates statistically significant difference compared with GM alone 
(p<0.05); §Indicates statistically significant difference compared with AM alone. 
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5.3.2. Dose-effects of EMD and the EMD Fractions on PDL cell chondrogenesis 
It was shown in Chapter 3 that under culture conditions that enable chondrogenic 
differentiation, PDL cells in pellet cultures were able to produce Alcian blue-positive acid 
mucopolysaccharide and glycosaminoglycan-rich ECM characteristic of terminal 
chondrogenic differentiation in vitro, whereas Alcian blue-positive ECM was not detected in 
cultures incubated in non-selective GM (Fig. 5.3 (i)).  
To examine the effects of EMD and the EMD Fractions on PDL cell chondrogenesis, 
cell pellets were cultured in CM in the presence of EMD, Fraction A and Fraction C (from 1-
100 µg/ml) for 3 weeks, sectioned and stained with Alcian blue, as described in Section 5.2. 
The results in Figure 5.3 (ii) show that increasing concentrations of EMD progressively 
stimulated mucopolysaccharide and glycosaminoglycan production. Thus, strong Alcian blue 
staining of the ECM was observed in the presence of 100 µg/ml of EMD, while at lower 
concentrations of EMD (between 1 and 30 µg/ml) weaker staining was observed. In marked 
contrast, little if any Alcian blue-positive ECM was observed when cell pellets were cultured 
in the presence of Fraction A (from 1-100 µg/ml) (Fig. 5.3 (ii)). Notably, increasing 
concentrations of Fraction C were, like EMD, also found to have an apparent stimulatory 
effect on PDL cell chondrogenesis. Thus, while 1 and 3 µg/ml of Fraction C had little effect, 
10 and 30 µg/ml appeared to produce substantial amounts of Alcian blue-positive ECM, 
which did not increase further at 100 µg/ml. These results indicate that 100 µg/ml of EMD 
and 10-30 µg/ml of Fraction C had the maximum stimulatory effect, whereas all the 
concentrations of Fraction A tested in the present study appeared to be inhibitory to terminal 
chondrogenic differentiation of the PDL cells.  
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(ii)  
 
 
Figure 5.3. Effects of varying concentrations of EMD and the EMD Fractions on terminal 
chondrogenic differentiation. Alcian blue staining of paraffin sections (3 µm) prepared from 
pellet cultures maintained for 3 weeks in  (i) GM and CM alone and (ii) in CM with 1, 3, 10, 
30 and 100 µg/ml EMD, Fraction A and Fraction C. Nuclei are counter-stained purple with 
Harris hematoxylin and the Alcian blue stained ECM was visualized blue, which is 
particularly apparent in CM + EMD and CM + Fraction C. Magnification x50.   
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It was shown in Chapter 3 and here that under chondrogenic conditions, PDL cells in 
pellet cultures expressed higher levels of the early chondrogenic transcription factor Sox-9 
(3.2-fold) and the late genes Aggrecan (1.7-fold) and Col2a1 (1.9-fold) compared with pellets 
cultures in GM alone (p<0.05) (Fig. 5.4 (i, ii)). However, representative PCR bands show that 
the presence of EMD, Fraction A and Fraction C in CM did not cause any significant change 
in the Sox-9 gene compared with the cells cultured in CM alone (Fig. 5.4 (i, ii)). In contrast, 
the late chondrogenic matrix gene Aggrecan and Col2a1 were both markedly stimulated by 
EMD (3.8- and 4.0-fold) and by Fraction C (9.4- and -10.5-fold) compared with cells cultured 
in CM alone (p<0.05). In contrast, as with terminal chondrogenic differentiation, Fraction A 
significantly suppressed the Aggrecan and Col2a1 genes compared with cells cultured in CM 
alone (p<0.05). These results thus suggest that EMD and Fraction C strongly stimulate, 
whereas Fraction A inhibits, PDL cell chondrogenesis. 
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Figure 5.4. Effects of EMD and the EMD Fractions on chondrogenic gene expression by PDL 
cells. (i) A representative RT-PCR gel showing the expression of Sox-9 (week 1) and the late 
Aggrecan and Col2a1 (week 2) genes by PDL cells cultured in CM in the presence of EMD, 
Fraction A and Fraction C. (ii) The values are the changes in PCR product band intensity 
relative to GAPDH obtained in CM in the presence of EMD and the EMD Fractions 
compared with CM alone, defined as 1.0. The values are the means ±SE of triplicate 
measurements. *Indicates statistically significant difference compared with GM alone 
(p<0.05);§Indicates statistically significant difference compared with CM alone (p<0.05). 
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5.4. Discussion 
Despite the histological absence of adipocytes and chondrocytes from PDL tissue, PDL cells 
have been shown (Chapter 3; Amin et al., 2011; Singhatanadgit et al., 2009; Tomokiyo et al., 
2007; Xu et al., 2009; Cheng et al., 2009) to be able to differentiate into functional 
adipocytes, cells capable of producing lipid-like droplets, and chondrocytes, cells with the 
ability to produce mucopolysaccharide- and glycosaminoglycan-rich ECM. It is thus likely 
that the PDL contains a precursor/stem cell-like population capable of undergoing these key 
mesenchymal differentiation pathways, in addition to osteogenesis as shown in Chapter 3, and 
the effects of EMD on these pathways have previously been investigated in order to 
understand the regulation of mesenchymal stem cells, including bone precursors (Narukawa 
et al., 2006; Narukawa et al., 2007; Ohyama et al., 2002). Thus EMD has previously been 
found to modulate adipogenic and chondrogenic differentiation of several different mouse 
mesenchymal and chondrogenic cell lines (Narukawa et al., 2006; Narukawa et al., 2007; 
Ohyama et al., 2002), and the present study investigated whether components in EMD were 
able to regulate the adipogenic and chondrogenic differentiation pathways in PDL cells.  
The present results showed that while culture in AM alone up-regulated both the early 
PPARγ2 and the late LPL gene, and produced lipid-like droplets which stained positive for oil 
red O, all concentrations of EMD and the EMD Fractions tested here strongly suppressed 
terminal adipogenic differentiation and markedly inhibited adipogenic genes. Similarly, 
although the Fractions of EMD were not used, EMD was shown to suppress adipogenic 
marker genes PPARγ2 and LPL and up-regulate osteogenic markers ALP and osteocalcin of 
the mouse mesenchymal cell line C2C12 (Ohyama et al., 2002). Although the exact reason for 
this is not clear, it possible that the inhibitory activity of EMD and the EMD Fractions may at 
least partly be due to the modulation of the Runx2-PPARγ2 ‘switch’, a mesenchymal cell 
differentiation regulatory mechanism in which the adipogenic PPARγ2 gene is down-
regulated while the osteogenic transcription factor Runx2 is concomitantly up-regulated 
(Takada et al., 2009), consistent with the observation that EMD- and the EMD Fraction A 
down-regulated PPARγ2 and up-regulated Runx2 (Chapter 4). Moreover, EMD has been 
shown to stimulate osteogenesis via BMP and TGFβ signal transduction pathways and these 
signaling pathways have previously been shown to inhibit adipogenesis (Katagiri et al., 1994; 
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Suzuki et al., 2005; Van der Pauw et al., 2000). These results thus demonstrate that the EMD 
and the EMD components strongly suppress adipogenic differentiation of PDL cells.  
As shown in Chapter 3, under CM PDL cell pellets expressed chondrogenic genes 
Sox-9 and aggrecan and stained for Alcian blue-positive mucopolysaccharide and 
glycosaminoglycan-rich ECM. The addition of EMD and Fraction C further increased, 
whereas Fraction A decreased, overall staining of mucopolysaccharide and 
glycosaminoglycan in ECM and the expression of the late chondrogenic genes Aggrecan and 
Col2a1 expression of the PDL cells. In contrast to a previous report (Narukawa et al., 2007) in 
which EMD was found to stimulate Sox-9 expression of chondrogenic ATDC5 cell line, the 
present study showed that EMD and the EMD Fractions did not affect the Sox-9 gene of PDL 
cells. This may be due at least partly to the use of non-heat treated EMD preparation in the 
previous study, which was found to have IGF and TGFβ-like growth factors, and also to 
differences in the types of cell. These findings thus suggest the possibility that while culture 
in CM resulted in stimulation of the key chondrogenic transcription factor Sox-9, the presence 
of EMD and Fraction C components in EMD up-regulated the late phase of chondrogenic 
differentiation (production of proteoglycan-rich ECM) by PDL cells cultured in pellets in 
vitro. 
These results demonstrate that although EMD and the EMD Fractions suppressed PDL 
adipogenesis, Fraction A and Fraction C exhibited differential effects on chondrogenesis of 
PDL cells, as found with osteogenesis (Chapter 4). 
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Chapter 6 
6.1. Introduction 
The PDL that supports the teeth is comprised primarily of fibroblasts, osteoblasts and 
osteoclasts and has recently been reported to also contain a progenitor/stem cell-like 
population that can undergo multi-lineage differentiation (Amin et al., 2011; Cheng et al., 
2009; Huang et al., 2008; Nagatomo et al., 2006; Singhatanadgit et al., 2009; Tomokiyo et al., 
2007; Xu et al., 2009). The homeostasis, repair and regeneration of PDL tissue are considered 
to be dependent on such progenitor cells and also the appropriate biological mediators and a 
sufficient blood supply (Cheng et al., 2009; Cochran et al., 1999; Huang et al., 2008; Molloy 
et al., 2003; Taba et al., 2005). Thus, growth factors, cytokines and morphogens have been 
shown to modulate the proliferation and differentiation of PDL cells and the production of 
extracellular matrix (ECM) in vitro (Cheng et al. 2009; Cochran et al., 1999; Huang et al., 
2008; Karring et al., 1993; Messenger et al., 2007; Molloy et al., 2003), while new vascular 
networks formed by progenitor cells ensure the supply of sufficient blood for the 
repair/wound healing of damaged PDL and the regeneration of healthy new tissue in vivo 
(Brey et al., 2005; Taba et al., 2005).  
It is now recognized that BV formation, the complex process of neovasculogenesis, 
comprises both vasculogenic and angiogenic differentiation during adult wound healing as 
well as in developing microenvironments (Brey et al., 2005; Flamme et al., 1997). The former 
process, vasculogenesis, the differentiation of progenitor/stem cells into endothelial cells 
(Brey et al., 2005; Flamme et al., 1997; Demir et al., 2007) and the latter, angiogenesis, the 
development of an organized network of tubular structures originating from endothelial 
precursors (Brey et al., 2005; D’Amore et al., 1987; Flamme et al., 1997), are regulated in 
vitro and in vivo by a number of biological mediators including vascular endothelial growth 
factor (VEGF), platelet-derived growth factor, insulin-like growth factor (IGF), transforming 
growth factor-beta (TGF-β), basic fibroblast growth factor (bFGF) and epidermal growth 
factor (EGF) (Brey et al., 2005; Cochran et al., 1999; Lynch et al., 1991; Molloy et al., 2003; 
Nomi et al., 2002; Pandya et al., 2006) and also by enamel matrix proteins (EMP) (Bertl et al., 
2009; Johnson et al., 2009; Kauvar et al., 2010; Messenger et al., 2007; Schlueter et al., 
2007). 
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EMP is a heterogeneous mixture of components consisting primarily of peptide 
isoforms derived from the full-length amelogenin gene transcript and is secreted during tooth 
development (Fincham et al., 1993). Crude preparation (non-heat treated) of EMP and 
commercially prepared heat-treated EMD has widely been used clinically for regenerating 
periodontal tissues, including PDL, alveolar bone and cementum, a mineralized tissue found 
uniquely in the periodontium (Hammarstrom et al., 1997; Cochran et al., 1999; Donos et al., 
2003). Several clinical studies carried out to evaluate the effects of EMP and EMD on 
periodontal soft tissue wound healing have led to a number of discrepancies (Wennstrom et 
al., 2002; Hagennars et al., 2004). For example, periodontal wounds treated topically with 
EMP exhibited rapid and complete healing, compared with the control sites that were not 
treated with EMP which exhibited only partial healing (Wennstrom et al., 2002). In contrast, 
it was shown that the test patient group treated with EMD exhibited only partial healing, 
similar to the control group that did not receive EMD (Hagennars et al., 2004). The reason(s) 
for this discrepancy are not known, but it may be at least partly due to lack of sufficient blood 
supply, i.e. differences in BV formation activity/neovasculogenic activity.  
A number of attempts have therefore been made in vitro to understand these apparent 
clinical discrepancies by examining the effects of EMD on angiogenic differentiation in vitro. 
However, such studies have been limited because some have used freshly isolated and non-
heat treated EMP while others have used commercially prepared and heat-treated EMD 
(Johnson et al., 2009; Yuan et al., 2003; Schlueter et al., 2007; Bertl et al., 2009; Thoma et al., 
2010). For example, while freshly extracted EMP has been found to strongly stimulate 
migration/chemotaxis and formation of a tubular network of human microvascular endothelial 
cells (HMVEC) in vitro (Johnson et al., 2009; Yuan et al., 2003), both Schlueter (2007) and 
Bertl (2009) showed that commercially prepared EMD did not induce HMVEC 
migration/chemotaxis in an in vitro monolayer cell wound healing assay. Since the 
components of EMP preparations are likely to vary qualitatively and quantitatively (detailed 
description in Section 9.1.2), a number of attempts have also been made to delineate the 
specific protein fractions in freshly isolated (and non-heat-treated) EMP and commercial 
preparation EMD that have angiogenic activity (Johnson et al., 2009; Thoma et al., 2010). For 
example, Johnson (2009) examined the effects of EMP fractions on HMVEC angiogenesis in 
vitro and observed that both low and high molecular weight fractions stimulate chemotaxis 
and tube formation of HMVEC, but the EMP fractions used contained proteins of differing 
sizes, with all the fractions containing some low molecular weight peptides. In addition, 
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Thoma (2011) examined the effects of EMD in a murine angiogenesis model in vivo and 
reported that both the low (< 6 KDa) and high (< 15 kDa) molecular weight fractions of heat-
treated EMD exhibited angiogenic activity, but could not identify specific component(s). 
Again, low molecular weight proteins were found to be present in all the fractions isolated 
from EMD (Thoma et al., 2011) and indicating that discrepancies in the effects of EMP and 
EMD on angiogenesis in vitro and in vivo could be associated with the use of heterogeneous 
fractions whose components could have differential effects on angiogenesis and use of 
differing endothelial cell culture conditions including culture media and length of time of 
EMP and EMD treatment.  
As described in previous Chapters (Chapters 4 and 5), two sub-fractions of the 
commercially available EMD, Fraction C and Fraction A, have been obtained by industrial 
scale protein fractionation methodologies (Mumulidu et al., 2007), with Fraction C 
comprising < 6 kDa peptides (mainly a 5.3 kDa tyrosine-rich amelogenin peptide (TRAP)) 
and Fraction A containing a mixture of > 6 kDa peptides including a leucine-rich amelogenin 
peptide (LRAP), sheathlin proteins and the full-length amelogenin protein (Mumulidu et al., 
2007). The latter components have been shown to have a role in the formation of hard tissue, 
including bone and cementum (Kanazashi et al., 2006; Warotayanont et al., 2008; Chapter 4), 
but neither Fraction C nor Fraction A have hitherto been examined to determine whether they 
affect neovasculogenesis. It was shown in Chapter 3 that PDL cells have the capacity to 
undergo vasculogenic differentiation when cultured in endothelial medium in vitro. The 
present study has therefore examined the response of PDL cells to EMD, Fraction A, Fraction 
C and chemically synthesized TRAP, the 5.3 kDa peptide that is the main component of low 
molecular weight Fraction C, when cultured under conditions that facilitate vasculogenic 
differentiation in vitro. 
In Chapter 3 it was also shown that the PDL cells when cultured on gel of a basement 
membrane proteins (laminin, collagen type IV, heparan sulfate proteoglycan, entactin and 
nidogen) were able to undergo angiogenic differentiation and form tubular-like structures 
with minimal sprouting. Thus, the present study examined the effects of EMD components on 
PDL cell angiogenesis in vitro, including PDL cell chemotaxis and the ability to form such 
BV-like structures. In addition, the chick embryo chorio-allantoic membrane (CAM), an 
extra-embryonic highly vascularized membrane that serves as a transient gas exchange 
surface similar to the lungs (New, 1955; Auerbach et al., 2003; Chapman et al., 2001), was 
used in the present study to determine the effects of EMD components on angiogenesis ex 
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vivo. The CAM model has been used extensively to test angiogenic factors (banzoxazine, 
VEGF, bFGF, EGF) due to the readily accessible vascularized CAM surface that enables 
precise monitoring and the reproducibility of the experimental system (Dong et al., 2010; 
Auerbach et al., 2003; Chapman et al., 2001; Kauvar et al., 2010).  
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6.2. Materials and methods 
PDL cells were used to examine the effects of EMD components on vasculogenic and 
angiogenic differentiation (Amin et al., 2011; Chapter 3). Human umbilical vein endothelial 
cells (HUVEC) (Lonza, Slough, UK) were used as the positive control for angiogenic 
differentiation, as they have previously been shown to be capable of angiogenic 
differentiation (Dong et al., 2010; Schlueter et al., 2007; Johnson et al., 2009). PDL and EC 
culture and RT-PCR were performed as described in Chapter 2; additional methods used in 
this chapter are described below. 
 
6.2.1. Treatment of cells with EMD components 
EMD and the EMD-derived < 6 kDa (Fraction C) and > 6 kDa (Fraction A) fractions were 
diluted in 0.1% acetic acid and a range of concentrations (1-100 µg/ml) added directly to the 
PDL cell cultures when they reached approximately 90% confluence. In addition, the 
chemically synthesized TRAP (sequence: NH2-
MPLPPHPGHPGYINFSYEVLTPLKWYQNMIRHPYTSYGYEPMGGW–COOH; provided 
by Institut Straumann, Basel, Switzerland), the major component of Fraction C, was diluted in 
cell culture grade water (Thermo Scientific, Basingstoke, UK) and 30 µg/ml added directly to 
the cells when they reached approximately 90% confluence. The concentration of TRAP was 
determined from the dose effects of EMD and the EMD Fractions on terminal vasculogenesis 
of PDL cells in vitro, as described in Section 6.3.1.1. 
 
6.2.2. Effects of EMD and the EMD Fractions on PDL cell vasculogenic differentiation 
6.2.2.1. Immunocytochemical evidence of vasculogenesis 
PDL cells were seeded into 24-well plates at a density of 2.5 x 104 cells/well, cultured in GM 
for 2-3 days and the medium replaced with endothelial basal medium-2 containing increasing 
concentrations of EMD components (1-100 µg/ml). EBM-2 supplemented with the 
endothelial growth factors (GF) VEGF (150 ng/ml) and EGF (50 ng/ml) (EBM-2 + GF) 
(Peprotech, London, UK), a medium which has previously been shown to induce murine and 
human mesenchymal stem cell (MSC) vasculogenesis in vitro (Wang et al., 2010; Gang et al., 
2006), was used to facilitate vasculogenic differentiation, as previously described (Wang et 
al., 2010; Gang et al., 2006). The EBM-2, EBM-2 + EMD components and EBM-2 + GF 
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were changed every 3-4 days. After 5 weeks, immunostaining for the vasculogenic markers 
VE-cadherin, an EC adhesion protein, and von Willebrand factor (vWF), a blood glycoprotein 
localized in EC-specific vesicles, was also carried out on replicate cultures, as previously 
described (Amin et al., 2011). Briefly, cells were fixed in 4% paraformaldehyde (Merck, 
Poole, UK) for 15 min at room temperature (RT) and permeabilised using 0.1% Triton X 
(Sigma) for 15 min at RT. They were then treated with a blocking solution containing 10% 
normal goat serum (NGS) in PBS for 1 h and incubated for 1 h at RT with primary mouse 
monoclonal anti-VE-cadherin (Insight Biotechnology, London, UK) and anti-vWF (Abcam, 
Cambridge, UK) antibodies diluted 1:100 in PBS containing 1% NGS. Incubation was then 
carried out with goat anti-mouse Alexa Fluor secondary antibody (Invitrogen, Paisley, UK) 
diluted 1:200 in PBS containing 1% NGS for 1 h at RT. VE-cadherin- and vWF-positive cells 
were visualized by their green fluorescent staining. Nuclei were stained blue using Hoechst 
dye. The proportion of VE-cadherin and vWF-positive cells was determined by manual 
counting of 3 separate fields of each culture.  
Total RNA was extracted from replicate cultures for conventional RT-PCR analysis of 
the VEGF receptor-1 (VEGFR1) and VEGFR2 (measured at week 1) genes involved at an 
early stage of VEGF-mediated vasculogenic differentiation. The Tie-1 and Tie-2 genes 
involved in an angiopoietin-mediated late stage of vasculogenesis were measured after 2 
weeks, and the VE-cadherin gene involved in producing EC adhesion protein at a late stage of 
vasculogenesis was measured at week 3, as described in Chapter 2. Since mRNA transcripts 
are expressed much earlier than the corresponding proteins, the VE-cadherin gene was 
measured at week 3 and immunostaining of VE-cadherin protein was carried out at week 5.  
  
6.2.2.2. Functional assay of vasculogenic differentiation by Flow Cytometry (FCM) 
Receptor-mediated endocytosis of low-density lipoprotein (LDL), involved in the transport of 
triglycerides and cholesterol into the blood, is a key functional indicator of terminal 
vasculogenic differentiation (Anderson et al., 1977). To determine whether PDL cells 
exhibited this activity when cultured in differentiation medium with EMD component(s), 
PDL cells were cultured in 24-well plates in GM for 2-3 days and then replaced with EBM-2 
alone, EBM-2 + EMD components (test sample) and EBM-2 + GF (positive control sample). 
After 5 weeks, cultures were incubated for 2 h in EBM-2 with 100 ng/ml Alexa Fluor 
labelled-acetylated-LDL (Invitrogen, Paisley, UK), fixed with 4% PFA for 15 min at RT and 
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nuclei stained using Hoechst dye. Flow cytometry (FCM) was also carried out on replicate 
cultures to measure the intracellular levels of Alexa Fluor labelled-acetylated-LDL, as 
previously described (Singhatanadgit et al., 2009). The cells were detached from the culture 
dish by incubating with trypsin-ethylenediaminetetraacetic acid (EDTA) (0.25% trypsin, 1 
mM EDTA) (Gibco) for 5 min at 37oC, centrifuged, fixed in 4% PFA and permeabilised using 
0.1% Triton X (Sigma) for 15 min at RT. The cells were then centrifuged and re-suspended in 
200 µl of PBS and the fluorescence intensity of 10,000 individual cells measured using a flow 
cytometer (FACScan; Becton-Dickinson, Cowley, UK). Data analysis was carried out using 
the WinMDI 2.8 software program. 
 
6.2.3. Effects of EMD components on angiogenesis 
6.2.3.1. Chemotaxis assay 
One of the initial events of angiogenic differentiation in vivo is the chemotaxis/migration of 
endothelial precursors to the wound site followed by formation of angiogenic structures by 
the accumulated endothelial precursors (Bauer et al., 2005; Yuan et al., 2003). To examine the 
effect of EMD components on PDL cell chemotaxis, a 2-dimentional cell ‘wound healing’ 
migration assay was performed, as previously described (Bertl et al., 2009; Staton et al., 
2009). Briefly, 2.5 x 104 EC/well were cultured in GM alone in a 24-well plate for 3-4 days or 
until confluent, after which a ‘wound’ was created in vitro by scraping off the cells using a 
pipette tip (200 µl) in a straight horizontal line (1 mm wound in width). The cultures were 
then washed with PBS and re-cultured with EBM-2 alone, EBM-2 + EMD components (test 
samples) and EBM-2 + GF (positive control samples) for 12 h. For analysis of cell migration 
(i.e., wound healing activity), microscopic images of the wound were taken immediately after 
scraping the cells (0 h) and after 6 and 12 h in the absence and presence of EMD components 
and GF. Cell migration was quantified by measuring the area of the wound (in pixel counts) 
using ImageJ software, using the following equation: area of wound (no cells) at 0 h minus 
area of wound at 6 or 12 h in the absence and presence of TRAP and GF. Full healing of a 
monolayer wound is the full closure of wounded area as a result of cell migration, while no 
healing is equivalent to zero (the cell-free wound area is the same at the 0 h test time period). 
Replicate experiments were also performed using HUVEC as a positive control. 
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6.2.3.2. Angiogenic structure formation in vitro 
Angiogenic structure formation by endothelial precursors in vitro was performed using an 
angiogenesis assay kit, as described in Chapter 3 and also in previous reports (Millipore, 
Billerica, MA, USA) (Dong et al., 2010; Auerbach et al., 2003; Zhang et al., 2008). The assay 
comprises a gel of basement membrane proteins (laminin, collagen type IV, heparan sulfate 
proteoglycan, entactin and nidogen) on which the endothelial precursors are cultured and 
align to form polygonal tube-like structures in a multi-step process involving cell adhesion, 
migration, growth and differentiation (Bauer et al., 2005; Auerbach et al., 2003; Zhang et al., 
2008). In this assay, 104 PDL cells were plated on gel-coated 96-well plates and cultured in 
the presence of EBM-2 alone, EBM-2 + EMD components (test samples) and EBM-2 + GF 
(positive control sample). After 5 and 15 h, digital images were obtained using bright-field 
microscopy. For quantitative analysis, branch points of polygonal tube-like structures in each 
culture condition were scored in 5 random fields, as described by the manufacturer of the kit 
and other reports (Dong et al., 2010; Schlueter et al., 2007). Similar experiments were also 
carried out using HUVEC as a positive control.  
 
 
6.2.3.2. Chick chorioallantonic membrane (CAM) assay of angiogenesis ex vivo 
The CAM is a specialized highly vascular extra-embryonic tissue formed during avian 
embryogenesis. The chick embryo CAM angiogenesis assay has been widely used to test 
angiogenic compounds including bFGF (Esch et al., 1985; Rabatti et al., 1995), VEGF 
(Wilting et al., 1992), EGF (Stewart et al., 1989), retinoids (Oikawa et al., 1989) and 
somatostatin (Woltering et al., 1991), mainly due to its readily accessible vascularized CAM, 
relatively rapid outcome and accessibility for monitoring BV formation over the course of the 
experiment (New, 1955; Auerbach et al., 2003; Chapman et al., 2001). The present study 
therefore used this model to examine the effects of EMD components on angiogenesis ex 
vivo. Fertilized White Leghorn chick eggs (Joice and Hill Poultry Ltd, Peterborough, UK) 
were incubated at 370C in 70-80% relative humidity in air for 3.5 days. The eggs were then 
carefully cracked open and the developing embryos transferred into 10 cm2 petri dishes and 
re-cultured. On day 7, UV-sterilized filter disks (3 mm2) were placed on the CAM where BV 
were visible and 15 µl of EMD components containing 1, 25, 50 and 100 µg/ml (test samples) 
added drop-wise onto the disks. Replicate eggs were treated with 15 µl of 100 µg/ml bovine 
serum albumin in cell culture grade water (Thermo Scientific) as control samples. The eggs 
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were then re-incubated for a further period of 3 days and the capillaries sprouted from the 
arteries of the CAM around the disks were photographed, and total number of capillaries 
which had sprouted were counted in each micrograph and analyzed using ImageJ software, as 
previously described (Borges et al., 2003; Dong et al., 2010).    
 
6.2.4. Statistical analysis 
The RT-PCR data are shown as the mean fold-change ± standard error (± SE) of three 
separate experiments compared with that of control cells cultured in EBM-2 alone (defined as 
1.0). One-way ANOVA was used to assess statistically significant differences (p<0.05) 
followed by the post-hoc Bonferroni test (p<0.05) for multiple comparisons between the 
means (SPSS 11.0 software, Chicago, IL). 
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6.3. Results 
6.3.1. Vasculogenic differentiation 
6.3.1.1. Effects of increasing concentrations of EMD and the EMD Fractions on 
vasculogenic differentiation of PDL cells 
Vasculogenic differentiation of progenitor/stem cells into EC is considered pivotal in new BV 
formation in embryological development and also in adult wound healing (Brey et al., 2005; 
Flamme et al., 1997). Vasculogenesis of adult cells has been examined here by culturing PDL 
cells in endothelial basal medium (EBM-2) for 5 weeks (Chapter 3). To examine whether 
EMD and the EMD Fractions modulate this process the PDL cells were cultured in EBM-2. 
The representative micrographs in Figure 6.1 show that when PDL cells were incubated in 
EBM-2 alone and EBM-2 + EMD, only few VE-cadherin immunostained cells were 
observed. However, in the presence of Fraction C (30 µg/ml) VE-cadherin-positive cells were 
more evident and the staining was found to be localized at the lateral borders of the cells 
(junctions), as previously reported using endothelial precursors derived from human umbilical 
cord (Alghisi et al., 2009; Muller et al., 2002) (Fig. 6.1). In contrast, in the presence of 
Fraction A there were no VE-cadherin-positive cells. The results in Table 5 show the effects 
of increasing concentrations (1-100 µg/ml) of EMD, Fraction C and Fraction A. 8.5±1.3% of 
PDL cells were found to stain positive for VE-cadherin when cultured in EBM-2 alone for 5 
weeks, as previously noted in Chapter 3. When the cells were cultured in EBM-2 in the 
presence of 1, 3 and 10 µg/ml of EMD there was no increase in % of VE-cadherin-positive 
cells (9.2, 9.7 and 10.2% positive cells, respectively). However, in the presence of 30 µg/ml 
and 100 µg/ml of EMD, 13.0 and 15.4% of VE-cadherin-positive cells were observed, 
significantly higher than the cells cultured in EBM-2 alone (Table 5). Increasing 
concentrations of Fraction C markedly increased the number of VE-cadherin-expressing cells, 
with 30 µg/ml resulting in 29.2% positive cells, although the presence of 100 µg/ml of 
Fraction C did not further increase the relative proportion of positive cells (Table 5). It is 
notable that the % of VE-cadherin-positive cells in the presence of Fraction C (30 and 100 
µg/ml) were significantly higher than the % of positive cells observed in the presence of EMD 
(30 and 100 µg/ml) (Table 5). These results thus indicate that Fraction C appears to actively 
promote vasculogenic differentiation and further experiments were therefore carried out (see 
Section 6.3.1.2, below) to clarify the activity of this Fraction by using the TRAP peptide, the 
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main component of Fraction C, which was obtained by chemical synthesis. Fraction A, which 
was found to suppress PDL cell vasculogenic differentiation was not further examined. 
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VE-cadherin-positive cells                    
(% of total cells)  
 
Conc.         
(µg/ml) EMD Fraction C Fraction A 
1 9.2±1.6 9.3±1.9 3.1±1.4* 
3 9.7±1.7 15.1±2.2*§ 2.6±1.7* 
10  10.2±1.8 20.7±3.0*§ 1.1±0.8* 
30  13.0±2.2* 29.2±3.4*§ 0.0 
100  15.4±1.2* 27.4±4.0*§ 0.0 
Table 5. Effect of increasing concentrations (1-100 
µg/ml) of EMD and the EMD Fractions on VE-cadherin 
staining of PDL cells cultured for 5 weeks in EBM-2. The 
numbers are the % of VE-cadherin-positive cells, as 
described in the Materials and methods. The values are 
the means ±SE of three measurements of three separate 
experiments. *Indicates significant difference compared 
with EBM-2 alone (p<0.05). §Indicates significantly 
higher than EMD (p<0.05). 
The control cultures (EBM-2 alone) had 8.5±1.3% VE-
cadherin positive cells after 5 weeks 
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6.3.1.2. Effects of TRAP on vasculogenic differentiation 
As noted above, Fraction C, which has previously been reported to contain the TRAP peptide 
(Mumulidu et al., 2007), was found here to markedly increase vasculogenic differentiation of 
PDL cells (Section 6.3.1.1). The TRAP peptide was therefore obtained by chemical synthesis 
and its activity was examined as shown in Figure 6.2 and Table 6. As with Fraction C, the 
results in Figure 6.2 show that VE-cadherin staining was localized at the lateral borders 
(junctions) of the PDL cells and vWF staining was in diffuse intracellular vesicle-like 
structures (probably Weibel-Palade bodies) within the PDL cells treated with EBM-2 alone 
and EBM-2 + TRAP, as also observed previously using HUVEC (Alghisi et al., 2009; Muller 
et al., 2002). Measurement of the effect of TRAP on PDL cell vasculogenic differentiation 
showed that, as with Fraction C, the presence of 30 µg/ml of TRAP resulted in 26.2% of the 
PDL cells exhibiting VE-cadherin staining when cultured in EBM-2 for 5 weeks, compared 
with only 8.5%-positive cells in the control cultures of EBM-2 alone (p<0.05) (Table 6). A 
similar proportion of VE-cadherin-positive cells were also found in the positive control 
cultures containing GF (21.7%) (p<0.05). Moreover, in the presence of TRAP, 23.1% of the 
PDL cells were found to also express vWF, a late endothelial protein unique to specific 
endothelial cell vesicles (Weibel-Palade bodies) (Valentijn et al., 2011), again similar to the 
proportion of cells in the positive control culture containing GF (17.4%) (p<0.05). Thus the 
TRAP peptide was found to stimulate PDL cell vasculogenic differentiation in vitro, 
comparable with the stimulation observed in the presence of endothelial growth factors. 
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Figure 6.2. Representative micrographs of PDL cells immunostained for VE-cadherin and 
vWF after culture in EBM-2 alone, EBM-2 + TRAP (30 µg/ml) and EBM-2 + GF for 5 weeks. 
The nuclei are stained blue with Hoechst dye and the white arrows show the green 
fluorescence of VE-cadherin staining at the lateral borders (junctions) of the cells. The white 
arrowheads show the punctate green fluorescence staining of vWF.     
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VE-cadherin and vWF-positive cells              
(% of total cells) 
 
Markers 
EBM-2 alone + TRAP + GF 
VE-cadherin 8.5±1.3 26.2±3.7* 21.7±3.1* 
vWF 7.1±2.8 23.1±5.6* 17.4±4.7* 
Table 6. Effects of TRAP (30 µg/ml) on VE-cadherin and vWF 
staining of PDL cells cultured for 5 weeks in EBM-2. Cells 
cultured in EBM-2 + GF was used as a control. The numbers are 
the % of VE-cadherin- and vWF-positive cells. The values are 
the means ±SE of three measurements of three separate 
experiments. *Indicates significant difference compared with 
EBM-2 alone (p<0.05). 
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It was shown in Chapter 3 that the expression of endothelial genes was up-regulated 
when cultured in EBM-2 alone. The present study therefore examined whether addition of 
TRAP in EBM-2 affects the expression of endothelial genes (VEGFR1, VEGFR2, Tie-1, Tie-
2 and VE-cadherin) by PDL cells. The representative RT-PCR gels in Figure 6.3 show that 
the presence of 30 µg/ml of TRAP increased the mRNA transcript levels of all the endothelial 
genes examined here, except for VEGFR1. Thus, the presence of TRAP significantly up-
regulated the early endothelial gene VEGFR2 (3.9-fold increase) and the late genes Tie-1, 
Tie-2 (tyrosine kinases essential for angiopoietin-mediated vasculogenesis (Demir et al., 
2007)) (6.2- and 6.8-fold increase) and VE-cadherin (2.4-fold increase), compared with cells 
cultured in EBM-2 alone (p<0.05) (Fig. 6.3). Similar results were obtained when the PDL 
cells were cultured in EBM-2 in the presence of GF (positive control). In contrast, under both 
conditions the early gene VEGFR1 was unaffected (Fig. 6.3).  
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Figure 6.3. Effect of TRAP on vasculogenic genes of PDL cells. (i) A representative RT-PCR 
gel showing the expression of the early vasculogenic genes VEGFR1 and VEGFR2 and the 
late genes Tie-1, Tie-2 and VE-cadherin by PDL cells cultured for 3 weeks in EBM-2 alone, 
EBM-2 + GF and EBM-2 + TRAP. (ii) The values are the changes in PCR product band 
intensity relative to GAPDH of cells cultured in the presence of GF and TRAP compared with 
EBM-2 alone, defined as 1.0. The values are the means ±SE of triplicate measurements. 
*Indicates significant difference compared with EBM-2 alone (p<0.05). 
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PDL cells cultured in the presence of 30 µg/ml of TRAP or GF for 5 weeks were also 
examined for internalization of LDL, a key functional indicator of terminal vasculogenic 
differentiation (Anderson et al., 1977), by incubating the cells with green fluorescent-tagged 
acetylated-LDL at 37°C for 2 h and examining the cells under the fluorescence microscope 
and measuring the relative levels of green fluorescence using FCM. The results in Figure 6.4 
(i) show that the PDL cultures incubated in the presence of TRAP and the GF appeared to 
express a similarly high proportion of fluorescent-labelled cells (an indication of internalized 
LDL), compared with many fewer positive cells when cultured in GM alone or EBM-2 alone 
(control cultures). FCM analysis (Figure 6.4 (ii)) showed that approximately 72% of the cells 
internalized LDL when cultured in EBM-2 + TRAP for 5 weeks and nearly 67% when 
cultured with GF (positive control). In contrast, only 26.2% of the cells were positive after 
culture in EMB-2 alone (p<0.05; Fig. 6.4 (ii)). These results thus demonstrate that the 
presence of TRAP resulted in an increase in LDL uptake, similar to that found in the presence 
of GF. 
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Figure 6.4. Up-take of fluorescent-labelled LDL by PDL cells cultured in EBM-2 alone, 
EBM-2 + TRAP and EBM-2 + GF for 5 weeks. (i) White arrows show the internalization of 
LDL as visualized by fluorescence microscopy. (ii) Representative FCM histogram of the 
levels of intracellular fluorescent-labelled LDL. The shaded profile shows the fluorescence 
distribution of the TRAP and GF-treated cells, while the open profile shows the control cells 
cultured in EBM-2 alone. The vertical lines have been selected at a value of 75 fluorescence 
units. The events on the left side of the vertical lines are considered as non-fluorescent cells 
(negative cells) and events on the right side of the vertical line are considered as fluorescent 
cells (positive cells).   
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6.3.2. Angiogenic differentiation in vitro 
Once progenitor/stem cells differentiate into endothelial precursors through the process of 
vasculogenesis, as described above, the process of angiogenesis takes place at the wound site 
and results in the formation of BV (Brey et al., 2005; Flamme et al., 1997; Nomi et al., 2002). 
Angiogenic differentiation, the development of an organized network of tubular structures 
involving the degradation of the basement membrane and the migration of endothelial 
precursors to the wound site in vivo, is a prerequisite for BV formation (Bauer et al., 2005; 
Yuan et al., 2003). In vitro it has previously been shown that such precursors are induced to 
migrate to wound sites by angiogenic growth factors, including VEGF and EGF, in a 2-
dimensional wound healing assay (Staton et al., 2009; Lamalice et al., 2007). In view of 
previous results that 30 µg/ml of TRAP appears to induce vasculogenic differentiation 
(Section 6.3.1), the effects of 30 µg/ml of TRAP on PDL cell chemotaxis was examined in a 
similar 2-dimentional in vitro wound healing assay, in which an approximately 1 mm (in 
width) wound was created by scraping a confluent monolayer culture of PDL cells in a 
straight line of 1 mm width using a pipette tip. Then, after treatment with TRAP and GF, as 
described in Materials and methods, microscopic images were taken at 0, 6 and 12 h. The 
results in Table 7 show that the PDL cells incubated with EBM-2 alone (control cultures) 
migrated over an area of approximately 22500 pixels after 6 h and 32986 pixels after 12 h 
within the wound site. In contrast, a marked increase in the migration of PDL cells was 
observed when cultured with EBM-2 + TRAP for 6 h (58360 pixels) and for 12 h (67996 
pixels) (p<0.05). At this later time complete closure of the wound appeared to have occurred 
in the presence of TRAP, compared with PDL cells cultured in EBM-2 alone which exhibited 
only partial closure, as shown in Figure 6.5. Similarly, as with TRAP, a marked increase in 
PDL cell migration was observed in the positive control of EBM-2 + GF (49053 and 53136 
pixels after 6 and 12 h, respectively) (p<0.05) (Table 7). Similar results were also observed 
when HUVEC (positive control cells) were treated with EBM-2 alone, EBM-2 + TRAP and 
EBM-2 + GF, as shown in Appendix Materials 2.1 and 2.2. These results thus indicate that 
TRAP induces an initial chemotactic phase comparable with angiogenic GF.   
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 Figure 6.5. Representative microscopic images of PDL cells cultured in EBM-2 alone, EBM-
2 + TRAP (30 µg/ml) and EBM-2 + GF for 6 and 12 h followi ng the creation of an in vitro 
cell wound, as described in Materials and methods. The area between the black dashed lines 
shows the size of the wound (space without cells) which were measured in pixels. 
Magnification x 10. 
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Cell migration (in pixels x 103)  
Conditions 6 h 12 h 
EBM-2 alone 22.5±370    33.0±2169 
+ TRAP 58.3±1190* 68.0±1479* 
+ GF 49.0±2100* 53.1±2244* 
Table 7. Effects of TRAP on migration of PDL cells 
when cultured in EBM-2 alone, EBM-2 + TRAP (30 
µg/ml) and EBM-2 + GF for 6 and 12 h after creating 
the cell wound in vitro. The numbers are the average 
(of 3 separate experiments) of the measurement of 
area (in pixel counts x 103) of PDL migration (area of 
wound (no cells) at 0 h minus area of wound at 6 or 12 
h in the absence and presence of TRAP and GF).   
 *Indicates significant difference compared with EBM-
2 alone (p<0.05). 
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In vivo, the accumulation of platelets (thrombocytes) at a fibrin clot provides a growth factor-
rich environment that attracts the endothelial precursors to migrate to the wound site and 
induces their organization into tubular-like structures that ultimately form BV (Chang et al., 
2004; Madri et al., 1988). The process of tubule-like structure formation by endothelial 
precursors has previously been shown morphologically by culturing the cells on a gel of 
basement membrane proteins with angiogenic factors (Dong et al., 2010; Auerbach et al., 
2003; Zhang et al., 2008). The present study therefore examined the effects of TRAP on 
angiogenic structure formation using an in vitro angiogenesis kit in which PDL cells were 
cultured in EBM-2 on a basement membrane gel layer in a 96-well plate in the absence and 
presence of TRAP and GF, as described in Materials and methods. The results in Figure 6.6 
(i) show that a complex polygonal tubular network, morphologically characteristic of 
angiogenesis, was formed when PDL cells were cultured in EBM-2 in the presence of TRAP 
for 5 h. In contrast, relatively fewer of these structures were present in control cultures in 
which PDL cells were cultured in EBM-2 alone (Fig. 6.6 (i)). The branching points of these 
polygonal tubular-like structures were manually counted and the results demonstrated that in 
the presence of TRAP there were nearly 97 branch points of the polygonal tubular structures, 
similar to the 91 branch points observed in the presence of EBM-2 + GF (p<0.05; Fig. 6.6 (i)). 
Cells cultured in EBM-2 alone contained only 18 branch points. Further, PDL cells cultured 
for an extended period of 15 h in the presence of TRAP demonstrated the formation of 
distinct elongated BV-like structures (Fig. 6.6 (ii)), in contrast to PDL cells cultured with 
EBM-2 alone in which these structures were not detected (data not shown). Similar results 
were also obtained when HUVEC (positive control cells) were cultured on a gel of basement 
membrane proteins in the presence of EBM-2, EBM-2 + TRAP and EBM-2 + GF, as shown 
in Appendix Material 2.3. These results thus indicate that TRAP induces PDL cell 
organization into tubule-like structures in an in vitro angiogenesis assay, comparable with the 
inductive effects of angiogenic GF. 
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         (ii)  
 
 
 
 
 
 
Figure 6.6. Angiogenic structure formation by PDL cells in vitro. (i) PDL cells cultured for 5 
h in EBM-2 alone, EBM-2 + TRAP (30 µg/ml) and EBM-2 + GF. The numbers are the 
angiogenic structure branching points. The black arrows show the polygonal tubule-like 
structures formed by PDL cells. The blue arrows show branching points of the PDL cells. 
Black arrowheads show PDL cells that did not form polygonal tubular-like structures. The 
values are the mean ±SE of five measurements of three separate experiments. (ii) An 
elongated BV-like structure formed by PDL cells cultured for 15 h in EBM-2 + TRAP. 
Magnification x 10.    
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6.3.3. Effects of TRAP on CAM angiogenesis ex vivo 
The chick embryonic chorio-allantoic membrane (CAM) model has been shown to be a 
reproducible, efficient and readily accessible for examining the angiogenic potential of drugs 
and other external factors ex vivo (Esch et al., 1985; Rabatti et al., 1995; Auerbuch et al., 
2003; Dong et al., 2010). Since TRAP was found to stimulate angiogenic differentiation of 
mature EC in vitro, as shown above, the present study used the CAM model to examine 
whether TRAP also exhibited angiogenic activity ex vivo, as described in Materials and 
methods. The results in Figure 6.7 show that when 7 days old chick embryos were treated 
with 25 and 50 µg/ml TRAP for 3 days, the filter disks that had been placed over the CAM 
appeared to be surrounded by capillaries that had sprouted from arteries (Fig. 6.7). Although 1 
µg/ml of TRAP had no significant effect on the appearance of such ‘allantoic capillaries’ 
(capillaries sprouted from the arteries (AR) of the developing CAM of chick embryo 
responsible for gas exchange and removal of the waste products; Esch et al., 1985; Rabatti et 
al., 1995; Auerbuch et al., 2003), compared with the control CAM, the presence of 25 and 50 
µg/ml TRAP significantly increased the number of capillaries in the CAM (2.6- and 2.8-fold 
respectively; p<0.05). Increasing the TRAP concentration to 100 µg/ml increased the overall 
number of capillaries (2.0-fold increase; p<0.05) compared with the control CAM, but the 
tissue near the filter disk did not exhibit extensive sprouted capillaries as observed in the 
presence of 25 and 50 µg/ml of TRAP, as noted above. These results thus suggest that 25 to 
50 µg/ml of TRAP appeared to strongly stimulate BV formation in this ex vivo model. 
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Figure 6.7. Effects of increasing concentrations of TRAP in angiogenesis ex vivo. BV 
development after 3 days of treatment with TRAP (1-100 µg/ml) of chick embryo CAM ex 
vivo. Embryos treated with bovine serum albumin were used as a control. The numbers show 
the relative capillary density (number of total capillaries in a micrograph) in the presence of 
TRAP compared with the control CAM. The black arrows show vascular bundle-like 
‘allantoic capillaries’ (C). AR shows an artery from which allantoic capillaries are sprouted. 
The values are the mean ±SE of measurements of 6 separate experiments. *Indicates 
significant difference compared with the control (bovine serum albumin), defined as 1.0 
(p<0.05). 
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6.4. Discussion 
The process of neovascularization, fundamental in both development and the 
repair/regeneration of adult tissue (Brey et al., 2005; Flamme et al., 1997; Nomi et al., 2002), 
involves vasculogenic differentiation of stem cells into endothelial precursors (Brey et al., 
2005; Flamme et al., 1997) and angiogenic formation of an organized network of BV-like 
tubular structures by endothelial precursors (Brey et al., 2005; D’Amore et al., 1987; Flamme 
et al., 1997). The vasculogenic potential of PDL cells and the effects of EMD on vasculogenic 
differentiation have previously not been examined. It was shown in Chapter 3 that PDL cells 
when cultured in media that facilitates vasculogenesis are able to form endothelial-like cells. 
The present study therefore examined the effects of EMD and recently fractionated EMD 
components on PDL cells cultured in differentiation media and demonstrated that the low 
molecular weight Fraction C of EMD strongly stimulated PDL cells to undergo vasculogenic 
differentiation, whereas the high molecular weight EMD Fraction A (in which Fraction C 
components are absent) suppressed vasculogenic differentiation. Moreover, the present study 
also showed for the first time that the main component of Fraction C, a tyrosine-rich 45-
amino acid amelogenin peptide (TRAP) derived by N-terminal proteolytic clipping of the 
full-length amelogenin, appeared to elicit PDL cell vasculogenesis, based on up-regulation of 
expression of the endothelial markers VEGFR2, Tie-1, Tie-2, VE-cadherin and vWF by the 
PDL cells and the increased ability of these cells to internalize LDL.  
The marked stimulation of vasculogenic differentiation of PDL cells by the TRAP 
peptide was found to be comparable with the effects of known GF (VEGF and EGF) on 
vasculogenic differentiation of human umbilical cord blood-derived mesenchymal stem cells 
and the murine embryonic mesenchymal cell line C3H/10T/1/2, in which the expression of 
VE-cadherin, vWF, Tie-1 and Tie-2 were also up-regulated (Wang et al., 2010; Gang et al., 
2009). In addition, the present study showed that PDL cells cultured in vasculogenic 
conditions in the presence of TRAP were found to be able to internalize markedly higher 
levels of acetylated-LDL, indicating that TRAP induced the expression of LDL receptors, a 
key functional characteristic of EC (Anderson et al., 1977). Notably, the proportions of PDL 
cells that were able to internalize acetylated-LDL after the incubation with EBM-2 alone and 
EBM-2 + TRAP were found to be significantly higher than the PDL cell subpopulation that 
expressed VE-cadherin and vWF after EBM-2 alone and EBM-2 + TRAP treatment. 
Cholesterol is one of the major building blocks of mammalian cell membrane and notably, 
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synthesis of cholesterol has been shown to occur to some extent in fibroblasts, in addition to 
EC, depending on the cellular requirements of the lipids. These cells (EC, fibroblasts) have 
been shown to express LDL receptors to which LDL ligands bind, internalize and are 
transported to the lysosomes where the cholesterol esters of LDL are hydrolyzed to make 
cholesterol freely available for the cells and the receptors are sent back to the plasma 
membrane (Goldstein et al., 1977). PDL tissue has previously been reported to contain 
fibroblast-like population, based on elongated spindle shape-like morphological appearance 
and their ability to secrete substantial amounts of collagen, a major building block of 
connective tissue (Tencate, 1989; Hassell, 1993; Kuru et al., 1998; Parker et al., 2001), 
indicating the possibility that some of the LDL receptor-positive cells in the heterogeneous 
PDL population used here may be of fibroblastic lineage which may at least partly account for 
the higher proportion of PDL cells being able to internalize LDL, noted above (Anderson et 
al., 1977; Goldstein et al., 1977).   
Under vasculogenic conditions, TRAP was also found to stimulate the expression of 
the early endothelial marker gene VEGFR2, a tyrosine kinase receptor for the VEGF ligand, 
the late genes Tie-1 and Tie-2 (tyrosine kinase receptors for the angiopoietins that are 
expressed exclusively by EC; Jones et al., 2001) and the late gene VE-cadherin, an 
endothelial cell adhesion molecule, of PDL cells when cultured under selective 
differentiation-inducing media. In contrast, the early endothelial gene VEGFR1 was found to 
be unaffected by the TRAP peptide, similar to that previously reported in PDL cells when 
cultured under non-selective growth conditions in the presence of EMD (Brett et al., 2002). 
This receptor has been characterized previously as ‘src’ oncogene involved in abnormal cell 
proliferation and development of a neoplastic cellular phenotype (i.e., high population 
doubling level, lack of contact inhibition) (Maru et al., 1998; Schwartz et al., 2010). In 
addition, knockdown of the VEGFR1 gene from human melanoma cells lose the ability of this 
cell population to undergo unlimited population doubling and to form tumours upon 
subcutaneous transplantation into mice, suggesting that the elevated levels of VEGFR1 
transcripts, which was not found in PDL cells used here, may be of functional importance to 
the neoplastic cell lines (Frank et al., 2011). Thus, although the reason(s) for lack of VEGFR1 
transcript up-regulation in EBM-2 alone and EBM-2 + TRAP-induced PDL cultures are not 
yet known, but it may partly be due to the non-neoplastic cellular physiology of PDL cells in 
which the mechanism(s) responsible for the up-regulation of VEGFR1 transcripts might be 
absent or inactive. 
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It is now recognized that the process of angiogenesis has two essential steps, 
endothelial precursor chemotaxis and the organization of endothelial precursors into tubular-
like structure (Auerbach et al., 2003; Obeso et al., 1990). The present study therefore 
investigated the effect of TRAP on PDL cell chemotaxis using the cell monolayer wound 
healing assay, the results showing that TRAP markedly stimulated the chemotactic activity of 
PDL cells. Previous studies have also examined the effects of unfractionated (non-heat 
treated) EMP and heat-treated EMD on chemotaxis/migration of HUVEC and HMVEC in 
vitro (Johnson et al., 2009; Yuan et al., 2003; Bertl et al., 2009; Schlueter et al., 2007). For 
example, 100 µg/ml of EMP was found to stimulate the highest migration/chemotaxis of 
human microvascular endothelial cells (HMVEC) in vitro (Johnson et al., 2009; Yuan et al., 
2003). However, another study observed that 100 µg/ml EMD did not induce HMVEC 
migration/chemotaxis (Schlueter et al., 2007) and Bertl (2009) reported that 100 µg/ml of 
EMD also did not stimulate HUVEC migration/chemotaxis in vitro. These discrepancies 
might be partly due to the use of different preparations of EMP and EMD containing different 
proportions of the constituent proteins, including the TRAP peptide. In addition, some of 
these studies suggested that the chemotactic effects of EMP are likely to be due to the 
presence of GF (TGF β and PDGF) in the non-heat treated preparation (Johnson et al., 2009; 
Yuan et al., 2003), although in the present study the synthetic TRAP peptide was used since 
Fraction C which was found to stimulate vasculogenic differentiation mainly contains TRAP, 
and demonstrated that the TRAP peptide in EMD is likely to be at least partly responsible for 
PDL cell chemotaxis induction. However, it is not yet clear whether the TRAP peptide-
induced wound healing observed here was an outcome of cell chemotaxis alone since it may 
in part also be due to proliferation of these cells. Full healing of in vitro PDL cell wound was 
observed after 12 h in the presence of TRAP, whereas the population doubling time of PDL 
cells is approximately 18.5 h, suggesting that proliferation of PDL cells is unlikely to be 
involved in the process of TRAP-induced wound healing.    
In Chapter 3 it was shown that the PDL cells when cultured on a basement membrane 
protein gel could form tubule-like structures with minimal sprouting. Thus, the effects of the 
TRAP peptide on PDL cell angiogenic structure-formation was examined here, the results 
showing that TRAP induced PDL cells to form greater numbers of complex polygonal tubule-
like structures than found in control cultures (in the absence of TRAP), demonstrating that 
this synthetic peptide stimulates angiogenesis in vitro. In contrast, in a recent study using 
fractionated components from a non-heat treated preparation of EMP, it was shown that the 
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high (> 15 kDa) and low molecular (< 6 kDa) weight components of EMP were not 
responsible for the increase in angiogenic structure formation activity of HMVEC (Johnson et 
al., 2009). However, the protein fractions used in Johnson (2009) to examine the angiogenic 
activity were inadequately purified, mainly because the higher molecular weight fraction (> 
15 kDa) contained < 6 kDa peptides and the lower molecular weight fraction (< 6 kDa) 
contained > 15 kDa peptides, compared with the present study which used synthetically 
prepared peptide. 
The angiogenic activity of TRAP was further established using an ex vivo chick 
embryo CAM model, which showed that in the presence of the TRAP peptide an increased 
number of allantoic vessels were found compared with control eggs treated with bovine serum 
albumin. Using a murine angiogenesis model, it was shown that both the low (< 6 KDa) and 
high (<15 kDa) molecular weight fractions of heat-treated EMD exhibited strong angiogenic 
activity in vivo, although the specific active component(s) of these fractions were not 
identified (Thoma et al., 2011) and both the fractions contained components of differing 
molecular sizes that may have differential effects on angiogenesis, unlike the synthetic 
peptide used here.  
In conclusion, the present study demonstrates for the first time that the low molecular 
weight EMD Fraction C promotes vasculogenic differentiation in vitro and the components of 
higher molecular weight Fraction A suppress this process. In addition, the data here shows 
that the presence of the TRAP peptide is likely to be at least partly responsible for the 
vasculogenic and angiogenic differentiation in vitro and ex vivo.  
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Chapter 7 
7.1. Introduction 
The PDL, a proprioceptive sensory apparatus of the periodontium, receives dense peripheral 
sensory nerve innervations from both the trigeminal ganglion and mesencephalic trigeminal 
nucleus that are responsible for touch, pressure and pain sensations (Nishikawa et al., 2006; 
Imai et al., 2003). At least two types of sensory nerve endings have been shown to be present 
in the PDL: (i) nociceptive free nerve endings which respond primarily to injury, sending 
signals to the brain and spinal cord and enabling localized pain sensation; and (ii) specialized 
mechanoreceptive endings (ruffini endings), responsible for jaw movement and applied 
pressure during mastication (Nishikawa et al., 2006; Imai et al., 2003). Two types of glial 
cells have also been identified in the PDL: (i) astrocytes, responsible primarily for nerve 
myelination (Nishikawa et al., 2006; Imai et al., 2003) and (ii) specialized glia-associated 
Schwann cells, responsible for guiding nerve growth during PDL regeneration as well as for 
nerve myelination (Atsumi et al., 1999b; Hiroshima et al., 1998; Youn et al., 1997; Bhatheja 
et al., 2006). The oligodendrocytes, a type of glial cell exclusively found in the central 
nervous system (CNS), are not present in PDL tissue (Atsumi et al., 1999b; Hiroshima et al., 
1998; Youn et al., 1997; Bhatheja et al., 2006). In the continuously repairing/remodeling 
environment of the PDL these nerve-associated tissues are of crucial importance, along with 
connective tissue and BV, for normal healthy periodontal function (Nishikawa et al., 2006; 
Imai et al., 2003; Atsumi et al., 1999b; Hiroshima et al., 1998; Youn et al., 1997; Bhatheja et 
al., 2006).  
Damage due to periodontal disease also affects PDL nerves and causes debilitating 
pain (Imai et al., 2003). A number of growth factors (e.g. glial cell line-derived neurotrophic 
factor (GDNF), brain-derived neurotrophic factor (BDNF), neurotrophin (NT)-4/5) have been 
used to help repair/regenerate damaged PDL nerves and have achieved some degree of 
success in vivo (Imai et al., 2003, Wakisaka et al., 2003; Harada et al., 2003; Jabbar et al., 
2007). However, such growth factors primarily target nerve repair and conversely, not elicit 
‘full’ periodontal regeneration, which also includes PDL, BV, bone and cementum.  
Although EMD has been shown to stimulate the osteogenic and chondrogenic 
differentiation of PDL cells and angiogenic differentiation of HUVEC in vitro (Gestrelius et 
al., 1997; Van der Pauw et al. 2000; Ohyama et al., 2002; Schlueter et al., 2007; Narukawa et 
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al., 2007a; Narukawa et al., 2007b) and also to promote regeneration of PDL, BV, bone and 
cementum in animals and humans (Cochran et al., 1999; Donos et al., 2003; Hammarstrom, 
1997a; Heijl et al., 1997; Gkranias et al., 2010; Thoma et al., 2011), its effect on PDL nerve 
cells and nerve tissue are not yet known.  
Degree III inter-radicular (furcation) defects in molar teeth in monkeys treated with 
EMD have been shown to develop functionally oriented cementum with inserting PDL fibres 
and AB, compared with the untreated defects in which little if any regeneration was observed 
(Donos et al., 2003). Since this animal model has been of value in investigating the effects of 
EMD on periodontal regeneration, in the present study it was also used for examining the 
effect of EMD on PDL nerve regeneration in vivo. In addition, since the present study also 
showed (Chapter 3) that the PDL contains progenitor cells capable, under the appropriate 
condition in vitro, of forming nerve-like cells having a morphology similar to sensory nerve 
cells (Nishikawa et al., 2006; Imai et al., 2003) and glia-associated astrocytes, 
oligodendrocytes and Schwann cells, EMD and the EMD Fractions were examined to 
determine which if any of these components influence the neural and glial differentiation 
pathways of PDL cells under conditions which facilitate neurogenic and gliogenic 
differentiation in vitro. 
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7.2. Materials and methods 
PDL cell culture and RT-PCR were performed as described in Chapter 2; additional methods 
used in this chapter are described below. 
 
1.8.1. 7.2.1. Treatment of cells with EMD and the EMD Fractions 
EMD, Fraction C and Fraction A were diluted in 0.1% acetic acid and increasing 
concentrations (1-100 µg/ml) were added to confluent PDL cell cultures, as described below. 
In addition, the chemically synthesized 45-amino acid TRAP sequence (NH2-
MPLPPHPGHPGYINFSYEVLTPLKWYQNMIRHPYTSYGYEPMGGW–COOH; provided 
by Institut Straumann, Basel, Switzerland), a major component of Fraction C, was diluted in 
water (Thermo Scientific, Basingstoke, UK) and 10 µg/ml added directly to the cells in 
differentiation medium for each experiment. The concentrations of EMD, EMD Fractions and 
TRAP were determined from the dose effects on terminal neurogenesis and gliogenesis in 
vitro, as described below.  
 
7.2.2. Effects of EMD and the EMD Fractions on neural differentiation in vitro 
2 x 104 cells were seeded onto poly-L-lysine/laminin coated 8-well chamber slides (Nunc) 
and cultured in 0.2 ml of GM for 2 days. Neural differentiation medium (NM) (0.2 ml) was 
then added, consisting of 20 ng/ml EGF, 20 ng/ml bFGF, 4 µM forskolin, 10 µM retinoic acid 
and 50 ng/ml NT-3 and BDNF in the absence and presence of 1, 3, 10, 30 and 100 µg/ml of 
EMD, Fraction C and Fraction A. After 5 days the cells were fixed with 4% 
paraformaldehyde (PFA) (Merck) for 15 min at RT and permeabilised using 0.1% Triton X 
(Sigma) for 15 min at RT. They were then treated with a blocking solution containing 10% 
NGS in PBS for 1 h and incubated for 1 h at RT with mouse monoclonal anti-βIII tubulin 
(1:1000) (R&D Systems, Minneapolis, MN, USA), anti-neurofilament (NF)-L (1:200) 
(Abcam, Cambridge, UK) (both markers of intermediatory nerve cell filaments expressed at 
the late stage of nerve cell differentiation; Techawattanawisal et al., 2007; Widera et al., 
2007) and anti-protein gene product 9.5 (PGP9.5) (1:100) (Insight Biotechnology Ltd, 
London, UK), a nerve cell-specific ubiquitin-protein hydrolase expressed at the late stage of 
nerve cell differentiation (Nandasena et al., 2007), in PBS containing 1% NGS. After 
incubation with goat anti-mouse Alexa Fluor secondary antibody (Invitrogen, Paisley, UK), 
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diluted 1:200 in PBS containing 1% NGS, for 1 h at RT, neuron-like cells were visualized by 
their green fluorescent staining (for βIII tubulin and NF-L). HRP staining was also carried out 
for PGP9.5 to examine nerve cell morphology. Immunostaining of the PDL cells for βIII 
tubulin, NF-L and PGP9.5 was carried out to examine the effects of EMD and the EMD 
components on terminal stages of neurogenic differentiation of PDL cells. Nuclei were 
stained blue using Hoechst dye. The proportions of βIII tubulin-, NF-L- and PGP9.5-positive 
cells were determined by manual counting of 3 separate fields of 3 separate cultures.  
Total RNA was extracted from replicate cultures after 2 and 5 days for PCR analysis 
of the early neurogenic marker NGF and the late markers NF-L and PGP9.5, as described in 
Chapter 2. Up-regulation of NGF is one of the key early events of neuronal differentiation 
(Angelastro et al., 2000). In addition to the late neurogenic differentiation events including 
up-regulation of NF-L and PGP9.5, to determine the effects of EMD components on the early 
event of neuronal differentiation, the expression of the NGF gene of PDL cells was also 
examined, as above.  
 
7.2.3. Effects of EMD and the EMD Fractions on glial differentiation 
2 x 104 cells were seeded onto poly-L-lysine/laminin coated 8-well chamber slides (Nunc) 
and cultured in GM for 2 days. Glial differentiation medium (GDM) was then added, 
consisting of 10 ng/ml heregulin β-2 and 4 µM forskolin, in the absence and presence of 1, 3, 
10, 30 and 100 µg/ml of EMD, Fraction C and Fraction A. After 7 days the cells were fixed 
with 4% paraformaldehyde (Merck, Poole, UK) for 15 min at RT and permeabilised using 
0.1% Triton X (Sigma) for 15 min at RT. They were then treated with a blocking solution 
containing 10% NGS in PBS for 1 h and incubated for 1 h at RT with mouse monoclonal anti-
glial fibrillary acid protein (GFAP) (1:1000) (R&D Systems, Minneapolis, MN, USA) (an 
intermediatory filament protein found in the cytoplasm of all three types of glial cells 
(Hermann et al., 2004; Donato et al., 2007; Chi et al., 2010)) and anti-S-100β (1:100) 
(Abcam, Cambridge, UK) (a Schwann cell-associated protein found both in the cell nucleus 
and cytoplasm (Hermann et al., 2004; Donato et al., 2007; Chi et al., 2010)) antibodies in PBS 
containing 1% NGS. Incubation was then carried out with goat anti-mouse Alexa Fluor 
secondary antibody (Invitrogen, Paisley, UK) diluted 1:200 in PBS containing 1% NGS for 
1 h at RT, glial-like cells were visualized as green fluorescent (GFAP)-stained astrocytes and 
red fluorescent (S-100β) stained Schwann-like cells. Immunostaining of the PDL cells for 
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GFAP and S-100 β was carried out to examine the effects of EMD and the EMD components 
on terminal gliogenic differentiation of PDL cells. Nuclei were stained blue using Hoechst 
dye. The proportions of glia-specific GFAP- and S-100β-positive cells were determined by 
manual counting of 3 separate fields of 3 separate cultures.  
Total RNA was extracted from replicate cultures after 2 and 7 days for PCR analysis 
of the early gliogenic marker Notch1, a key early marker of glial differentiation (Lutolf et al., 
2002) and the late markers GFAP and S-100β, as described in Chapter 2. To determine the 
effects of EMD components on the early events of neuronal differentiation, the expression of 
the NGF gene by PDL cells was examined, as above. 
 
7.2.4. Statistical analysis 
The RT-PCR data are presented as the mean of the triplicate measurements of cells cultured 
in NM or GDM in the presence of EMD and the EMD Fractions compared with that of cell 
cultured in NM or GDM alone (defined as 1.0). One-way ANOVA followed by post-hoc 
Bonferroni test set for p<0.05 (for multiple comparison) was used for statistical analysis 
(SPSS 12.0 software, Chicago, IL). 
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7.3. Results 
7.3.1. Effects of increasing concentrations of EMD and the EMD Fractions on 
PDL cell neurogenesis in vitro 
It was shown in Chapter 3 that PDL cells cultured in NM alone stained positive for the 
neuronal intermediatory filament marker βIII tubulin and exhibited nerve cell-like 
morphology in vitro. To determine possible effects of EMD and the EMD Fractions the 
present study cultured PDL cells in NM in the absence and presence of EMD, Fraction C and 
Fraction A for 5 days and immunostained for βIII tubulin, as described in Section 7.2, to 
examine whether these protein preparations affect the expression of this antigen. The 
representative micrographs in Figure 7.1 shows that PDL cells cultured in the presence of NM 
alone and NM + Fraction C exhibited βIII tubulin-positive nerve cell-like morphology, 
elongated axon with dendritic projections, as shown previously (Kriegstein et al., 1983; 
Techawattanawisal et al., 2007), in contrast to cells cultured with NM + EMD and NM + 
Fraction A which did not express βIII tubulin or exhibit nerve cell-like morphology. To 
examine the effects of increasing concentrations of EMD, Fraction C and Fraction A PDL 
cells cultured for 5 days in NM in the absence and presence of 1-100 µg/ml of EMD and the 
EMD Fractions. PDL cells cultured in NM alone were found to contain 7.1% of βIII tubulin-
positive nerve-like cells whereas cultures in non-differentiation-inducing GM alone contained 
no positive cells (Chapter 3). The results in Table 8 show that in the presence of EMD (at all 
concentrations) there was a very low proportion of PDL cells which expressed βIII tubulin 
(0.0 to 1.7%), significantly lower compared with cells cultured in NM alone (7.1% positive 
cells) (p<0.05). In addition, all concentrations of Fraction A also appeared to suppress the 
proportion of βIII tubulin-positive cells (0.0 to 1.1% positive cells; Table 8), significantly 
lower compared with cells cultured in NM alone (7.1% positive cells) (p<0.05). In marked 
contrast to this apparently inhibitory effect of EMD and Fraction A, the results in Table 8 
show that increase in the concentration of Fraction C from 1 to 3 µg/ml increased the number 
of βIII tubulin-positive cells from the control levels (7.9% to 11.6%), while at 10 µg/ml of 
Fraction C the proportion of positive cells increased further, to 16.9%. However, when the 
concentration of Fraction C was increased to 30 and 100 µg/ml the proportion of βIII tubulin-
expressing cells did not increase further and remained at the same high level (15.4 and 16.2% 
positive cells, respectively). These results thus indicate that Fraction A suppressed PDL cell 
neural differentiation and this sub-fraction was not examined further. However, Fraction C 
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was found to actively promote neural differentiation and further experiments were therefore 
carried out to clarify the activity of this Fraction by using the TRAP peptide, the main 
component of Fraction C, which was obtained by chemical synthesis. 
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 Figure 7.1. Representative micrographs of PDL cells immunostained for βIII tubulin after 5 
days of culture in NM alone, NM + EMD (100 µg/ml), NM + Fraction C (10 µg/ml) and NM 
+ Fraction A (100 µg/ml). The nuclei are stained blue with Hoechst dye and the white arrows 
show βIII tubulin-positive dendritic projections. Red arrow shows βIII tubulin-positive 
elongated axon of a nerve-like cell. Magnification x 20. 
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βIII tubulin-positive cells                        
(% of total cells§) 
 
Conc.         
(µg/ml) EMD Fraction C Fraction A 
1  1.7±1.0* 7.9±2.5 1.1±1.0* 
3 1.6±0.7* 11.6±2.0* 0.9±0.4* 
10 1.3±0.8* 16.9±1.7* 0.0 
30 0.8±0.4 15.4±3.4* 0.0 
100 0.0 16.2±2.4* 0.0 
Table 8. Effects of increasing concentrations of EMD 
and the EMD Fractions on βIII tubulin expression by 
PDL cells. PDL cells were cultured for 5 days in NM in 
the presence of 1-100 µg/ml of EMD, Fraction C and 
Fraction A and stained for βIII tubulin, as described in 
the Materials and methods. The numbers are the % of 
βIII tubulin-positive cells. The values are the means 
±SE of three measurements of three separate 
experiments. *Indicates significant difference compared 
with NM alone (p<0.05). 
§Control cultures in NM alone had 7.1±1.9% βIII 
tubulin-positive cells 
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7.3.2. Effects of TRAP on neural differentiation of PDL cells 
As demonstrated above (Section 7.3.1), 10 µg/ml of Fraction C markedly increased the 
apparent neurogenic differentiation of the PDL cells in vitro. Since the TRAP peptide has 
previously been reported to be the main component of Fraction C (Mumulidu et al., 2007), the 
neurogenic activity of a synthetic 45-amino acid TRAP peptide was examined by culturing 
PDL cells in NM in the absence and presence of 10 µg/ml of TRAP and immunostained for 
nerve intermediatory filament markers βIII tubulin and NF-L and nerve cell-specific ubiquitin 
hydrolase protein PGP9.5. The representative immunomicrographs in Figure 7.2 and 
quantitative analysis of immunostained cells in Table 9 indicate that in the presence of 10 
µg/ml of TRAP approximately 20% of the PDL cells were found to be positive for βIII 
tubulin, NF-L and PGP9.5 when cultured in NM for 5 days, significantly higher than the cells 
cultured in NM alone (7.1, 3.2 and 2.8% positive cells, respectively) (p<0.05).  
Conventional RT-PCR was carried out for NGF (neuronal marker pivotal for the early 
events of neural differentiation; Angelastro et al., 2000), NF-L and PGP9.5 to examine 
whether addition of TRAP in NM affects these early and late neuronal genes. The 
representative RT-PCR gel in Figure 7.3 shows that the presence of 10 µg/ml of TRAP 
elevated the mRNA transcripts of the early and the late neuronal genes examined here. Thus, 
results in Figure 7.3 show that, in the presence of TRAP, PDL cells expressed significantly 
elevated levels of the early neuronal gene NGF (5.3-fold higher than GM alone), compared 
with cells cultured in NM alone (2.2-fold higher than GM alone) (p<0.05). Similarly, the 
TRAP peptide markedly stimulated the late gene NF-L (7.0-fold increase), compared with 
cells cultured in NM alone (4.2-fold increase) (p<0.05). The PDL cultures did not express 
transcripts of the late neuronal gene PGP9.5 under growth conditions (in GM alone), 
although, cells cultured in NM in the presence of TRAP expressed an elevated level of this 
gene (4.8-fold higher than NM alone) (p<0.05). These results thus indicate that TRAP 
stimulates both early and late neuronal genes and that the presence of synthetic TRAP, similar 
to Fraction C, promoted differentiation of PDL cells to the nerve-like cells. 
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Figure 7.2. Representative micrographs of PDL cells immunostained for βIII tubulin, NF-L 
and PGP9.5 after culture for 5 days in NM in the presence of TRAP (10 µg/ml). βIII tubulin 
and NF-L-positive cells are visualized as green fluorescent cells (Magnification x 20). 
PGP9.5-positive cells are visualized as HRP stained cells (Magnification x40). HRP staining 
was used for the PGP-9.5 to visualize clear morphological appearance of the cells. Nuclei of 
the cells (stained for βIII tubulin and NF-L) are stained blue with Hoechst dye. The red 
arrows show elongated axons of the βIII tubulin, NF-L and PGP9.5-positive cells. The white 
arrows show multiple dendritic projects. 
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βIII tubulin, NF-L and 
PGP9.5-positive cells                             
(% of total cells) 
 
Markers 
NM alone NM + TRAP 
βIII tubulin 7.1±1.9 20.4±2.3* 
NF-L 3.2±0.9 19.3±2.5* 
PGP9.5 2.8±1.0 19.1±1.9* 
Table 9. Effects of TRAP on βIII tubulin, NF-L 
and PGP9.5 staining of PDL cells cultured for 5 
days in NM in the presence of 10 µg/ml of 
TRAP, as described in the Materials and 
methods. The numbers are the % of βIII tubulin, 
NF-L and PGP9.5-positive cells. The values are 
the means ±SE of three measurements of three 
separate experiments. *Indicates significant 
difference compared with NM alone (p<0.05). 
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Figure 7.3. Effect of TRAP on neuronal genes of PDL cells. (i) A representative RT-PCR gel 
showing the expression of the early neural gene NGF and the late genes PGP9.5 and NF-L by 
PDL cells cultured for 2 and 5 days, respectively, in GM alone, NM alone and in the presence 
of NM + TRAP. (ii) The values are the changes in PCR product band intensities relative to 
GAPDH obtained of cells cultured in NM alone and NM with TRAP compared with GM 
alone, defined as 1.0. PDL cells cultured in GM alone did not express PGP9.5, thus for this 
particular gene the values obtained from cells cultured in NM alone were defined as 1.0. The 
values are the means ±SE of triplicate measurements. * Indicates significant difference 
compared with GM alone (p<0.05); § Indicates significant difference compared with NM 
alone. 
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7.3.3. Effects of increasing concentrations of EMD and the EMD Fractions on 
PDL cell gliogenesis in vitro 
As noted above, glial cells are essential for myelinating nerve cells and enabling them to 
communicate via electric (action potential) and chemical (neurotransmitter) signals (Atsumi 
et al., 1999b; Hiroshima et al., 1998; Youn et al., 1997; Bhatheja et al., 2006). They have also 
been reported to be involved in the process of nerve regeneration by secreting essential 
neuronal growth factors such as NGF and GDNF (Atsumi et al., 1999b; Hiroshima et al., 
1998; Youn et al., 1997; Bhatheja et al., 2006). In the present study the cell population 
obtained from PDL tissue was found to have the potential to differentiate into peripheral 
nervous system (PNS)-associated glial cells (astrocytes and Schwann cells) as well as CNS-
associated glial cells (oligodendrocytes) in vitro (Chapter 3) when cultured under gliogenic 
conditions for 10 days, although CNS-associated oligodendrocytes have not been identified 
histologically in PDL tissue (Atsumi et al., 1999b; Hiroshima et al., 1998; Youn et al., 1997; 
Bhatheja et al., 2006), indicating that the PDL may have the gliogenic precursors capable of 
forming all three glial cell types. The results in Sections 7.3.2 and 7.3.3 indicated that 
Fraction C and the TRAP peptide have the ability to induce neural differentiation of PDL 
cells in vitro, although their effects on gliogenic differentiation of PDL cells have not 
previously been examined. The present study therefore examined whether EMD 
component(s) affect PDL cell gliogenesis in vitro when the cells were cultured in GDM in the 
absence and presence of EMD, Fraction C and Fraction A and, after 7 days, immunostained 
for GFAP, an intermediate filament protein found in all three types of glial cells (Hermann et 
al., 2004; Donato et al., 2007; Cora et al., 2009). The representative immunomicrographs in 
Figure 7.4 indicate that PDL cells cultured in GDM alone and in GDM + Fraction C exhibited 
a morphology similar to astrocytes, cells with 3-10 dendritic projections, and also a Schwann 
cell-like population, cells with two dendritic projections at opposite ends of the soma, which 
were also found to be positive for the glial marker GFAP. In contrast, PDL cells cultured in 
GDM in the presence of EMD and Fraction A did not exhibit this morphology or GFAP 
staining (Fig. 7.4). Notably, none of these cultures (GDM alone and GDM + EMD and the 
EMD Fractions) contained cells which were morphologically similar to oligodendrocytes  
(glial cells consisting of more than 20-30 dendritic projections) after 7 days (Hermann et al., 
2004; Donato et al., 2007; Chi et al., 2010).  
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The effects of increasing concentrations (1-100 µg/ml) of EMD, Fraction C and 
Fraction A on PDL cell gliogenesis were examined by culturing PDL cells in GDM in the 
absence and presence of 1, 3, 10, 30 and 100 µg/ml of EMD and the EMD Fractions for 7 
days, then immunostaining for GFAP. Measurement of the proportion of GFAP-positive cells 
shows that PDL cells cultured for 7 days in GDM alone produced 15.8±2.4% of GFAP-
positive glial-like cells (Table 10), whereas cells cultured in non-differentiation-inducing GM 
did not contain any GFAP-positive cells. In the presence of all concentrations of EMD (1-100 
µg/ml) and Fraction A (1-100 µg/ml) very few GFAP-positive glial-like cells were observed 
(1.2% to 4.1%), as shown in Table 10, significantly lower compared with GDM alone  
(15.8%; p<0.05). In marked contrast, even the lowest concentration of Fraction C (1 µg/ml) 
markedly increased the proportion of GFAP-positive cells in the culture, to 17.2%, while 10 
µg/ml of Fraction C produced the highest number of positive cells (28.3%) (Table 10). 
Further increasing the concentration of Fraction C to 30 and 100 µg/ml did not result in any 
further increase in the high proportion of GFAP-positive cells in the cultures. These results 
thus show that Fraction C significantly enhances the proportion of cells expressing the glial 
cell marker GFAP by PDL cells in vitro, and further experiments were therefore carried out to 
clarify the activity of this Fraction by using the TRAP peptide. These results also indicate that 
Fraction A suppresses PDL cell neural differentiation and this sub-fraction was therefore not 
examined further. 
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Figure 7.4. Representative micrographs of PDL cells immunostained for GFAP after culture 
in GDM alone, GDM + EMD (100 µg/ml), GDM + Fraction C (10 µg/ml) and GDM + 
Fraction A (100 µg/ml) for 7 days. The nuclei are stained blue with Hoechst dye. The white 
arrows show GFAP-positive cells with Schwann cell-like morphology. The red arrows show 
GFAP-positive cells with astrocyte-like morphology. Magnification x 20.  
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GFAP-positive cells                             
(% of total cells) 
 
Conc.         
(µg/ml) EMD Fraction C Fraction A 
1  3.4±2.1* 17.2±2.6 4.1±2.0* 
3 2.5±3.8* 19.1±3.8 4.0±3.4* 
10  1.2±0.5* 28.3±4.8* 1.5±2.1* 
30 0.0 27.1±3.5* 0.0 
100 0.0 27.8±2.8* 0.0 
Table 10. Effects of increasing concentrations of EMD 
and the EMD Fractions on GFAP expression of PDL 
cells. GFAP staining of PDL cells cultured for 7 days in 
GDM in the presence of 1-100 µg/ml of EMD, Fraction 
C and Fraction A, as described in the Materials and 
methods. The numbers are the % of GFAP-positive 
cells. The values are the means ±SE of three 
measurements of three separate experiments. *Indicates 
significant difference compared with GDM alone 
(p<0.05). 
§Control culture in GDM alone had 15.8±2.4% GFAP-
positive cells 
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7.3.4. Effects of TRAP on glial differentiation of PDL cells 
It was demonstrated in Section 7.3.4) that 10 µg/ml of Fraction C markedly increased the 
apparent gliogenic differentiation of the PDL cells in vitro. Moreover, the cells expressing the 
glial cell marker GFAP in the presence of Fraction C exhibited a morphology similar to 
astrocytes and Schwann cells. The present study therefore examined the effects of the TRAP 
peptide, a main component of Fraction C (Mumulidu et al., 2007), on the gliogenic activity of 
PDL cells in vitro, by culturing the cells in GDM in the absence and presence of 10 µg/ml of 
synthetic TRAP for 7 days followed by immunostaining for GFAP, an intermediate filament 
marker present in all three types of glial cells, and S-100β, a Schwann cell-specific marker. 
The results in Figure 7.5 indicate that, in the presence of 10 µg/ml of TRAP GFAP-positive 
cells were present which exhibited an astrocyte (glial cells with 3-10 dendritic projections) 
and a Schwann cell-like morphology (two dendritic projections at opposite end of the soma), 
whereas, S-100β-positive cells exhibited a morphological appearance similar to Schwann 
cells, as described previously (Chi et al., 2010). It is notable that the cells with morphology 
similar to oligodendrocytes, glial cells containing more than 20-30 dendritic projections, were 
not found in the control cultures (GDM alone) or in TRAP peptide-induced cultures (Fig. 
7.5). Measurement of GFAP-positive cells showed that 26.3% of the cell population were 
positive for this marker when cultured in GDM + TRAP for 7 days, significantly higher than 
PDL cells cultured in GDM alone (15.8%) (p<0.05). Furthermore, nearly 21% of the PDL 
cells cultured in the presence of TRAP were found to also be positive for the Schwann cell 
marker S-100β, compared with the cells cultured in GDM alone (13.4%) (p<0.05) (Table 11).  
Conventional RT-PCR was carried out for Notch1 (a glial cell protein pivotal for the 
early events of glial differentiation; Angelastro et al., 2000), and the late genes GFAP and S-
100β to examine whether addition of TRAP in GDM affects the early and the late glial gene 
regulation of PDL cells. The representative RT-PCR gel in Figure 7.6 shows that the presence 
of 10 µg/ml of TRAP elevated the mRNA transcripts of the early and the late glial genes 
examined here. Thus, in the presence of TRAP, PDL cells expressed significantly elevated 
levels of the early glial gene Notch1 (3.2-fold higher than GM alone), compared with cells 
cultured in GDM alone (1.9-fold higher than GM alone) (p<0.05). Similarly, the TRAP 
peptide markedly stimulated the late glial gene GFAP (3.8-fold increase), compared with cells 
cultured in GDM alone (2.5-fold increase) (p<0.05). PDL cells cultured in the presence of 
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TRAP expressed significantly higher levels of the Schwann cell-associated gene S-100β (2.7-
fold increase), compared with the cells cultured in GDM alone (1.6-fold increase) (Fig. 7.6). 
These results thus indicate that TRAP stimulates both the early and the late glial genes and 
that the presence of synthetic TRAP, similar to that of Fraction C, promoted differentiation of 
PDL cells to astrocyte and Schwann-like cells. 
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Figure 7.5. Representative micrographs of PDL cells immunostained for GFAP and S-100β 
after culture in GDM in the presence of TRAP (10 µg/ml) for 7 days. Nuclei of the cells are 
stained blue with Hoechst dye. GFAP-positive cells are visualized as green fluorescent cells 
and S-100β-positive cells are visualized as red fluorescent cells. The white arrows show cells 
with Schwann cell-like morphology (both GFAP and S-100β-positive cells) and the red 
arrows show GFAP-positive cells with astrocyte-like morphology. Magnification x20.  
Chapter 7                  Effects of EMD and the EMD Fractions on neurogenesis and gliogenesis 
  175 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GFAP and S-100β-positive 
cells (% of total cells) 
 
Markers 
GDM alone GDM + TRAP 
GFAP 15.8±2.4 26.3±3.6* 
S-100β 13.4±1.1 21.3±2.4* 
Table 11. Effects of TRAP on GFAP and S-100β 
expression of PDL cells cultured for 7 days in 
GDM in the presence of 10 µg/ml of TRAP, as 
described in the Materials and methods. The 
numbers are the % of GFAP and S-100β-
positive cells. The values are the means ±SE of 
three measurements of three separate 
experiments. *Indicates significant difference 
compared with GDM alone (p<0.05). 
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Figure 7.6. Effect of TRAP on glial gene expression by PDL cells. (i) A representative RT-
PCR gel showing the expression of the early gliogenic gene Notch1 and the late genes GFAP 
and S-100β by PDL cells cultured for 2 and 7 days, respectively, in GDM in the presence of 
TRAP. (ii) The values are the changes in PCR product band intensity relative to GAPDH 
obtained in GDM and GDM with TRAP compared with GM alone, defined as 1.0. The values 
are the means ±SE of triplicate measurements. * Indicates statistically significant difference 
compared with GM alone (p<0.05); §Indicates statistically significant difference compared 
with GDM alone. 
Chapter 7                  Effects of EMD and the EMD Fractions on neurogenesis and gliogenesis 
  177 
7.4. Discussion 
The PDL contains dense sensory nerves that are responsible for the rapid and efficient 
conduction of nerve impulses across the axonal bundles, the sensory signals are then 
transmitted to the brain (Nave et al., 2008). Unlike dental pulp nerves that react to pain only, 
the periodontal axonal bundles have been shown to contain receptive sites for touch and 
pressure sensations, orthodontic movements/tooth positioning and jaw movements as well as 
pain (Matthews et al., 1975; Taylor, 1990). Tissue damage resulting from periodontal disease 
also affects PDL sensory nerves and causes debilitating pain (Imai et al., 2003). Several 
attempts have therefore been made to elicit PDL nerve repair, including by the use of nerve 
cross-anastomosis (a surgical procedure in which damaged periodontal nerve connections are 
re-sutured with non-specific peripheral nerves) and by the use of growth factors (e.g. GDNF, 
BDNF, Neurotrophin-4/5) (Imai et al., 2003, Wakisaka et al., 2003; Harada et al., 2003; 
Jabbar et al., 2007). Although some degree of success has been obtained, these therapies were 
focused primarily on the nerve regeneration aspect of periodontal therapy. In contrast, 
although EMD has been extensively studied for its effects on periodontal tissue regeneration 
involving PDL, BV, bone and cementum (Donos et al., 2003; Sculean et al., 2004; Sculean et 
al., 2006; Gkranias et al., 2010), its ability to regenerate periodontal nerves is not yet clear. 
The present study therefore examined whether EMD and the EMD components promoted 
PDL cell nerve differentiation in vitro. 
The results in Chapter 3 demonstrated that βIII tubulin-positive cells with the 
morphological appearance of bipolar sensory nerve-like cells were present when PDL cells 
were cultured under neurogenic conditions and similarly, under gliogenic conditions, GFAP-, 
O4- and S-100β-positive cells were found which exhibited a glial-like cell (astrocytes, 
oligodendrocytes, Schwann cells) morphology. However, as found here, the addition of EMD 
and the higher molecular weight Fraction A completely ablated both the neural and glial 
differentiation of the PDL cells in vitro. In contrast, both the naturally occurring (Fraction C) 
and the TRAP isoform strongly stimulated neurogenesis of PDL cells, with nerve-like cells in 
these TRAP-induced cultures exhibiting a sensory neuron-like morphology and suggesting 
that this 5.3 kDa isoform is likely to be having neurogenic activity. Amelogenin and 
amelogenin isoforms, the main components of EMD, are known to be secreted during tooth 
formation (ten Cate et al., 1996). These proteins are also secreted within the developing 
peripheral nerve trunk, spinal cord, optic nerve, neural-crest cells and trigeminal ganglion of 
the mouse embryo (E13.5-E18.5) (Gruenbaum-cohen et al., 2009; Fincham et al., 1984), and 
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appear to be localized primarily to nerve fibre-like structures, suggesting that they might have 
a role in nervous system development and nerve cell differentiation, as observed here 
(Gruenbaum-cohen et al., 2009; Fincham et al., 1984). 
 The present results also demonstrated that PDL cells cultured in GDM alone and 
GDM with TRAP exhibited morphologies similar to astrocytes, found in both the CNS and 
PNS, and to Schwann cells, found exclusively in PNS (Maeda et al., 1999). Notably, the PDL 
cells did not exhibit the CNS-associated oligodendrocyte-like morphology in either the 
control cultures or the TRAP-induced cultures after 7 days, in contrast to the observations 
reported in Chapter 3 that the PDL cells cultured in GDM alone for 10 days exhibited all three 
types of glial cell-like morphology, including astrocytes, Schwann cells and oligodendrocytes. 
The reason for this discrepancy is not yet clear, but it may partly be due to differences in the 
length of time the PDL cells were cultured in GDM (in the absence or presence of TRAP) 
with 10 days of culture in GDM possibly being necessary for the development of 
oligodendrocyte-like morphology, as shown in Chapter 3.  
It has previously been shown that Schwann cells play an indispensible role in 
peripheral nerve development and regeneration, mainly by producing/secreting neural growth 
factors (NGF, BDNF, NT-4/5), surface adhesion molecules and forming a complex laminin-, 
fibronectin-, heparan sulphate- and tenascin-rich basement membrane for nerve cells. Thus, 
the TRAP-induced Schwann cell formation observed here in vitro may be at least partly 
responsible for the TRAP peptide-mediated nerve regeneration observed here (Yuan et al., 
2007; Frostick et al., 1998; Rodriguez et al., 2000). This is consistent with the other 
observation that elevated levels of amelogenin gene products are present within the sub-
cortical region of the brain containing a dense glial cell population, again suggesting the 
possible role of such proteins in glial cell development/differentiation (Gruenbaum-cohen et 
al., 2009). 
 
 In summary, the present study showed for the first time that the amelogenin isoform 
TRAP appears to promote the differentiation of PDL cells to nerve-like cells and to PNS-
associated glial cells, whereas the higher molecular weight EMD components ablated nerve 
and glial cell formation. 
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8.1. Introduction 
Stem cells can be defined as having the ability to give rise to at least one differentiated cell 
type as well as the capacity to self-renew (Collins et al., 2005; Lemoli et al., 2005). In 
contrast to the large majority of the cell population of adult tissues that are committed to a 
specific function, stem cells are uncommitted until they receive signals to differentiate into 
progenitor/precursor cells before forming fully differentiated and functionally active cells in 
culture in vitro and in the tissue microenvironment in vivo (Weissman et al., 2000; Lemoli et 
al., 2005). The stimuli for cell differentiation are therefore critical for tissue homeostasis, 
repair and replenishment (Weissman et al., 2000; Till and McCulloch, 1961; De Miguel et al., 
2010). For example, mouse embryonic cells have been shown to require external factors such 
as recombinant leukemia inhibitory factor (LIF), fibroblast growth factors (FGF) and bone 
morphogenetic proteins (BMP) to maintain their plasticity and capacity to self-renew in 
culture (Chen et al., 2008; Niwa et al., 1998; Smith et al., 2001; Ying et al., 2003; De Miguel 
et al., 2010). Similarly, recombinant BMP-2, Wnt3a, Wnt5a and insulin-like growth factor 
(IGF) have been shown to stimulate a range of differentiation pathways of precursor/stem 
cells, including osteogenesis, gliogenesis and myogenesis (Baksh et al., 2007; Singhatanadgit 
et al., 2008; Kasai et al., 2005; Husmann et al., 1996). Such growth mediators can induce cell 
differentiation by binding to specific cell surface transmembrane receptors to form ligand-
receptor complexes (Seto et al., 2002; Caron et al., 2001; Conner and Schmid, 2003). These 
activate intracellular second messengers, often involving a cascade of protein kinase 
intermediaries (Caron et al., 2001; Conner and Schmid, 2003), which ultimately translocate to 
the nucleus and modulate target genes, thus eliciting the biological response to the ligand 
(Barnes et al., 1999; Johnson and Vaillancourt, 1994). For example, the BMP-2 and 4 ligands 
bind specifically to the BMP receptors (BMPR) I and II, the resultant BMP2/4-BMPR 
complex then activating second messengers including Smad4 and Smad1/5/8 which 
translocate to the nucleus and up-regulate osteogenic transcription factor genes such as Runx2 
(Ryoo and Lee, 2006; Singhatanadgit et al., 2006).  
 Receptor-mediated endocytosis is generally considered to be the main mechanism by 
which ligand-receptor complexes are internalized into the cells, first into early endosomes and 
then transported to other organelles including the trans-Golgi network (TGN) and lysosomes. 
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Dissociation of the ligands from the receptors usually occurs in the acidic environment of 
these organelles, the receptors often being recycled back to the plasma membrane (Seto et al., 
2002) and the ligands undergoing hydrolytic breakdown in the lysosomes (French et al., 1995; 
Seto et al., 2002). Receptor-mediated endocytosis is generally considered a main mechanism 
by which cells regulate the availability of cell surface receptors and thereby the response to 
ligand (French et al., 1995; Seto et al., 2002). A number of studies have provided evidence for 
the importance of receptor-mediated endocytosis in growth factor-mediated signal 
transduction, including Wnt (Baksh et al., 2007), BMP (Singhatanadgit et al., 2006; Jortikka 
et al., 1997), FGF (Citores et al., 2001), IGF (Furlanetto, 1998) and VEGF (Wang et al., 
2002).  
In a number of studies of the mouse amelogenins in tooth development, the full-length 
amelogenin (M180) and its isoforms [A-4](M50) and [A+4] (M73) have also been reported to 
bind to a protein which is sometimes located at the cell surface, the lysosomal-associated 
membrane protein (LAMP)-1), in mouse embryonic dental follicle cells involved in dentin, 
cementum and PDL formation (Ten cate et al., 1996; Heritier et al., 1982; Zhang et al., 2010; 
Tompkins et al., 2006; Iacob et al., 2008). Additionally, the amelogenin peptides were shown 
to be transported to intracellular vesicles including early endosomes and lysosomes (Iacob 
and Veis, 2008; Tompkins et al., 2006; Xu et al., 2008). Similarly, a previous study has also 
suggested that at least some component(s) present in EMD may also be internalized into cells 
by receptor-mediated endocytosis (Reseland et al., 2006). Thus, EMD was found to 
internalize into osteoblasts via clathrin-coated pits, identified by co-immunolabelling of anti-
EMD antibody and anti-AP-2, a clathrin-associated protein (Reseland et al., 2006). However, 
the most crucial initial process of EMD binding to the osteoblast cell membrane and the 
intracellular transport and fate of EMD were not examined in this study (Reseland et al., 
2006). As noted in Chapter 1, EMD is a complex mixture of various proteins including 
amelogenins, sheathlins and enamelins (Brookes et al., 1995; Hu et al., 1997). Thus, the 
specificity of the antibody raised against EMD and the specific component(s) internalized into 
the osteoblasts remain unclear in this report (Reseland et al., 2006). As noted above, receptor-
mediated endocytosis is the main mechanism by which soluble ligands bind and internalize 
into the cell, but whether commercially prepared EMD and the EMD component(s) bind to 
the cell membrane and internalize via receptor-mediated endocytosis is not yet clear.   
During porcine development EMP has been shown to be secreted by specialized 
epithelial cells (ameloblasts) via unique extracellular projections (tome’s processes) (ten Cate 
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et al., 1996; Heritier et al., 1982) and to precipitate on the cell surface, leading to the 
development of tooth-associated tissues (Deutsch et al., 1995). Using Scanning Electron 
Microscopy (SEM) it was observed that the commercial preparation EMD precipitates on 
human PDL tissue sections ex vivo and forms spheres or short rod-like structures (Cattaneo et 
al., 2003). In addition, EMD has also been found to precipitate on the surface of PDL cells in 
vitro and to stimulate cell proliferation, ECM production and osteogenic differentiation 
(Cattaneo et al., 2003; Gestrelius et al., 1997; Zeichner et al., 2006). It has therefore been 
suggested that such insoluble complexes of the full-length hydrophobic amelogenin protein, a 
main component of EMD, may be at least partially responsible for these cellular activities by 
PDL cells (Cattaneo et al., 2003; Gestrelius et al., 1997; Zeichner et al., 2006), in addition to 
the possible responses resulting from the binding and internalization of soluble EMP 
component(s) by receptor-mediated endocytosis (Iacob and Veis, 2008; Tompkins et al., 
2006; Xu et al., 2008).  
However, in contrast to ‘soluble’ ligands, internalization of such insoluble particulate 
matter, including also certain viruses, bacteria, bacterial toxins and macromolecular 
complexes such as collagen, occurs via phagocytosis (Groves et al., 2008). In mammalian 
cells, this process is carried out primarily by the cells of the immune system (e.g. 
macrophages, dendritic cells, monocytes and neutrophils) and involves specialized 
intracellular vacuoles (phagosomes) in which ‘insoluble’ macromolecular substances are 
degraded (Greenberg et al., 1995; Groves et al., 2008). Although phagocytosis has also been 
shown to occur via receptors (e.g. FcγRs, complement receptor (CR)3) which elicit 
development of submembranous actin filament assemblies and pseudopod extensions 
(Lowell, 2006; Greenburg, 1995) via intracellular signal transduction processes and to be 
ultimately responsible for uptake of particulate matter (Lowell, 2006), they are unlikely to 
have a role in cell differentiation (Lowell, 2006; Greenburg, 1995). 
In the present study it has been shown that the components of EMD differentially 
regulate a range of PDL cell differentiation activities, including osteogenesis, adipogenesis, 
chondrogenesis, angiogenesis, vasculogenesis, neurogenesis and gliogenesis in vitro 
(Chapters 4-7). However, the interaction of (commercial heat-treated preparations) EMD and 
the various components of EMD with PDL cells is not yet known. Experiments were 
therefore carried out to determine: (i) whether EMD and the EMD Fractions (C and A) bind 
to PDL cells, (ii) whether EMD and the EMD Fractions are internalized into the cells, and 
(iii) intracellular localization/transport of EMD and the EMD Fractions. 
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8.2. Materials and methods 
PDL cell culture and SEM were performed as described in Chapter 2; additional methods 
used in this chapter are described below. 
 
8.2.1. Binding and intracellular uptake of EMD and the EMD Fractions by PDL 
cells 
To assess cell binding, PDL cells were seeded onto 24-well plates on glass coverslips at a 
density of 104 cells/well and cultured in GM for 2 days. The medium was replaced with cold 
GM containing 30 µg/ml of EMD, Fraction C and Fraction A which had been directly biotin-
labelled (provided by Institut Straumann, Basel, Switzerland) and the cells maintained at 4°C 
for 45 min, washed 3 x with cold PBS, fixed with 4% PFA for 15 min, reacted with Alexa 
Fluor-streptavidin (Invitrogen, Paisley, UK) for 30 min and visualized under the fluorescence 
microscope. To determine whether the EMD and the EMD Fractions were membrane-
associated, replicate cultures were washed 3 x with cold PBS, treated with trypsin-EDTA at 
37°C for 5 min and the detached cells centrifuged at 1500 rpm for 5 min. The cell pellets were 
washed and resuspended in PBS, fixed with 4% PFA for 15 min, reacted with Alexa Fluor-
streptavidin for 30 min, air dried on a glass slide and coverslips with mounting medium were 
placed on the cells.  
To examine whether EMD and the EMD Fractions internalized after the initial 
incubation at 4°C as above, the cells were washed 3 x with PBS, incubated with GM at 37°C 
for 3 and 6 h, fixed with 4% PFA, permeabilised using 0.1% Triton-X for 10 min and reacted 
with Alexa Fluor-streptavidin (Invitrogen) for 30 min. To eliminate the possibility that any 
positive staining (i.e. red fluorescence) might be due to membrane bound/extracellular ligand, 
replicate cultures were treated with trypsin-EDTA for 5 min prior to fixation with PFA. The 
detached cells were centrifuged at 1500 rpm for 5 min, re-cultured for a further period of 3 h 
to allow the cells to adhere/spread for visualizing cellular morphology, fixed with 4% PFA, 
permeabilised using 0.1% Triton-X for 10 min and reacted with Alexa Fluor-streptavidin 
(Invitrogen) for 30 min. Nuclei were stained blue using Hoechst dye.  
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8.2.2. Intracellular localization EMD and the EMD Fractions  
To examine intracellular localization of EMD and the EMD Fractions after binding, the 
biotinylated-EMD, Fraction C and Fraction A were co-localized with markers of the trans-
Golgi network (TGN) and lysosomes using specific antibodies as described below. The cells 
were seeded and cultured on 24-well plates on glass coverslips for 2 days and then incubated 
with the biotin-labelled ligands at 4°C for 45 min, as described above. The cells were then 
washed 3 x with cold PBS, incubated with warm GM at 37oC for 45 min and 3 h, fixed with 
4% PFA and permeabilised using 0.1% Triton-X for 10 min. These conditions were used 
because a number of ligands (mouse amelogenin isoform [A-4/A+4], Wnt, Basolateral 
proteins, STxB (non-toxic β-subunit of shiga toxin)) have previously been shown to be 
transported to the TGN after 30 to 60 min and to the lysosomes after 2 to 6 h of incubation at 
37°C following binding (Iacob and Veis, 2008; Cancino et al., 2007; Port and Basler, 2010; 
Mallard et al., 2002). The samples were immunostained for 58K, a marker of the TGN 
localized in the perinuclear region (Bashour et al., 1998), and LAMP-1, a membrane protein 
primarily associated with lysosomal organelles (Chen et al., 1985), as described previously 
(Singhatanadgit et al., 2008). After treating with a blocking solution containing 10% normal 
goat serum (NGS) in PBS for 1 h, the cells were incubated for 1 h at RT with the primary 
mouse monoclonal anti-58K (Sigma) (for the samples incubated at 37°C for 45 min) and anti-
LAMP-1 (Abcam) (for the samples incubated at 37°C for 3 h) antibodies diluted 1:200 and 
1:20, respectively, in PBS containing 1% NGS. Incubation was then carried out with goat 
anti-mouse Alexa Fluor 488 secondary antibody (green fluorescent) (Invitrogen) diluted 
1:200 in PBS containing 1% NGS for 1 h at RT. Cells treated with non-specific mouse IgG 
were used a control. The TGN was visualized by perinuclear green fluorescent staining after 
treatment with anti-58K and lysosomal vesicles were visualized by punctate green fluorescent 
staining after treatment with LAMP-1. The cells were then further reacted with Alexa Fluor-
streptavidin 594 (red fluorescent) (Invitrogen, Paisley, UK) for 30 min to visualize the biotin-
labelled EMD and the EMD Fractions; nuclei were stained blue using Hoechst dye.  
 Whether in lysosomes at 3 h, as indicated by the results of fluorescence microscopy, 
replicate cultures were prepared for immunogold electron microscopy (IEM) to elucidate 
localization of EMD, Fraction C and Fraction A at the ultrastructural level, as follows. The 
cell cultures were maintained at 4°C for 45 min with GM in the presence of biotinylated-
EMD, Fraction C and Fraction A, washed 3 x with cold PBS and incubated with warm GM at 
37°C for 3 h. The cells then detached by incubating in Trypsin-EDTA for 5 min, after which 
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they were centrifuged at 1500 rpm for 5 min and the cell pellets fixed with 0.5% 
glutaraldehyde at 4°C for 30 min, dehydrated in cold ethanol and embedded at -20°C in LR 
White resin (Agar Scientific, Stansted, UK). Ultra-thin sections (approximately 0.1 µm thick) 
were collected on specimen grids (Agar Scientific), rehydrated with distilled water and then 
were incubated with 10% NGS in PBS for 1 h to block non-specific binding, then washed 3 x 
washes with PBS. The sections were subsequently incubated with mouse-monoclonal LAMP-
1 antibody (1:20 in PBS containing 1% NGS) for 1 h at RT. Non-specific mouse IgG was 
used as the control for the primary antibody LAMP-1. After 3 x washes with PBS, the 
sections were incubated with 5 nm gold-conjugated goat antibody (Agar Scientific) (diluted 
1:200 in 1% NGS in PBS) for 1 h at RT, then treated with 20 nm gold-conjugated streptavidin 
for 30 min to visualize the biotinylated EMD and the EMD Fractions. Sections not treated 
with biotin-labelled EMD and the EMD Fractions were also incubated with 20 nm gold-
labelled streptavidin as a specificity control. The sections were stained with uranyl acetate (1 
min) and lead citrate (1 min) to enhance the contrast between intracellular structures of 
differing electron density and the presence of LAMP-1 indicated by small, round black gold 
particles (5 nm in size) and the presence of EMD, Fraction C and Fraction A indicated by the 
20 nm round gold particles. The sections were examined under a TEM (JEOL 100 CX II; Jeol 
Ltd, Welwyn Garden City, UK). 
  
8.2.3. Phase-contrast and SEM analysis of EMD, Fraction C and Fraction A 
interaction with PDL cells 
EMD has previously been shown to precipitate and form spheres and short rod-like structures 
on the PDL cell surface in vitro and on PDL tissue section ex vivo and it has been suggested 
that the proline-rich full-length hydrophobic amelogenin protein, a main component of EMD, 
is likely to be responsible for the formation of such structures (Cattaneo et al., 2003; 
Gestrelius et al., 1997; Zeichner et al., 2006). To examine whether Fraction C and Fraction A 
(sub-fractions of EMD which contain mainly amelogenin and/or amelogenin isoforms 
(Chapter 1)) also precipitate on the PDL cell surface, 104 cells/well were seeded onto 
coverslips in 24-well plates and cultured for 2-3 days in GM. EMD, Fraction C and Fraction 
A (all at 30 µg/ml) were then added and the cells incubated for 24 h at 37°C after which they 
were visualized under phase-contrast microscope to examine the possible formation of 
insoluble particulate material. Replicate cultures were also fixed in 1% glutaraldehyde at 4°C 
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for 30 min and prepared for SEM analysis. PDL cells without any treatment with EMD or the 
EMD Fractions were used as a control. To examine whether EMD, Fraction C and Fraction A 
in GM precipitate on tissue culture plastic in the absence of any cells, 30 µg/ml EMD and the 
EMD Fractions were added in GM on cover slips in 24-well plates and incubated for 24 h at 
37°C, after which they were fixed in 1% glutaraldehyde at 4°C for 30 min and prepared for 
SEM analysis.       
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8.3. Results 
8.3.1. Binding and uptake of EMD and the EMD Fractions by PDL cells 
To determine whether EMD and the EMD Fractions bind to the PDL cells, the cells were 
incubated for 45 min with biotinylated EMD, Fraction C and Fraction A at 4°C, at which 
temperature there is no uptake of exogenous ligand (Seto et al., 2002; Conner and Schmid, 
2003; Iacob et al., 2008). The results in Figure 8.1 show that, under these conditions, red 
fluorescent staining corresponding to EMD, Fraction C and Fraction A was observed to be 
localized at the cell membrane with little if any fluorescence present intracellularly. To 
establish whether the red fluorescent staining of EMD, Fraction C and Fraction A was 
extracellular/associated with the cell membrane, the cells which had been incubated with 
EMD and the EMD Fractions at 4°C for 45 min were then treated with trypsin-EDTA, 
centrifuged, fixed, reacted with streptavidin-Alexa Fluor 594 and air dried on glass slides. 
Figure 8.1 shows that after treatment with trypsin-EDTA there was no red fluorescent staining 
associated with any of the cells, indicating that EMD and the EMD Fractions were 
removed/digested by the trypsin/EDTA treatment and were therefore likely to have been 
entirely membrane-bound after incubation at 4°C.  
When the cultures were incubated with the biotinylated EMD and the EMD Fractions 
for 45 min at 4°C, washed and re-cultured at 37°C for 3 h, the red fluorescence corresponding 
to EMD and the EMD Fractions was found to be localized intracellularly, with a diffuse 
cytosolic distribution after 3 h, as shown in Figure 8.2. Moreover, after the cells were re-
cultured for 6 h at 37°C, the red fluorescence was found to be intracellular, but the fluorescent 
staining was localized mainly within few large, round intracellular vesicle-like structures 
(generally < 10). To establish whether the visualized EMD and the EMD Fractions were 
intracellular and not on the cell membrane, the cells were first incubated with biotinylated-
EMD and the EMD Fractions at 4°C for 45 min, washed, cultured for a further period of 3 h 
at 37°C, treated with trypsin-EDTA as before in order to digest any extracellular 
EMD/Fractions-ligands and then re-cultured for 3 h (total of 6 h of culture at 37°C). The 
results in Figure 8.2 show that the red fluorescent staining corresponding to EMD, Fraction C 
and Fraction A was still clearly evident (within large, round vesicle-like structures) even after 
trypsinization, indicating that EMD and the EMD Fractions were likely to have been 
internalized after incubation at 37°C for 3 and 6 h. Manual counting of the cells exhibiting  
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intracellular red fluorescent staining after 6 h showed that 8.5, 6.6 and 12.3% to the total PDL 
cells internalized EMD, Fration C and Fraction A, respectively (Appendix Material 3.1). 
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Figure 8.1. Micrographs of biotinylated EMD, Fraction C and Fraction A binding to PDL 
cells. Cells were cultured in the absence and presence of EMD and the EMD Fractions at 4°C 
for 45 min, washed, fixed and reacted with red fluorescent Alexa Fluor-streptavidin. 
Replicate cultures were washed, trypsinized, centrifuged, fixed, reacted with red fluorescent 
Alexa Flour-streptavidin and air-dried on glass slide. EMD and the EMD Fractions are 
visualized by red fluorescent staining. The nuclei are stained blue using Hoechst dye. White 
arrows show cell-associated EMD, Fraction C and Fraction A. Magnification x 60.     
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 8.3.2. Intracellular localization of EMD and the EMD Fractions in PDL cells 
The intracellular localization of biotinylated-EMD and the EMD Fractions was examined by 
co-labelling with an intracellular marker of the TGN and of the lysosomes, 58K and LAMP-1, 
respectively, as described in the Materials and methods. Figure 8.3 shows that in the control 
cultures which were not incubated with EMD and the EMD Fractions there was no red 
fluorescent staining, while 58K and LAMP-1 staining was observed by the peri-nuclear green 
fluorescence of the 58K antigen and the punctate green fluorescence of the LAMP-1 
(lysosomal) antigen, respectively, as shown previously (Tajika et al., 2004; Bashour et al., 
1998; Chen et al., 1985). It is notable that there were a large number (generally > 50) of 
LAMP-1 positive diffuse structures, most probably lysosomes, as previously reported (Chen 
et al., 1985; Iacob et al., 2008) (Figure 8.3). No green fluorescent staining was detected in the 
negative control in which sections were reacted with the non-specific mouse IgG antibody.  
When biotinylated-EMD and the EMD Fractions were incubated with PDL cells at 
4°C for 45 min, washed, re-cultured in GM at 37°C for 45 min, stained for TGN antigen 58K 
(Alexa Fluor 488; green fluorescent) and then reacted with streptavidin-Alexa Fluor 594, the 
red fluorescent staining corresponding to EMD and the EMD Fractions was found to co-
localize with the peri-nuclear green fluorescence of the TGN, as shown in Figure 8.3. When 
the incubation of the PDL cells was extended for 3 h at 37°C, EMD, Fraction C and Fraction 
A were found to be localized with LAMP-1-positive green fluorescent diffuse structures, 
presumably lysosomes, as shown in Figure 8.3. Similarly, when biotinylated-chemically 
synthesized TRAP peptide was incubated with PDL cells at 4°C for 45 min, washed and 
reacted with streptavidin-Alexa Fluor 594, red fluorescent staining corresponding to TRAP 
was found to be extracellular and possibly membrane-bound, as shown in Figure 8.4. After 45 
min of incubation at 4°C, when replicate cultures were washed and further incubated in GM 
at 37°C for 45 min the red fluorescent staining was found to co-localize with the peri-nuclear 
green fluorescence of TGN (Fig. 8.4). After 3 h at 37°C, the red fluorescent staining was 
found to co-localize with the diffuse green fluorescent staining of LAMP-1, demonstrating 
that the intracellular fate of the chemically synthesized biotinylated-TRAP was similar to that 
of the EMD Fractions.  
  To establish whether EMD and the EMD components are in lysosomes at 3 h, as 
indicated by the results of fluorescence microscopy, the precise ultrastructural localisation of 
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the internalized biotinylated EMD, Fraction C and Fraction A was examined using IEM by 
reacting sections of the cells with streptavidin-gold (20 nm particles) and anti-LAMP-1 (5 nm 
gold particles), as described in Materials and methods. The results in Figure 8.5 show that in 
the control sections which were not treated with EMD and the EMD Fractions, no 20 nm gold 
particles were detected, whereas the 5 nm gold particles corresponding to LAMP-1 appeared 
to localize in sub-cellular organelles, presumably lysosomes. No gold particles were detected 
in the negative control in which sections were reacted with the non-specific mouse IgG 
antibody (Appendix Material 3.2). In the sections incubated with EMD, Fraction C and 
Fraction A, 20 nm gold particles were observed to be co-localized with the 5 nm gold 
particles corresponding to the LAMP-1 antibody (Figs. 8.6, 8.7 and 8.8).  
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  Figure 8.3. Micrographs of co-labelled PDL cells, incubated with biotinylated EMD, 
Fraction C and Fraction A (observed by red fluorescent staining) and immunostained for 
either (A) TNG marker 58K or  (B) lysosome marker LAMP-1 (both observed by green 
fluorescent staining). PDL cells were cultured in the absence and presence of EMD and the 
EMD Fractions at 4°C for 45 min, washed and re-cultured at 37°C for 45 min (A) or 3 h (B). 
White arrows show co-localization of EMD and the EMD Fractions with 58K-positive TGN 
(A) and LAMP-1-positive structures (B). Nuclei are stained blue using Hoechst dye. 
Magnification x 100.     
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Figure 8.5. Control immunogold EM section demonstrating the ultrastructure of a PDL 
cell cultured in GM in the absence of biotinylated EMD and the EMD Fractions. The 
sections reacted with mouse monoclonal LAMP-1 antibody and reacted with 5 nm gold-
conjugated goat antibody (secondary antibody). In order to examine whether 20 nm gold-
conjugated-streptavidin reacts with the cells in the absence of biotinylated EMD and the 
EMD Fractions, the sections were also reacted with 20 nm gold-conjugated-streptavidin 
(control). Black arrows show 5 nm gold particles most probably localized within the 
lysosomes. Note the absence of 20 nm gold particles.    
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Figure 8.6. Double-labelling Immunogold EM demonstrating the ultrastructure of a PDL 
cell cultured in GM in the presence of biotinylated EMD for 3 h at 37°C. The sections 
were stained for LAMP-1 and reacted with 5 nm gold-conjugated goat antibody 
(secondary antibody) and 20 nm gold-conjugated-streptavidin. Black arrows show 5 nm 
gold particles corresponding to LAMP-1 that are most probably localized within the 
lysosomes and a red arrow shows a 20 nm gold particle corresponding to biotinylated 
EMD. Note the presence of EMD apparently closely associated with LAMP-1.      
Chapter 8                                       Interaction of EMD and the EMD Fractions with PDL cells 
  197 
 
 
 
Figure 8.7. Double-labelling Immunogold EM demonstrating the ultrastructure of a PDL 
cell cultured in GM in the presence of biotinylated Fraction C for 3 h at 37°C. The 
sections were stained for LAMP-1 and reacted with 5 nm gold-conjugated goat antibody 
(secondary antibody) and 20 nm gold-conjugated-streptavidin. Black arrows show 5 nm 
gold particles corresponding to LAMP-1 that are most probably localized within the 
lysosomes and a red arrow shows a 20 nm gold particle corresponding to biotinylated 
Fraction C. Note the presence of Fraction C apparently closely associated with LAMP-1.     
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Figure 8.8. Double-labelling Immunogold EM demonstrating the ultrastructure of a PDL 
cell cultured in GM in the presence of biotinylated Fraction A for 3 h at 37°C. The 
sections were stained for LAMP-1 and reacted with 5 nm gold-conjugated goat antibody 
(secondary antibody) and 20 nm gold-conjugated-streptavidin. Black arrows show 5 nm 
gold particles corresponding to LAMP-1 that are most probably localized within the 
lysosomes and a red arrow shows a 20 nm gold particle corresponding to biotinylated 
Fraction A. Note the presence of EMD apparently closely associated with LAMP-1.    
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8.3.3. Formation of EMD, Fraction C and Fraction A precipitates 
Commercially available lyophilized EMD has previously been shown to be soluble only in 
acidic solution (0.1% acetic acid) and to precipitate at neutral pH (Gestrelius et al., 1997). In 
the present study, although EMD, Fraction C and Fraction A also appeared to be readily 
soluble in 0.1% acetic acid (pH 4.1), based on the clear appearance of this solution, both 
EMD and Fraction A formed globular precipitates when added to GM (pH 7.4) and incubated 
on tissue culture plastic at 37°C for 24 h (in the absence of any cells), as shown by phase 
contrast microscopy and SEM (Fig. 8.9). In contrast, the low molecular weight Fraction C did 
not appear to form any type of precipitate, based on the absence of particulate material on the 
plastic surface (Fig. 8.9). When added to cultures of PDL cells for 24 h at 37°C, EMD and 
Fraction A were also found to precipitate and form spherical, aggregate-like structures (at the 
pH of GM (7.4)) that appeared to be closely associated with the cell surface (Fig. 8.10). 
However, no particulate material was detected when the PDL cells were cultured with 
Fraction C (Fig. 8.10). Moreover, Figure 8.11 show that the tissue culture plastic on which 
PDL cells were seeded and treated with EMD and Fraction A in GM at 37°C for 24 h 
exhibited precipitated globular aggregate-like structures on both the cell surface as well as on 
the tissue culture plastic surface, which could not be observed in higher magnification images 
in Figures 8.9 and 8.10. These results thus demonstrate that EMD and Fraction A precipitate 
on the PDL cell surface as well as on the plastic surface after 24 h of incubation in GM. In 
contrast, even in the presence of cells Fraction C produced no visible evidence of 
precipitation.   
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8.4. Discussion 
The PDL has previously been reported to contain a progenitor/stem cell-like population 
capable of multi-lineage differentiation and possibly playing a pivotal role in periodontal 
repair and regeneration (Amin et al., 2011; Singhatanadgit et al., 2009, Xu et al., 2009; Fujii 
et al., 2008; Chen et al., 2006). A number of biological mediators, including growth factors 
(Wnt, PDGF, BMP-2, IGF and TGF-β) and hormones (parathyroid hormone and 
dexamethasone), have been shown to elicit profound effects on PDL cell proliferation and 
osteogenic differentiation by acting as ligands that bind to the extracellular domain of 
transmembrane receptors. The subsequent changes in conformation/activity of the 
intracellular domains of the receptors (Kao et al., 2009; Zhao et al., 2002; Strayhorn et al., 
1999; Chien et al., 1999; Takayama et al., 1997) lead to a cascade of protein kinase 
phosphorylation, ultimately resulting in the activation of transcription factors (e.g. Runx2) 
that bind to specific gene promoter sequences that regulate mRNA and, ultimately, protein 
production (Trippel et al., 1996; Barnes et al., 1999). Receptor-mediated endocytosis of 
ligand-receptor complexes is general considered as one of the mechanisms by which the level 
of cell surface receptors responsible for signal transduction is regulated (French et al., 1995; 
Seto et al., 2002). For example, TGFβ has been shown to bind to TGFβR-I and II and to 
transduce intracellular signals and the ligand-receptor complexes subsequently internalized 
via clatherin-mediated endocytosis (Anders et al., 1997). The ligands are dissociated from the 
complexes in the early endosomes and the receptors recycled back to the cell surface where 
they once again become available for further TGFβ-mediated signal transduction activity 
(Anders et al., 1997).  
EMP has been reported to induce PDL cell attachment, proliferation and multi-lineage 
differentiation (osteogenesis, chondrogenesis and angiogenesis) in vitro and periodontal tissue 
regeneration in vivo (Gestrelius et al., 1997; Van der Pauw et al. 2000; Narukawa et al., 2007; 
Schlueter et al., 2007). Although it is not yet clear whether and which components of 
commercially prepared (heat-treated) porcine EMD bind to specific transmembrane 
receptor(s) and potentiate PDL cell proliferation and differentiation via signal transduction 
mechanism. However, previous reports examining the role of mouse amelogenins in tooth 
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development demonstrated that the full-length mouse recombinant amelogenin (M180) and its 
isoforms (M50) and (M73) bind to the receptor CD107a (also known as LAMP-1) and to the 
receptor CD63 (also known as LAMP-3), respectively, on mouse embryonic dental follicle 
cell membranes and transduce signals for odontogenic differentiation (Zhang et al., 2010; 
Tompkins et al., 2006; Iacob et al., 2008), indicating that certain component(s) within EMD 
may have an important signalling role in the process of cell differentiation. In addition, it was 
reported previously that when human osteoblasts were incubated with a crude preparation of 
EMP at 37°C for 3 h, protein component(s) were found to be internalized into cells via 
clathrin-coated pits, identified by simultaneous immunolabelling using anti-EMP and anti-
AP-2, a clathrin adaptor protein which is responsible for linking the ligand-receptor complex 
(cargo) into the clathrin-coated pits intracellularly (Reseland et al., 2006). However, in this 
study the binding of EMP to the cell membrane and intracellular transport and fate of EMP 
were not examined (Reseland et al., 2006). Moreover, EMP is a complex mixture of various 
proteins including amelogenin, sheathlins and enamelin, and growth factors have also been 
found to be present in non-heat-treated crude preparations (Brookes et al., 1995; Hu et al., 
1997). There is therefore uncertainty about the specificity of the antibody raised against crude 
EMP and thus the specific component(s) which may have been internalized into the 
osteoblasts (Reseland et al., 2006). In the present study it has been shown, for the first time, 
that at 4°C at least some component(s) of the commercial preparation of EMD and EMD 
components (Fraction C and Fraction A, isolated using industrial protein fractionation 
methodologies) bind to the PDL cell membrane and at 37°C these proteins are internalized 
and transported to the peri-nuclear region of the cells after 45 min, co-localizing with the 
TGN marker 58K. Moreover, after 3 h these protein components were found to have diffuse 
cytosolic distribution and were co-localized with LAMP-1-positive sub cellular lysosome-like 
structures. Similar to the present observations, a previous study using a recombinant mouse 
amelogenin isoform (M50) showed that this protein binds to the murine ameloblast (LS8) 
membrane after incubation at 4°C for 1 h and internalizes and co-localizes with LAMP-1-
positive lysosomes when cultures were further incubated at 37°C for 1 h (Iacob et al., 2008). 
In addition, using recombinant mouse amelogenin (M180) it was reported that this protein 
internalizes into mouse osteoblasts (MC3T3) and ameloblasts (LS8) when incubated at 37°C 
for 1 h, the internalized amelogenin having a diffuse cytosolic distribution and co-localizing 
with LAMP-1-positive intracellular vesicle-like structures (Shapiro et al., 2007). A previous 
study using Wnt3a, a developmental protein which has previously also been shown to be 
responsible for bone homeostasis and repair (Blitzer and Nusse, 2006; Port and Basler, 2010), 
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showed that this protein binds to Wnt receptor (Frizzle) on murine fibroblast (murine L cell 
line) membrane and the ligand internalizes into the cell via receptor-mediated endocytosis and 
is transported to the TGN and lysosomes, similar to the present observations using EMD and 
the EMD components and previously reported observations using recombinant mouse 
amelogenins, as noted above, indicating that at least some components of EMD, Fraction C 
and Fraction A used here internalize via the process of receptor-mediated endocytosis (Iacob 
et al., 2008; Shapiro et al., 2007). It is also notable that, in the present study when the 
heterogeneous PDL cell population used here was treated with EMD, Fraction C and Fraction 
A, only a proportion of the cells were able to bind and internalize these proteins, suggesting 
that there is a subpopulation of cells within the PDL that expresses receptor(s) involved in 
direct interaction with EMD and the EMD components.  
During porcine development EMP has been shown to be secreted by ameloblasts, 
specialized epithelial cells having unique extracellular projections mediating EMP secretion 
(tome’s processes) (ten Cate et al., 1996; Heritier et al., 1982), and to precipitate on the 
surface of these same cells, promoting development of tooth-associated tissues (Deutsch et 
al., 1995). Similarly, commercially available Emdogain®/EMD has been shown to precipitate 
and form aggregate-like structures on the PDL cell surface in vitro and in the tissue 
microenvironment ex vivo, mimicking natural tooth-associated tissue development, noted 
above (Gestrelius et al., 1997). The present study observed that both EMD and the higher 
molecular weight Fraction of EMD (Fraction A) precipitated and formed globular aggregate-
like structures on the PDL cell surface as well as on tissue culture plastic. Similarly, proline-
rich hydrophobic full-length recombinant mouse amelogenin (M180) has been reported to 
also form insoluble supramolecular aggregates (2-3 million Daltons molecular size under 
physiological conditions) (Fincham et al., 1994), suggesting that the full-length amelogenin, 
one of the main components of EMD and Fraction A, might be responsible for the aggregate-
like structures observed here. However, in contrast to the higher molecular weight 
components of EMD, it was observed here that the low molecular weight proteins (of Fraction 
C) did not precipitate and form such aggregate-like structures. Nevertheless, Fraction C, 
which contains mainly the 5 kDa peptide (TRAP) derived from full-length amelogenin, had 
the potential to stimulate chondrogenic, vasculogenic, angiogenic, neurogenic and gliogenic 
differentiation of PDL cells in vitro (Chapters 4-7), despite the lack of apparent ability to 
form precipitates and aggregates on the cell surface. It is thus likely that Fraction C acts by a 
receptor-mediated endocytosis mechanism rather than by a precipitation-related process. 
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However, the role of phagocytosis in EMD mode-of-action can not be entirely excluded since 
fibroblastic cells, which have been reported to be present in the PDL population (Kuru et al., 
1998), have also been shown to be capable of internalizing insoluble macromolecules via 
phagocytosis (Groves et al., 2008; Lee et al., 1996). For example, collagen (300 kDa) is 
internalized by human gingival and PDL fibroblasts via ‘phagosomes’, a specialized 
intracellular phagocytic vesicle for intracellular breakdown (Lee et al., 1996); Beertsen et al., 
1987). Although the present study did not investigate phagocytosis in relation to the uptake of 
EMD and Fraction A, it is possible that insoluble aggregates of these components could be 
subjected to phagocytic uptake and thereby generates some functional consequences. 
 In conclusion, the present study has shown that at least some components in Fraction 
A and the TRAP peptide in Fraction C can bind and be internalized via receptor-mediated 
endocytosis, and that putative receptor(s) specific for Fraction A and Fraction C are expressed 
by only a sub-population of PDL cells.    
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Chapter 9 
9.1. General discussion 
9.1.1. PDL cell plasticity 
Stem cell-like populations within adult tissue are considered to play a key role in tissue 
homeostasis and the replenishment of cells that have died because of injury or disease  
(Weissman et al., 2000). Such ‘stem’ cells have now been identified and isolated from many 
tissues, including bone marrow (Jiang et al., 2002; Haynesworth et al., 1992), CNS (Johe et 
al., 1996), olfactory epithelium (Barnett et al., 2004), dental pulp (Gronthos et al., 2000), 
epidermis of the skin (Niemann et al., 2002; Cotsarelis et al., 1990), gastrointestinal track 
(Potten et al., 1998), BV (Asahara et al., 1997), skeletal muscle (Collins et al., 2005), cornea 
(Chen et al., 2004), heart (Laugwitz et al., 2005), adipose tissue (Zuk et al., 2001) and lung 
(Wu et al., 2004). A stem cell-like population has also been reported in the PDL by 
McCulloch (1987), who identified a population of cells exhibiting cytological features of stem 
cells, including small size, responsiveness to stimulatory growth factors and biological 
mediators, slow cell cycle time, higher number of population doublings, colony forming 
capacity and multi-lineage differentiation ability (osteogenic and adipogenic) in vitro 
(McCulloch et al., 1987).  
A number of other studies have since reported the presence of a stem cell-like 
population within the PDL using a range of phenotypic markers such as STRO-1, CD29, 
CD44, CD105, CD106 and CD146 (Tomokiyo et al., 2008; Xu et al., 2009; Cheng et al., 
2009). However, since these surface antigens are also expressed by several other types of 
adult human cells which are not considered stem cells, such as mature keratinocytes, T-
lymphocytes, fibroblasts and glycophorin-A-positive red blood cells, the above phenotypic 
criteria may not be specific for identifying a PDL progenitor/stem cell-like population 
(Gronthos et al., 2003; Simmons and Torok-storb, 1991; Mareddy et al., 2007; Staquet et al., 
1989; Weninger et al., 2000; Pickl et al., 1997). PDL tissue is highly vascular and also has 
dense sensory nerve innervations which indicate that precursors of endothelial and neural 
lineage might also be present in this tissue. However, the above studies examining the 
differentiation potential of PDL cells have been limited to mesenchymal pathways 
(osteogenic, adipogenic and chondrogenic) and detailed studies of the possible non-
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mesenchymal differentiation pathways of PDL cells (e.g., vasculogenic, angiogenic, 
neurogenic and gliogenic) have previously not been carried out.  
The present study cultured heterogeneous PDL cells firstly under non-differentiation 
inducing growth conditions and observed that these cells expressed mRNA transcripts of the 
early Runx2, PPARγ2, Sox-9, NGF and Notch1 genes associated with osteoblasts, adipocytes, 
chondrocytes, nerve and glial cells, respectively. Furthermore, when the PDL cells were 
cultured in lineage-specific differentiation media, they were able to undergo osteogenic, 
adipogenic, chondrogenic, vasculogenic, angiogenic, neurogenic and gliogenic differentiation 
in vitro, based on expression analysis of lineage-associated early and late genes and 
histological/immunocytochemical characteristics (Chapter 3), suggesting that the PDL may 
contain precursors capable of mesenchymal as well as non-mesenchymal lineage 
differentiation. Moreover, despite of lack of expression of the endothelial precursor markers 
VE-cadherin and CD31 by PDL cells when cultured under growth conditions (Xu et al., 2009; 
Zhou et al., 2008; Chapter 3), the cells cultured under endothelial media/differentiation 
conditions nevertheless formed endothelial-like cells in vitro, indicating that the PDL may 
contain a primitive cell population with the ability to differentiate into endothelial cells. 
Although PDL cells were found to express mRNA transcripts of range of 
mesenchymal and non-mesenchymal pathway-associated genes under growth conditions, as 
noted above, only a certain proportion of cells within this heterogeneous cell population were 
found to undergo lineage-specific differentiation and form lineage-associated cells under 
differentiation conditions (between 7 to 36%; Chapter 3) in vitro. This suggests the possibility 
that the PDL may contain subpopulations of lineage-specific precursor cells. Singhatanadgit 
(2009) obtained direct evidence of 4 clonal cell subpopulations within the PDL which, 
although they expressed a similar phenotype (positive for CD29 and CD44 and negative for 
CD34 and CD45) and exhibited spindle-shaped morphology, nevertheless differed in their 
ability to proliferate and differentiate into osteogenic, adipogenic and chondrogenic lineages. 
Thus, while 1 of 4 cell clones (Clone 7) exhibited a prolonged total population doubling (60 
population doublings before cell senescence) and the ability to differentiate into multiple 
lineages (osteoblasts, adipocytes and chondrocytes), the other 2 clones (Clones 5 and 6) 
exhibited only a limited population doubling level (20 population doublings before cell 
senescence) and differentiation potential (only osteogenic differentiation). One of the clonal 
populations (Clone 8) exhibited less than 20 population doublings before cell senescence and 
did not differentiate into any of the lineages noted above. These observations are thus 
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consistent with the presence of subpopulations of precursors within the PDL having varying 
differentiation potential. Furthermore, Xu (2009) showed that the PDL contains a STRO-1-
positive cell population which exhibits the ability to proliferate extensively and differentiate 
into bone, fat and cartilage cells in vitro, in contrast to the observations reported by 
Singhatanadgit (2009) in which the heterogeneous PDL cell population was shown to be 
negative for STRO-1, including clone 7. These findings again indicate that the PDL is likely 
to contain a number of cell subpopulations with different proliferation, differentiation and 
phenotypic characteristics.  
Fibroblast-like cells have been shown to be the predominant resident cell type of the 
PDL and such cells are mainly responsible for overall production and turnover of ECM. 
However, previous reports have suggested that the fibroblast population within the PDL is not 
homogeneous and may consist of different subpopulations with unique phenotypes and 
distinct functional activities such as osteogenic differentiation in vitro and bone formation in 
vivo (Hakkinen and Larjava, 1992; Irwin et al., 1994; Kuru et al., 1998). For example, Kuru 
(1998) showed that the PDL contains fibroblast subpopulations expressing high and low 
fibronectin, an extracellular matrix glycoprotein that binds to integrin receptors and regulates 
cell adhesion, migration, differentiation and wound healing (Pankov et al., 2002; Grinnell et 
al., 1984), despite similarities in size, granularity and morphology, again suggesting 
heterogeneity in PDL cell subpopulations. In addition to the possible presence of a range of 
lineage-associated precursors that give rise to multiple cell types, as evident by the proportion 
of cells which were found to be able to differentiate into mesenchymal and non-mesenchymal 
lineages as shown here, it is also possible that the PDL may also contain a subpopulation of 
‘primitive’ stem cells, as discussed in Section 9.1.3. 
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9.1.2. Identification of bioactive components of EMD 
Periodontitis is an infectious disease that results in a progressive loss of PDL, PDL-associated 
nerves, BV, cementum and AB and may ultimately lead to tooth loss. The goal of periodontal 
therapy is to restore the complex structure and function of the lost periodontal tissue. EMD 
(Institut Straumann, Basel, Switzerland), a commercially available heat-treated preparation of 
EMP extracted from developing pig, has been widely used in attempting to rebuild 
periodontal tissues (Cochran et al., 1999; Fincham et al., 1993; Margolis et al., 2006; 
Kanazashi et al., 2006; Donos et al., 2003; Sculean et al., 1999; Rathe et al., 2008), although 
clinical outcomes following EMD treatment have not always been consistent or predictable. 
For example, a histological study examining the effects of EMD on periodontal regeneration 
in a buccal dehiscence defect in humans observed that EMD-treated test sites exhibited a 
regenerated PDL with functionally oriented collagen fibres, cementum and AB compared 
with an untreated control group where little if any regeneration was observed (Heijl et al., 
1997). In contrast, another study observed that only 2 out of 7 intrabony defects treated with 
EMD developed fully regenerated PDL, cementum and AB whereas the other 5 defects were 
characterized by insufficient bone regeneration (Sculean et al., 1999). Similarly, another 
clinical study observed that out of 10 intrabony defects only 3 exhibited full periodontal 
regeneration (Yukna and Mellonig, 2000). Similar discrepancies have also been reported in a 
number of animal studies, for example, Donos (2003) treated furcation degree III defects with 
EMD and observed that only 1 of 3 monkeys exhibited full closure with fully regenerated 
PDL, cementum and AB, the other 2 defects showing only partial closure with incomplete 
bone regeneration. Critical-size calvarial defects in rats treated with EMD have also been 
reported to exhibit little if any regenerated bone (Donos et al., 2004). In addition, while a 
number of in vitro studies have demonstrated that commercial preparations of EMD and crude 
preparations of EMP both stimulate bone-associated markers and bone-like nodule formation 
of PDL and other bone-forming cells (Gestrelius et al., 1997; Van der pauw et al. 2000; 
Nagano et al. 2004), other studies have shown that these preparations inhibit the expression of 
osteogenic genes and mineralized bone-like nodule formation in vitro (Hamma et al., 2008; 
Hakki et al., 2001).  
The reason(s) for these discrepancies is not yet known, but it is possible that the 
components of EMP (including growth factors) vary qualitatively and quantitatively during 
different stages of enamel formation and crude extracts of EMP may therefore also vary in 
their components. EMP is synthesized by specialized epithelial cells (ameloblasts) during 
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tooth-supporting tissue and enamel development. The secretion of EMP can be observed 
during three distinct stages of enamel formation: The pre-secretory stage, the secretory stage 
and the maturation stage (Deutsch et al., 1995; ten Cate et al., 1996; Heritier et al., 1982). 
Although the major biosynthesis and secretion of EMP containing amelogenin, sheathlins, 
enamelin and tuftelin has been shown to take place in the secretory stage, the full-length 
amelogenin and its splicing forms (e.g., LRAP) are also secreted in the early pre-secretory 
and late maturation stages (Deutsch et al., 1995). Within hours after secretion, progressive 
proteolytic clipping of amelogenins have been shown to give rise to amelogenin peptides 
(including TRAP), and secreted peptides are gradually degraded and removed from the site by 
enzymatic digestion (Deutsch et al., 1995; Deutsch, 1989). Thus, the production and secretion 
of EMP components varies between different stages of enamel development.  
In contrast to EMP, commercially available EMD is a heat-treated acid extract of 
EMP derived from six-month-old piglets (Heijl, 1997; Gestrelius et al., 1997), and the 
contents/components of EMD are rigidly controlled qualitatively and quantitatively (FDA 
approved quality control processes; Institut Straumann, Basel, Switzerland) to avoid 
variations between different batches (personal communications, Institut Straumann). Thus, 
different preparations of EMD are likely to be consistent qualitatively and quantitatively, 
suggesting the possibility that discrepancies in the effects of EMD on periodontal 
regeneration in humans, as noted above, may be at least partly due to varying experimental 
conditions, including age of patients, severity of periodontal and other systemic diseases (e.g., 
diabetes), life style (i.e., eating habits, smoking) and oral hygiene/removal of bacterial plaque 
prior to regenerative procedures (Armitage et al., 1999; Garrett, 1996). Similarly, 
discrepancies between animal studies could be due to the use of different animal 
models/defects, varying age and healing conditions.  
Several attempts have been made to fractionate freshly isolated porcine EMP in order 
to delineate the active components in this heterogeneous protein mixture. For example, Iwata 
(2002) fractionated EMP from developing porcine teeth and reported that the fraction 
containing 20 kDa peptides exhibited osteoinductive properties, as assessed by stimulation of 
ALP activity and mineralized nodule formation and up-regulation of OC, BSP and ALP genes 
in the mouse bone marrow stromal cell line ST2. However, the methodology used in this 
study could not exclude the possibility that the osteoinductive fraction may have contained 
additional lower-molecular weight components which were bioactive. In addition, crude 
preparations of EMP are known to contain BMP and TGF β growth factors, which may have 
Chapter 9                                                                                                       General Discussion 
  212 
also contributed to the osteoinductive effects observed in this report (Iwata et al., 2002). This 
is consistent with the conclusion reported by Nagano (2006), who showed that the 
osteoinductive property of EMP fraction consisting of proteins of size > 10 kDa (Fraction 3; 
Nagano et al., 2006) was due to the presence of the TGF β1 growth factor. These observations 
suggest that more purified protein components are needed in order to assess the potential 
value of EMP in PDL and bone regeneration.  
The present study used two sub-fractions of the commercial preparation of EMD 
(Fraction C and Fraction A) that were obtained by industrial scale protein fractionation 
methodologies (Mumulidu et al., 2007), and examined the effects of these Fractions on bone, 
BV, nerve and glial cell formation by PDL cells in vitro. The results showed, for the first 
time, that the low (< 6 kDa; Fraction C) and the high (> 6 kDa; Fraction A) molecular weight 
Fractions of EMD differentially regulated these pathways of PDL cell differentiation. Thus, 
while Fraction C strongly suppressed bone-forming activity, Fraction C promoted BV, nerve 
and glial cell formation by PDL cells (Chapter 4, 6 and 7). In contrast, Fraction A induced 
bone-forming activity but strongly suppressed BV, nerve and glial cell differentiation 
(Chapters 4, 6 and 7). Since the amelogenin-derived TRAP is a main component of Fraction 
C and LRAP is an amelogenin-derived component of Fraction A (Mumulidu et al., 2007; 
Fincham et al., 1994), the present study also examined the effects of chemically synthesized 
TRAP and LRAP on osteogenic differentiation. The results showed that, as with Fraction C, 
TRAP suppressed the bone-forming activity of PDL cells whereas, as with Fraction A, LRAP 
induced osteogenic differentiation of the PDL cells in vitro (Chapter 4). Moreover, the TRAP 
peptide was also found to stimulate BV, nerve and glial cell formation, as found with Fraction 
C (Chapters 6-8), suggesting that LRAP and TRAP may be at least partly responsible for the 
regenerative activities of EMD.  
By amino acid sequence comparison of TRAP, LRAP and amelogenin, the study also 
identified the TCT peptide as the unique 12-amino acid C-terminal sequence present in 
TRAP, and LCT as the unique 23-amino acid C-terminal sequence present in LRAP. TCT and 
LCT were therefore chemically synthesized and examined for their effects on PDL cell 
osteogenesis, the results showing, for the first time, that the TCT sequence suppressed 
osteogenic differentiation whereas LCT stimulated this process (Chapter 4). These data 
suggest that these sequences are the active domains of the parent TRAP and LRAP peptides, 
respectively. The mechanism(s) of action of these peptides is not yet known, but it is 
noteworthy that initial experiments using TRAP and LRAP showed that they differentially 
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regulate the expression of Wnt3a and Wnt5a developmental genes which have been shown to 
induce osteogenesis (Williams et al., 2009; Wu et al., 2004) of PDL cells when cultured in 
GM for 6 h (Appendix Material 4.1). Thus, TRAP was found to suppress both of these Wnt 
genes, whereas LRAP up-regulated Wnt3a and 5a, indicating that TRAP and LRAP may 
possibly regulate osteogenic differentiation via a Wnt-dependent signal transduction pathway.  
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9.1.3. Interaction of EMD components with PDL cells 
It has been shown here that Fraction C and Fraction A differentially regulated a range of PDL 
cell differentiation activities, including osteogenesis, adipogenesis, chondrogenesis, 
vasculogenesis, angiogenesis, neurogenesis and gliogenesis in vitro (Chapters 4-7). Although 
the mechanism(s) by which these Fractions exert their biological activity is not yet known, it 
is likely to involve interaction of one or more components directly with the target PDL cells. 
Thus, the possible binding and internalization of EMD and the EMD Fractions into PDL cells 
was also examined here, the results indicating that at least some component(s) of Fraction C 
and Fraction A bind to the cell membrane and are internalized most probably via receptor-
mediated endocytosis (Chapter 8). Although receptor(s) on the PDL cells responsible for the 
binding and uptake of these EMD components have not yet been identified, the CD63 and 
CD107a receptors on mouse dental follicle cells have previously been shown to be 
responsible for binding mouse full-length amelogenin (M180) and the amelogenin (M50) 
isoform and for transducing signals for odontogenic differentiation, as well as for 
internalization of these mouse amelogenins (Zhang et al., 2010; Tompkins et al., 2006; Iacob 
et al., 2008). These findings suggest the possibility that the amelogenin-derived components 
studies here may regulate PDL cell differentiation via signal transduction mechanism(s) and 
become internalized via receptor mediated endocytosis.  
It was observed here that only a certain proportion of PDL cells were able to internalize 
Fraction C and Fraction A. Thus, the results in the present study showed that only 
approximately 6 and 12% of the cells within heterogeneous PDL cell population were able to 
internalize Fraction C and Fraction A, respectively, when cultured under growth conditions 
(Chapter 8). These results thus indicate that there may be subpopulation of cells within the 
PDL expressing receptor(s) responsible for binding and uptake of Fraction C and Fraction A 
and capable of specifically responding to Fraction C/TRAP and Fraction A. Similarly, it was 
also observed here that optimal concentrations of Fraction C and TRAP stimulated only 
limited proportion of the PDL cell population to form endothelial, nerve and glial cells in 
culture (Alizarin red staining, used to quantify the levels of bone-like nodule 
formation/mineralization by the PDL cultures, did not allow for measurement of the 
proportion of bone-forming cells, and it was not possible to determine the proportion of PDL 
cells capable of osteogenic differentiation in the presence of Fraction A). Thus, when PDL 
cells were cultured under differentiation conditions (endothelial, neural and glial media) in the 
presence of Fraction C and TRAP for up to 5 weeks, 15-30% of the cells exhibited 
Chapter 9                                                                                                       General Discussion 
  215 
characteristics of endothelial, nerve and glial cells in vitro, the remaining cells exhibiting a 
spindle-shape fibroblastic morphology (Chapter 6 and 7), again suggesting that there may be 
a Fraction C/TRAP-specific subpopulation of cells within the PDL. It is notable that the 
proportion of cells with the ability to internalize Fraction C was found to be markedly lower 
than the proportion of cells that developed endothelial, nerve and glial characteristics in the 
presence of Fraction C/TRAP. The reason for this discrepancy is not yet clear, but it is 
possible to speculate that Fraction C/TRAP might have induced proliferation and expansion 
of a Fraction C/TRAP-responsive subset of cells which could subsequently be induced to 
undergo differentiation to lineage-specific cells under differentiation-stimulating conditions in 
vitro. It is also possible that the relatively low proportion of Fraction C/TRAP-responsive 
cells may comprise the ‘true’ stem cells with the potential for multi-lineage specification, as 
described above (Section 9.1.1).  
Chapter 9                                                                                                      Concluding remarks       
9.2. Concluding remarks 
This thesis has demonstrated that the PDL contains one or more subpopulations of cells 
capable of differentiation to multiple lineages in vitro. Moreover, Fraction C and Fraction A 
derived from EMD were found to differentially regulate the apparent multi-lineage 
specification of the PDL cells, with Fraction C up-regulating chondrogenic, vasculogenic, 
angiogenic, neurogenic and gliogenic genes and ‘terminal’ differentiation and Fraction A 
stimulating osteogenic genes and terminal osteogenic differentiation. In addition, the TRAP 
and LRAP peptides of Fraction C and Fraction A, respectively, were found to be at least 
partly responsible for the activities of these two Fractions.  
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9.3. Future work 
9.3.1. Effects of LRAP-depleted Fraction A and TRAP-depleted Fraction C on 
PDL cell differentiation 
This thesis has provided evidence that higher molecular weight EMD Fraction A stimulates 
osteogenesis and lower molecular weight EMD Fration C stimulated chondrogenesis, 
vasculogenesis, angiogenesis, neurogenesis and gliogenesis. Moreover, chemically synthetic 
LRAP, major component of Fraction A, and TRAP, major component of Fraction C, 
exhibited similar bioactivities to naturally occuring heterogeneous Fractions. Thus, in order to 
examine whether the LRAP and TRAP peptides are solely responsible for the bioactivities of 
Fraction A and Fraction C, respecitvely, it may be useful to prepare Fraction A depleted of 
LRAP and Fraction C depleted of TRAP and determine the bioactivities of these LRAP and 
TRAP depleted Fractions on PDL cell differentiation. This will establish whether LRAP and 
TRAP alone are responsible for the bioactivity of whole EMD preparation and the EMD 
Fractions or there are other components present in EMD/Fractions which also potentially 
regulate the differentiation pathways investigated in this thesis.   
9.3.2. Effect of the LCT and TCT peptides on vasculogenesis, angiogenesis, 
neurogenesis and gliogenesis of PDL cells  
This thesis has provided evidence that the amelogenin-derived peptides LRAP and TRAP and 
their specific amino acid sequences LCT and TCT differentially regulate bone-forming cell 
activity in vitro. Thus, while LRAP and LCT have been shown to stimulate osteogenic 
differentiation of range of adult human bone-forming cells (PDL cells, AB cells, osteogenic 
PDL clone 7 and BMSC), TRAP and TCT suppressed this activity in vitro. In addition, the 
TRAP peptide was shown here, for the first time, to stimulate chondrogenic, vasculogenic, 
angiogenic, neurogenic and gliogenic differentiation in vitro. However, the effects of the 
newly-identified LCT and TCT sequences on these differentiation pathways have not hitherto 
been examined and experiments are now needed to examine the effects of these peptides on 
the in vitro assays used in this thesis for PDL cell chondrogenesis, vasculogenesis, 
angiogenesis, neurogenesis and gliogenesis. This will establish whether LCT and TCT are the 
specific amino acid sequences of the parent LRAP and TRAP peptides, and their potential 
efficacy for therapeutic applications in future. 
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9.3.3. Identification of the minimal amino acid sequences within LCT and TCT for 
inducing cell differentiation  
Protein homology analysis of the TCT and LCT amino acid sequences using the National 
Centre for Biotechnology Information (NCBI) protein database and BLAST software (NCBI, 
Bethesda, MD) identified a number of amino acid sub-sequences that were most ‘conserved’ 
within TCT and LCT sequences among > 100 different animal species, as shown in Table 12. 
This indicates the possibility that these smaller unique C-terminal amino acid sequences may 
retain the bioactivity of the parent LRAP/LCT and TRAP/TCT and may have the potential to 
modulate the multiple lineages of putative precursor cells. Identifying such conserved 
minimal amino acid sequences, as noted in Table 12, would have a number of important 
advantages: (i) chemical synthesis would be cost effective and can be produced in a large 
quantity with high purity for clinical use; (ii) likely to have markedly decreased 
immunogenicity; (iii) chemical modifications of the peptides, to prevent break-down, target to 
specific cells/tissue and enhance activity, would be relatively easy.    
 
 
 
 
 
            -NH2   -COOH 
 
9.3.4. Effects of LCT and TCT on other non-dental cells 
In addition to PDL cells, determining the effects of the peptides may prove beneficial in 
increasing the spectrum of possible clinical use for regenerating non-dental adult tissues. For 
example, use of BMSC and primary chondrocitic cultures obtained from synovial joints could 
be used to examine the chondrogenic differentiation activity of the peptides. Vasculogenic 
differentiation, reported to take place mainly in developing embryos, female reproductive 
track/endometrium and healing wounds (Vailhë et al., 2001), could be studied using the 
human embryonic stem cell line (MEL-1; Millipore), primary cultures from endometrium and 
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developing/foetal heart. In addition, the TRAP peptide has been shown here to have the 
ability to stimulate neurogenesis of PDL cells and generate differentiated nerve-like cells, and 
it may therefore be useful to examine its effect on primary cultures isolated from sensory 
neuron compartments such as dorsal root ganglion, spinal cord and enteric tissue.  
Further, since initial studies in this thesis demonstrated that TCT suppresses bone-
forming cells, it might therefore be of value for blocking the development/progression of 
bone-associated tumours. The peptide could therefore be examined for its effects on the 
growth of osteosarcoma cell lines (e.g., MG63, Saos-2, HOS) and the expression of key cell 
cycle-associated genes involved in tumourigenesis (e.g. p53, INK4, COPS4 and CDKs and 
CDKLs). 
 
 
9.3.5. Molecular mechanism(s) involved in TRAP/TCT and LRAP/LCT-mediated 
differentiation  
The molecular mechanisms by which these peptides elicit their biological activities are not yet 
known, but in initial experiments it was found that TRAP suppressed both the Wnt 3a and 5a 
genes, developmental factors which have been shown to induce osteogenesis (Williams et al., 
2009; Wu et al., 2004). In contrast, LRAP up-regulated the mRNA transcripts of both Wnt3a 
and 5a (Appendix Material 4.1), indicating that the differential regulation of osteogenic 
differentiation by TRAP and LRAP may be in part through signal transduction pathways 
associated with Wnt proteins. In addition, since a number of other Wnt ligands (i.e., Wnt-1, -
2, -4, -7a, -7b) have previously been shown to regulate vasculogenic, angiogenic and 
neurogenic differentiation during embryonic development (Franco et al., 2009; Inestrosa et 
al., 2010), it is possible that the TRAP and TCT and LRAP and LCT peptides might 
differentially affect the expression of these other Wnt genes of PDL cells. Further, the 
functional activity of the peptides can be established by examining the effects of the peptides 
following si-RNA-mediated specific Wnt gene knockdown on terminal differentiation in 
vitro, which may be useful in identifying a possible molecular basis by which these peptides 
control lineage specification.  
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 In addition to the specific Wnt gene pathways, cDNA PCR array (SABioscience, 
Crawly, UK) analysis of the changes in the expression of genes involved in a number of ‘key’ 
signal transduction pathways (e.g., FGF, Notch, Hedgehog, TGFβ, pluripotency maintenance 
pathways) associated with stem cell regulation may be useful in identifying other early 
molecular events involved in TRAP/TCT and LRAP/LCT-mediated PDL precursor/stem cell 
differentiation. Moreover, cDNA PCR arrays involving each differentiation pathway 
investigated in this thesis (i.e., osteogenic, adipogenic, chondrogenic, vasculogenic, 
angiogenic, neurogenic and gliogenic) may also be useful in delineating the pathway-specific 
mechanism(s) by which TRAP/TCT and LRAP/LCT differentially regulate the above 
differentiation pathways.    
 
 
9.3.6. Identification and characterization of subsets of TRAP and LRAP-
responsive cells and TRAP and LRAP-specific receptor(s) 
Although the TRAP peptide was found to bind and internalize into the PDL cells, the binding 
and intracellular fate of LRAP and the TCT and LCT amino acid sequences derived from 
TRAP and LRAP have not yet been studied, nor whether these peptides are recognized by 
only a certain subset of the PDL cells, as indicated by the results obtained here using Fraction 
C and Fraction A. In addition, it was observed that only a certain proportion of cells exhibited 
endothelial, neural and glial cell-like characteristics when cultured in the presence of Fraction 
C/TRAP. It is therefore possible that a Fraction C/TRAP-specific subpopulation of cells may 
have the ability to differentiate into non-mesenchymal lineages and that a Fraction A/LRAP-
specific subpopulation of cells may have mesenchymal lineage characteristics in vitro. 
Fraction C/TRAP- and Fraction A/LRAP-specific subpopulations within heterogeneous PDL 
cultures could be isolated by seeding PDL cells on Fraction C/TRAP and Fraction A/LRAP-
pre-coated plates, washing away the non-attached cells and recovering the cells which had 
bound to the Fraction C/TRAP and Fraction A/LRAP-coated surfaces for further 
characterization (i.e., proliferation ability, multi-lineage differentiation potential and 
functional characteristics, FCM analysis for the expression of stem cell-associated markers 
such as Oct3/4, nanog, rex-1, STRO-1 and MUC18/CD146). 
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Identification of the TRAP/TCT and the LRAP/LCT-specific receptor(s) could help to 
delineate the signal transduction pathway(s) of these peptides. This could be carried out by 
electrophoretic analysis of specific TRAP/TCT and LRAP/LCT-binding surface protein(s) 
obtained from TRAP/TCT and LRAP/LCT-positive cells isolated by panning techniques, as 
described above. For example, the primary PDL cell population could be seeded on to 
biotinylated-TRAP/TCT and -LRAP/LCT-pre-coated tissue culture plates, cell population that 
bound specifically to the peptide-coated plates detached using EDTA and then streptavidin 
affinity used to isolate the specific receptor-biotinylated peptide complexes. Determining the 
receptor(s) involved in peptide binding and uptake might then be used for modulating the 
biological activity/efficacy of the peptides by intracellular trafficking drugs, by agents and by 
biological and chemical modification of the peptide-receptor interaction.  
 
 
9.3.7. Evaluation of bone regenerative properties of LRAP and LCT in vivo 
The critical-size calvarial defect model treated via Guided Bone Regeneration (GBR) (Bosch 
et al., 1998; Donos et al., 2004; Mardas et al., 2002; Mardas et al., 2008) can be used to 
investigate the ability of LRAP and LCT to promote intra-membranous bone regeneration. 
The critical-size calvarial defect is generally considered as an osseous defect that cannot heal 
on its own (Schmitz & Hollinger, 1986), but can sometimes be successfully treated via guided 
bone regeneration (Appendix Materials 4.2 and 4.3) (Dahlin et al., 1988, Donos et al., 2004; 
Mardas et al., 2002; Donos et al., 2011). This has been achieved via surgical placement of a 
cell-occlusive barrier membrane on the bone surface, preventing the invasion of non-bone 
forming cells from the surrounding soft tissues but enabling re-population of the defect site by 
osteoprogenitor cells originating from the skull diploe (spongy bone structure) (Hammerle et al., 
1995; Donos et al., 2004; Retzepi et al., 2007; Donos et al., 2011).  
The absorbable collagen sponge (ACS) could be used as a selective carrier material to 
deliver the LRAP and LCT peptides before placement of the resorbable membrane, as 
previously used successfully with osteogenesis-inducing factors for enhancing bone healing 
(Donos et al., 2004; Retzepi et al., 2007; Donos et al., 2011). A dose-effect of LRAP and LCT 
(e.g., from 0.1 to 1 µg/ml) would need to be established. Following healing periods between 7 
to 30 days, control and test sites are removed and processed for qualitative and quantitative 
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histological evaluation of undecalcified sections, with new bone formation 
histomorphometrically measured. In replicate experiments animals could be sacrificed at 5 and 
10 days post-operatively, the tissue within the osseous defect could be obtained for RNA 
extraction and evaluated using Affymetrix oligonoucletide microarrays (Rat GeneArray 
St1.0s) to examine the molecular changes induced by LRAP and LCT.
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Appendices 
 
Appendix 1: Supplementary material for Chapter 4 
 
Appendix Material 1.1. Effects of synthetic amelogenin isoforms and 
peptides on bone-forming cells  
Conc. 
(µg/ml) 
TRAP LRAP TCT LCT ONT 
0.1 0.9±0.04 1.9±1.40*     0.8±0.06 1.7±1.14* 1.1±0.16 
1  0.5±0.09* 4.4±1.17* 0.5±0.07* 5.9±1.88* 1.0±0.22 
10  0.6±0.10* 3.9±1.30* 0.7±0.07* 5.5±2.18* 1.2±0.29 
100    0.5±0.16* 3.2±1.43* 0.6±0.12* 4.9±0.77* 0.9±0.11 
Effects of TRAP, LRAP, TCT, LCT and ONT on terminal osteogenic differentiation of PDL 
cells. Alizarin red staining of the cells cultured for 3 weeks in OM in the presence of peptides 
at concentrations 0.1, 1, 10 and 100 µg/ml for the PDL cells. The numbers are the relative 
staining intensities compared with OM alone, defined as 1.0.  
*Indicates statistically significant difference compared with OM alone p<0.05. 
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Appendix 2: Supplementary material for Chapter 6 
Appendix Material 2.1. Representative microscopic images of HUVEC (positive control cells) 
cultured in EBM-2 alone, EBM-2 + TRAP (30 µg/ml) and EBM-2 + GF for 6 and 12 h 
following the creation of an in vitro cell wound, as described in Materials and methods. The 
area between the black dashed lines shows the size of the wound (space without the cells). 
Magnification x 10. 
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Cell migration (in pixels x 103)  
Conditions 6 h 12 h 
EBM-2 alone 15.8±3136  21.7±3250 
+ TRAP 29.1±3568* 51.2±4275* 
+ GF 27.0±5130* 47.8±3204* 
Appendix Material 2.2. Effects of TRAP on migration 
of HUVEC (positive control cells) when cultured in 
EBM-2 alone, EBM-2 + TRAP (30 µg/ml) and EBM-2 
+ GF for 6 and 12 h after creating the cell wound in 
vitro. The numbers are the average (of 3 separate 
experiments) pixel counts (x 103) of HUVEC migration 
(pixels of wound (area with no cells) at 0 h minus 
pixels of wound at 6 or 12 h in the absence and 
presence of TRAP and GF).  Pixels are defined as a 
point of reference that has a specific recorded location 
within the micrograph. 
 *Indicates statistically significant difference 
compared with EBM-2 alone (p<0.05). 
                                                                                                                                    Appendices 
  260 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Material 2.3. Angiogenic structure formation by HUVEC (positive control cells) 
in vitro. (i) HUVEC cultured for 5 h in EBM-2 alone, EBM-2 + TRAP (30 µg/ml) and 
EBM-2 + GF. The numbers are the angiogenic structure branching points. The black 
arrows show the polygonal tubule-like structures formed by HUVEC. The blue arrows 
show branching points of the HUVEC. Black arrowheads show cells that did not form 
polygonal tubular-like structures. The values are the mean ±SE of five measurements of 
three separate experiments. (ii) Elongated BV-like structure formation by EC cultured for 
15 h in EBM-2 + TRAP. Magnification x 10.    
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Appendix 3: Supplementary material for Chapter 8 
 
 
 
 
 
 
 
 
Appendix Material 3.1. Micrographs of the internalization of biotinylated EMD, Fraction C 
and Fraction A by PDL cells. Cells were incubated at 4°C for 45 min in the absence and 
presence of EMD, Fraction C and Fraction A, then washed and further incubated at 37°C for 
3 h, washed, trypsinized to digest membrane-bound ligands and further cultured for 3 h to 
allow the cell attachment to the tissue culture plastic and the cells thereafter were reacted 
with red fluorescent Alexa Fluor-streptavidin. EMD and the EMD Fractions are visualized by 
red fluorescent staining in PDL cells. The numbers are the % of total cells exhibiting red 
fluorescent staining. Note the white arrows showing red fluorescent EMD and the EMD 
Fractions localization within distinct intracellular vesicle-like structures. The nuclei are 
stained blue using Hoechst dye. Magnification x 20. 
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Appendix Material 3.2. Immunogold EM showing the negative control performed LAMP-
1. The sample sections were immunogold-stained with non-specific mouse IgG primary 
antibody and 5 nm gold-goat anti-mouse IgG. Note that no non-specific 5 nm gold 
particle observed in the negative control section.   
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Appendix 4: Supplementary material for Chapter 9 
 
 
 
 
 
Appendix Material 4.1. Effects of LRAP (1 µg/ml) and TRAP (1 µg/ml) on Wnt3a and Wnt5a 
genes of PDL cells. Representative RT-PCR gels showing the expression of Wnt3a and 5a by 
PDL cells cultured for 6 h in GM alone and in the presence of LRAP and TRAP. Note the 
elevated levels of the Wnt3a and 5a mRNA transcripts of PDL cells cultured in the presence 
of LRAP. In contrast, note the constant level of Wnt3a and the reduced levels of Wnt5a mRNA 
transcripts in PDL cells cultured in the presence of TRAP.   
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Appendix Material 4.2. Demonstration of the creation 
of standardized, bicortical, critical size (5 mm) 
calvarial defects at the midportion of each parietal 
bone in the rat (Donos et al., 2011).   
Appendix Material 4.3. Healing of two critical size calvarial 
defects after 4 months post-operatively. The left defect 
(untreated control; black arrows) demonstrates little if any 
bone regeneration occurred. The right defect (red arrows) 
which was treated with occlusive membranes/GBR exhibited 
complete bone regeneration (Donos et al., 2004). 
